 
HPTN 067  
The ADAPT study:  
A Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of the Use of 
Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate  
Pre-Exposure Prophylaxis (PrEP)  
 
A Study of the HIV Prevention Trials Network  
 
 
 
Sponsored by:  
 
[CONTACT_132804] (DAIDS), US National Institute of Allergy and Infectious Diseases (NIAID)  
US National Institute of Mental Health (NIMH)  
US National Institutes of Health (NIH)  
 
Drug Donated by:  
[CONTACT_10869], Inc.  
 
 
Protocol Chair:  
Robe rt M. Grant, MD, MPH  
Gladstone Institute of Virology and Immunology  
Associate Professor of Medicine, University of [LOCATION_004], San Francisco  
 
Protocol Co -Chair : 
Frits van Griensven, PhD, MPH  
Associate Professor of Epi[INVESTIGATOR_69637], University  of [LOCATION_004], San Francisco  
 
Final  Version 5.0 
June 10 , 2013  
 
IND# 71,859 (held by [CONTACT_106898])  
DAIDS Document ID#[ZIP_CODE]  
 
 
 
 
 
 
 
 
 
 
 
  
HPTN 067, Final  Version 5.0 Page i June 10 , 2013  
 HPTN 067  
The ADAPT study:  
A Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of the Use of 
Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate  
Pre-Exposure Prophylaxis (PrEP)  
 
 
TABLE OF CON TENTS  
 
 
LIST OF ABBREVIATIONS AND ACRONYMS  ................................ ................................ ... v 
TERMINOLOGY FOR TENOFOVIR, EMTRICITABINE, AND THEIR DERIVATIVES  viii 
PROTOCOL TEAM ROSTER  ................................ ................................ ................................ .. ix 
INVESTIGATOR SIGNATURE [CONTACT_1783]  ................................ ................................ ..................  xii 
SCHEMA   ................................ ................................ ................................ ......................  xiii 
OVERVIEW OF STUDY DESIGN AND RANDOMIZATION SCHEME  ...........................  xv 
A) Randomization Scheme  ................................ ................................ ................................ ....... xv 
B) Study Design  ................................ ................................ ................................ ......................  xvi 
1.0 Introduction  ................................ ................................ ................................ .........................  1 
1.1 Background and prior research  ................................ ................................ ...............  1 
1.2 Animal studies of chemoprophylaxis ................................ ................................ ...... 3 
1.3 Human FTC/TDF trials  ................................ ................................ ...........................  3 
1.4 Significance of Determining Pharmacology of Intermittent PrEP  .........................  3 
1.5 Drug Concentration as an Adherence Measure  ................................ ......................  4 
1.6 Development and Validation of Tenofovir Hair Assay  ................................ ..........  5 
1.7 Drug Concentration Simulation Models  ................................ ................................ . 6 
1.8  Dose -proportionality and Drug Accumulation  ................................ .......................  7 
1.9 TDF and FTC drug resistance  ................................ ................................ ...............  10 
1.9.1  Patterns of drug resistance associated with TDF and FTC  ................................ ... 10 
1.9.2  Substantial barrier to HIV resistance to TDF and FTC  ................................ ........  11 
1.10  Rationale  ................................ ................................ ................................ ...............  11 
1.10.1  Justification for Intermittent PrEP  ................................ ................................ ........  11 
1.10.2  Justification for comparing event -driven dosing and time-driven dosing to daily 
dosing  ................................ ................................ ................................ ....................  13 
1.10.3  Theoretical basis for postulating behavioral effects of intermittent dosing  ..........  14 
Figure 1 -2: Adapted IMB -model of PrEP and Condom Use  ................................ ....................  19 
1.10.4  Rationale for drug level testing  ................................ ................................ .............  20 
1.10.5  Relevance to the goals of the HPTN  ................................ ................................ ..... 20 
1.10.6  Design advantages  ................................ ................................ ................................  21 
2.0 STUDY OBJECTIVES AND DESIGN  ................................ ................................ ...........  22 
2.1 Primary Objective:  ................................ ................................ ................................  22 
2.2 Secondary Objectives:  ................................ ................................ ..........................  22 
2.3 Study Design  ................................ ................................ ................................ .........  22 
2.4 Description of the intervention  ................................ ................................ .............  23 
2.4.1  Once -a-week directly observed dosing lead -in component  ................................ .. 23 
2.4.2  Self-administered dosing component  ................................ ................................ .... 23 
[IP_ADDRESS]  Daily usage ................................ ................................ ................................ ........  26 
[IP_ADDRESS] Time -driven usage  ................................ ................................ ................................  26 
HPTN 067, Final  Version 5.0 Page ii June 10 , 2013  
 [IP_ADDRESS]  Event -driven usage ................................ ................................ ............................  27 
3.0 STUDY POPULATION  ................................ ................................ ................................ ... 27 
3.1 Inclusion Criteria  ................................ ................................ ................................ .. 28 
3.1.1  MSM/TGW  ................................ ................................ ................................ ...........  28 
3.1.2  WSM  ................................ ................................ ................................ .....................  29 
3.2 Exclusion Criteria  ................................ ................................ ................................ . 29 
3.2.1  Vulnerable Populations  ................................ ................................ .........................  29 
3.3 Recruitment Process ................................ ................................ ..............................  30 
3.4 Co-Enrollment Guidelines  ................................ ................................ ....................  31 
3.5 Participant Retention  ................................ ................................ .............................  31 
3.6 Participant Withdrawal  ................................ ................................ .........................  32 
4.0 STUDY DRUG/INTERVENTION  ................................ ................................ ..................  32 
4.1 Study Drug/Intervention Formulation/Content  ................................ .....................  32 
4.2 Study Drug/Intervention Regimen(s) and Administration  ................................ .... 32 
4.3 Study Drug/Intervention Supply and Accountability  ................................ ...........  [ADDRESS_1024688]/ALT Elevations  ................................ ................................ ............................  37 
4.5.3  Calculated Creatinine Clearance  ................................ ................................ ...........  38 
4.5.4  Hypophosphatemia  ................................ ................................ ...............................  39 
4.5.5  Proteinuria  ................................ ................................ ................................ .............  40 
4.5.6  Glycosuria  ................................ ................................ ................................ .............  41 
4.5.7  HIV Infection  ................................ ................................ ................................ ........  41 
4.6 Clinical Management of Pregnancy  ................................ ................................ ...... 42 
4.7 Criteria for Early Termination of Study Participation  ................................ ..........  43 
4.8 Concomitant Medications  ................................ ................................ .....................  44 
5.0 STUDY PROCEDURES  ................................ ................................ ................................ .. 44 
5.1 Screening ................................ ................................ ................................ ...............  45 
5.2 Enrollment ................................ ................................ ................................ .............  46 
5.3 Weeks 1 -5 ................................ ................................ ................................ .............  47 
5.4 Week 6/Randomization  ................................ ................................ .........................  [ADDRESS_1024689] suspected or documented HIV infection during the study  51 
5.9 Participants Who Become Pregnant ................................ ................................ ...... 52 
5.10  Behavioral Data Collection  ................................ ................................ ...................  52 
5.10.1  Quantitative Behavioral Component ................................ ................................ ..... 52 
[IP_ADDRESS]  Coverage and Sexual Behavior  ................................ ................................ ..... 52 
5.10.2  Qualitative Behavioral Component ................................ ................................ ....... 53 
[IP_ADDRESS]  Focus groups and key informant interviews  ................................ .................  53 
6.0 SAFETY MONITORING AND ADVERSE EVENT REPORTING  ..............................  56 
6.1 Safety Monitoring  ................................ ................................ ................................ . 56 
HPTN 067, Final  Version 5.0 Page iii June 10 , 2013  
 6.2 Clinical Data Safety Review  ................................ ................................ .................  56 
6.3 Adverse Event definition and reporting to DAIDS  ................................ ...............  57 
6.3.1  Adverse Events  ................................ ................................ ................................ ..... 57 
6.3.2  Serious Adverse Events  ................................ ................................ ........................  58 
[IP_ADDRESS]  AE Reporting to DAIDS  ................................ ................................ ...................  58 
[IP_ADDRESS]  Grading severity of adverse events  ................................ ................................ ... [ADDRESS_1024690]  ................................ ......................  59 
6.4 Pregnancy Outcomes  ................................ ................................ ............................  59 
6.5 Regulatory Requirements ................................ ................................ ......................  59 
6.6 Social Harms Reporting  ................................ ................................ ........................  59 
7.0 STATISTICAL CONSIDERATIONS ................................ ................................ ..............  60 
7.1 Review of Study Design  ................................ ................................ .......................  60 
7.2 Study Endpoints  ................................ ................................ ................................ .... 60 
7.2.1  Primary Endpoints  ................................ ................................ ................................  60 
7.2.2  Secondary Endpoints  ................................ ................................ ............................  61 
7.3 Accrual, Follow -up, and Sample Size ................................ ................................ ... 63 
7.4 Random Assignment  ................................ ................................ .............................  67 
7.5 Data Analysis  ................................ ................................ ................................ ........  67 
7.5.1  Primary Analyses  ................................ ................................ ................................ .. 67 
7.5.2  Secondary analyses on coverage, pi[INVESTIGATOR_4382] -use and side effects/symptoms  .................  [ADDRESS_1024691] Containment  ................................ ................................ ........................  89 
9.5 Sample storage  ................................ ................................ ................................ ...... 89 
10.0  ADMINISTRATIVE PROCEDURES  ................................ ................................ .............  89 
10.1  Study Activation  ................................ ................................ ................................ ... 89 
10.2  Study Coordination  ................................ ................................ ...............................  90 
10.3  Study Monitoring  ................................ ................................ ................................ .. 91 
HPTN 067, Final  Version 5.0 Page iv June 10 , 2013  
 10.4  Protocol Compliance  ................................ ................................ .............................  91 
10.5  Investigator's Records  ................................ ................................ ...........................  91 
10.6  Use of Information and Publications  ................................ ................................ .... 92 
11.0  REFERENCES  ................................ ................................ ................................ .................  93 
APPENDICES  ................................ ................................ ................................ ............................  101 
Appendix I:  Schedule of Study Visits and Procedures  ................................ .......................  101 
Appendix IA.  All study participants  ................................ ................................ ..................  101 
Footnotes for Appendix IA  ................................ ................................ ................................ . 102 
Appendix IB.  Additional Procedures for Participants with Confirmed HIV Infection  .... 103 
Appendix II:  Additional power calculation with a range of average coverage rates for two 
primary hypothesis tests.  ................................ ................................ ................................ ..... 104 
Appendix III:  SAMPLE  INFORMED  CONSENT  FORMS  ................................ .............  106 
SAMPLE SCREENING AND ENROLLMENT INFORMED CONSENT FORM  ..........  106 
SAMPLE FOCUS GROUP INFORMED CONSENT  ................................ .......................  120 
SAMPLE KEY INFORMANT INTERVIEW INFORMED CONSENT FOR SELECTED 
STUDY PARTICIPANTS  ................................ ................................ ..................  125 
SAMPLE KEY INFORMANT INTERVIEW INFORMED CONSENT FOR CLINIC 
STAFF ................................ ................................ ................................ .................  129 
HPTN 067, Final  Version 5.0 Page v June 10 , 2013  
 HPTN 067  
The ADAPT study:  
A Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of the Use of 
Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre -Exposure Prophylaxis 
(PrEP)  
 
LIST OF ABBREVIATIONS AND ACRONYMS  
 
3TC   Lamivudine  
ABV    Abacavir  
ADAPT   Alternative Dosing to Augment PrEP pi[INVESTIGATOR_749302] (study)  
AE   Adverse event  
ALT    Alanine transaminase  
APTIMA   Amplified Probe by [CONTACT_749397]    (HPTN) Coordinating and Operations Center  
CPQA    Clinical Pharmacology Quality Assurance Committee  
CRF    Case report form  
CRPMC   (NIAID) Clinical Research Products Management Center  
CV   Coefficient of variation  
DAIDS   Division of AIDS  
DAERS   DAIDS Adverse Event Reporting System  
DBS    Dried blood spots  
DDI   Didanosine  
DNA    Deoxyribonucleic acid  
DOT    Directly observed therapy  
DSMB    Data and Safety Monitoring Board  
EAE    Expedited adverse event  
EC   Ethics Committee  
EDM    Electronic drug monitoring  
EFV    Efavirenz  
EQA    External quality assurance  
FDA    ([LOCATION_002]) Food and Drug Administration  
FTC   Emtricitabine  
FTC/TDF   Emtricitabine / Tenofovir Disoproxil Fumarate  
FTC-TP  Emtricitabine Triphospate  
GEE    General Estimating Equation  
GLP    Good Laboratory Practice  
HBsAg   Hepatitis B Surface Antigen  
HPTN 067, Final  Version 5.[ADDRESS_1024692]    Lower limit of normal  
LV   Laboratory verified (adherence)  
MSM    Men who have sex with men  
MSM /TGW  Men who have sex with men  and transgender women  
NIAID    ([LOCATION_002]) National Institute of Allergy and Infectious Diseases  
NIH   ([LOCATION_002]) National Institutes of Health  
NIMH    National Institutes of Mental Health  
NL   (HPTN) Network Laboratory  
NRTI    Nucleoside Reverse Transcriptase Inhibitor  
NNRTI   Non-Nucleoside Reverse Transcriptase Inhibitor  
OHRP    Office of Human Research Protection  
PBMC    Peripheral Blood Mononuclear Ce ll 
PD   Pharmacodynamic  
PEP   Post-Exposure Prophylaxis  
PK   Pharmacokinetic  
PrEP    Pre-Exposure Prophylaxis  
PRO    (DAIDS) Protocol Registration Office  
pSMILE   Patient Safety Monitoring and International Laboratory Evaluation  
PSRT    Protocol Safety Review  Team  
QA/QC   Quality assurance/Quality control  
RE   Regulatory entity  
RNA    Ribonucleic acid  
RSC    (DAIDS) Regulatory Support Center  
SAE    Serious Adverse Event  
SD   Standard deviation  
SDMC    (HPTN) Statistical and Data Management Center  
SIV   Simian immunodeficiency virus  
SMC    Study Monitoring Committee  
SOP   Standard Operating Procedure  
SRC    Scientific Review Committee  
SR   Self-reported (adherence)  
SSP   Study Specific Procedure  
HPTN 067, Final  Version 5.0 Page vii June 10 , 2013  
 STI   Sexually transmitted infection  
TDF    Tenofovir Disopro xil Fumarate  
TFV    Tenofovir  
TFV -DP  Tenofovir Diphosphate  
TLFB    Timeline follow -back  
TUC  Thailand Ministry of Public Health –[LOCATION_002] (U.S.) Centers 
for Disease Control (CDC)  
UCSF    University of [LOCATION_004] at San Francisco  
ULN    Upper limit of no rmal 
[LOCATION_003]ID   [LOCATION_002] Agency for International Development  
U.S.   [LOCATION_002]  
VOICE   Vaginal and Oral Interventions to Control the Epi[INVESTIGATOR_901]  (study)  
VQA    Virology quality assurance  
WIHS    Women’s Interagency HIV Study  
WSM    Women who have sex with m en 
ZDV    Zidovudine  
 
HPTN 067, Final  Version 5.0 Page viii June 10 , 2013  
 TERMINOLOGY FOR TENOFOVIR, EMTRICITABINE, AND THEIR 
DERIVATIVES  
 
 
Abbreviation  Compound 
name  [CONTACT_572029], oral formulation of tenofovir (TFV, 
trade name: [CONTACT_18129] ®).  The ester form enhances oral 
absorption and bioavailability.  TDF is rapi[INVESTIGATOR_749303] -esterified pro -drug, which is also 
inactive.   
TFV  Tenofovir  This is the inactive, de -esterified form of TDF.  This is the 
form of the drug that is measured in serum, blood, other 
body fluids, and non -cellular tissue samples.   
TFV -DP Tenofovir 
diphosphate  This is the active, phosphorylated form of TFV that is 
generated in cells.  This is the form of the drug that is 
measured in cells ( e.g., peripheral blood mononuclear cells, 
PBMCs).  It is rapi[INVESTIGATOR_18061], and has a very short half -life outside 
of cells in tissue.  
FTC  Emtricitabine  FTC is an inactive pro -drug that is activated in cells by 
[CONTACT_18094].  This is the form of the drug that is 
measured in serum, blood, other body fluids, and non -
cellular tissue samples.  
FTC -TP Emtricitabine 
triphosphate  This is the active form of FTC that is generated in cells.  
This is the form measured in cells ( e.g., PBMCs).   
Truvada®  FTC/TDF  This is the trade name [CONTACT_4007] a co -formulated drug produced by 
[CONTACT_10869], Inc.  Each pi[INVESTIGATOR_18062] 300 mg of TDF and 
200 mg of FTC.  
HPTN 067, Final  Version 5.0 Page ix June 10 , 2013  
 HPTN 067  
The ADAPT study:  
A Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of the Use of 
Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre -Exposure Prophylaxis 
(PrEP)  
PROTOCOL TEAM ROSTER  
 
Lead Investigators  
Robert M Grant, MD, MPH 
(Chair) Investigator, Gladstone 
Institute of Virology and 
Immunology Associate  
Associate Professor of Medicine, 
University of [LOCATION_004], San 
Francisco  
San Francisco, CA [ZIP_CODE]  
Phone: 415 -734-4810  
Fax: 415 -738-5384  
Email: [EMAIL_14309]  
 
Frits van Griensven, PhD, MPH 
(Co-Chair)  Professor, Division of 
Preventive Medicine and Public 
Health  
Department o f Epi[INVESTIGATOR_749304], University of 
[LOCATION_004] at San Francisco  
Box 1224, [ADDRESS_1024693]  
San Francisco, CA, [ZIP_CODE] -1224  
Phone : 66-9-009-[ZIP_CODE]  
Email: [EMAIL_14310]   
 
Timothy Mastro, MD  
FHI 360 
2224 E. Hwy 54  
Durham, NC [ZIP_CODE]  
Phone: 919 -544-7040 , Ext. [ZIP_CODE]  
Fax: 919 -544-0207  
Email: tmastro@fhi 360.org  
 
Nirupama Sista, PhD  
FHI 360 
2224 E.  Hwy 54  
Durham, NC [ZIP_CODE]  
Phone: [PHONE_10232] , Ext. [ZIP_CODE]  
Fax: 919 -544-0207  
Email: [EMAIL_11681]  
 Linda -Gail Bekker,  
MBChB, FCP (SA), PhD  
Associate [CONTACT_749506] HIV Centre  
Ground Floor, Werner and 
Beit Building North  
Institute of Infectious 
Diseases and Molecular 
Medicine  
University of Cape Town 
Faculty of Health Sciences  
Anzio Road, Observatory, 
7925  
Cape Town, South Africa  
Phone: 27 -21- 633-6599  
Fax: 27 -[PHONE_15626]  
Email: Linda -
Gail.Bekker@hiv -
research.org.za  
 
[COMPANY_009] Sciences, Inc.  
James Rooney, MD  
[COMPANY_009] Sciences, Inc.  
[ADDRESS_1024694]  
Foster City, CA  [ZIP_CODE]  
Phone: 650 -522-5708  
Fax: 650 -522-5854  
Email: 
[EMAIL_14311]  
 
PAB  
Ana I. Martinez, R.Ph  
Protocol Pharmacist  
Division of 
AIDS/NIAID/NIH  
[ADDRESS_1024695], Room 
4115  
Bethesda, MD [ZIP_CODE]  
Phone: 301 -435-3734  
Fax: 301 -402-1506  
Email: 
amartinez@niaid.n ih.gov  Site Investigators  
Timothy H. Holtz, MD, MPH, 
FACP, CAPT USPHS,  
Director  
HIV/STD Research Program  
Thailand MOPH  - US CDC 
Collaboration (TUC)  
DDC 7 Building, 4th floor  
Ministry of Public Health, Soi 4  
Nonthaburi [ZIP_CODE] Thailand  
Phone : 66-2-580-0669 ext 456  
Fax: 66 -2-580-0712  
E-mail: [EMAIL_14312]   
 
Surita Roux, MBChB, MPH  
Desmond Tutu HIV Foundation  
[ADDRESS_1024696], Old 
Crossroads  
Nyanga  
Cape Town, South Africa  
Phone: 27 -21-386-0053  
Fax: 27 -21-386-0054  
Email: surita.roux@hiv -
research.org.za  
 
Sharon Man nheimer , MD  
Columbia University  
Mailman School of Public Health  
Harlem Prevention C enter  
[ADDRESS_1024697], A -100 
[LOCATION_001], NY [ZIP_CODE]  
Phone:   [PHONE_15627]  
Fax:  [PHONE_15628]  
Email:   [EMAIL_14313]   
HPTN 067, Final  Version 5.0 Page x June 10 , 2013  
  
CORE  
Bonnie J. Dye, MPH  
Clinical Research Manager  
FHI 360 
2224 E.  Hwy 54  
Durham, NC [ZIP_CODE]  
Phone: 919 -544-7040, Ext. [ZIP_CODE]  
Fax: 919 -544-0207  
Email: [EMAIL_14314]  
 
Scott Mitchell Rose, BS  
Sr. Clinical Research Manager  
FHI 360 
2224 E. Hwy 54  
Durham, NC [ZIP_CODE]  
Phone: 919 -405-1447  
Fax: 919 -544-0207  
Email: [EMAIL_14315]  
 
Kevin  Bokoch, BA  
Prevention Research Specialist  
FHI 360 
2224 E.  Hwy 54  
Durham, NC [ZIP_CODE]  
Phone: 919 -544-7040,  Ext. [ZIP_CODE]  
Fax: 919 -544-0207  
Email: [EMAIL_14316]  
 
Rhonda White, R. H. Ed.  
Community Program Manager  
FHI 360 
2224 E. Hwy 54  
Durham, NC [ZIP_CODE]  
Phone: 919 -544-7040 , Ext. [ZIP_CODE]  
Fax: 919 -544-0207  
Email: rwhite@fhi 360.org  
 
NIH  
Michael J. Stirratt, PhD  
Program Chief, HIV Treatment 
Adherence Program  
Center for Mental Health 
Research on AIDS  
National Institute of Mental 
Health  
[ADDRESS_1024698], MSC -9619  
Bethesda, MD [ZIP_CODE] (Postal mail)  
Phone: 301 -443-6802  
Fax: 301 -443-9719  
Email: [EMAIL_14317]    
Vanessa Elharrar, MD, MPH  
Medical Officer  
Prevention Science 
Program/DAIDS/NIAID/NIH  
[ADDRESS_1024699], 5th 
Fl. Rm. 5249  
Bethesda, MD [ZIP_CODE]  
Phone: 301 -827-0845  
Fax: [PHONE_15629]  
Email: [EMAIL_14318].g
ov 
 
Network Laboratory  
Susan Eshleman, MD, PhD  
Johns Hopkins University  
[ADDRESS_1024700]  
Ross Bldg., Room 646  
Baltimore, MD [ZIP_CODE]  
Phone: 410 -614-4734  
Fax: 410 -502-9244  
Email: [EMAIL_2665]  
 
Estelle M. Pi[INVESTIGATOR_269812] -
Manning, BS, MT (ASCP), 
SI 
Johns Hopkins University  
Pathology Bldg, Room313  
[ADDRESS_1024701]  
Baltimore MD [ZIP_CODE]  
Phone:  [PHONE_10235]  
Fax: [PHONE_15630] 
Email: [EMAIL_11672]  
 
Craig Hendrix, MD  
Johns Hopkins University  
[ADDRESS_1024702]  
Harvey Bldg, Room 502  
Baltimore, MD [ZIP_CODE] -5554  
Phone: 410 -955-9707  
Fax: 410 -955-9708  
Email: [EMAIL_5013]   
Sociologist  
John H. Gagnon, PhD  
[CONTACT_749507] of [LOCATION_001] at 
Stony Brook  
Stony Brook, NY [ZIP_CODE]  
Phone:  631- 632-7700  
Fax: 631 - 632-8203  
Email: [EMAIL_14319]  
 
Ethicist  
Robert Klitzman, MD  
Professor of Clinical Psychiatry  
Director, Masters of Bioethics 
Program  
Director, Ethics and Policy Core, 
HIV Center Columbia  University  
[ADDRESS_1024703]./Unit #15  
[LOCATION_001], NY [ZIP_CODE]  
Phone: 212 543 -3710  
Fax: 212 543 -6003  
Email: [EMAIL_14320]  
 
Community Advisors  
Reverend David Galetta  
NY5, No. 24 Gugulethu, 7750  
Cape Town  
South Africa  
Phone: 27 -21-79-079-7184  
Email:  
[EMAIL_14321]
nesa.co.za  
 
[CONTACT_749508]  
MSM /TGW  Community 
Representative  
120/118 Moo 2, Moo Baan, 
Amarinnives 3 /3 Kwang Saimai, 
Khet Saimai  
Bangkok, Thailand  
Phone: 66 -818-249-063 
Email: 
[EMAIL_14322]  
HPTN 067, Final  Version 5.0 Page xi June 10 , 2013  
  
CDC  
R. Michael Hendry, D.Sc.  
DHAP/NCHHSTP/CCID/CDC  
Bldg. 18, Rm [ADDRESS_1024704].  
Atlanta, GA [ZIP_CODE]  
Phone: 404 -639-1033  
Fax: 404 -639-1174  
Email: [EMAIL_14323]  
 
Janet M. McNicholl, MD  
DHAP - Laboratory Branch  
[ADDRESS_1024705], MS A25  
Atlanta, GA [ZIP_CODE]  
Phone: 404 -639-1520  
Fax: 404 -639-2108  
Email: [EMAIL_14324]  
 
Anupong Chitwarakorn, MD  
Senior Expert in Preventive 
Medicine  
Dept. of Disease Control  
Ministry of Public Health  
Soi 4, Tivanon Road  
Nonthaburi, Thailand [ZIP_CODE]  
Phone: 66 -2590 -3225  
Fax: 66 -2965 -9573  
Email: [EMAIL_14325]   
Statistics and Data  
Jim Hughes, PhD  
HPTN SDMC  
University of Washington  
Mailstop 359931  
Seattle, WA [ZIP_CODE]  
Phone: 206 -731-3633/206 -
616-2721  
Fax: 206 - 731-3693/206 -616-
2724  
Email: 
[EMAIL_8010]  
 
James Y. Dai, PhD  
SCHARP -FHCRC  
[ADDRESS_1024706] North, 
M2-C200  
[PO_BOX]  
Seattle, WA [ZIP_CODE], [LOCATION_003]  
Phone: 206 -667-6364  
Fax: 206 -667-4812  
Email: [EMAIL_12339]  
 
Laura McKinstry, MPH  
SCHARP -FHCRC  
[ADDRESS_1024707]. N.  
Mailbox E3 -129 
Seattle, WA [ZIP_CODE] -1024  
Phone: 206 -667-7322  
Fax: 206 -667-4812  
Email: [EMAIL_5015]  
 
Behavioral Scientist  
K. Rivet Amico, PhD  
Research Scientist  
Center for Health, 
Intervention & Prevention  
University of Connecticut  
[ADDRESS_1024708] [ZIP_CODE]  
Phone: 810 -360-8716  
Fax: 860 -518-0243  
Email: 
[EMAIL_14326]   
Hair Pharmacologist  
Albert Liu, MD, MPH  
Director, HIV Prevention 
Intervention Studies  
HIV Research Section  
San Francisco Department of 
Public Health  
[ADDRESS_1024709]  
San Francisco, CA [ZIP_CODE]  
Phone: 415 - 554-9104  
Fax: 415 - 621-0641  
Email: [EMAIL_14327]  
 
HPTN 067, Final  Version 5.0 Page xii June 10 , 2013  
  
INVESTIGATOR SIGNATURE [CONTACT_579054] 067  
The ADAPT study:  
A Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of the Use of 
Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre -Exposure Prophylaxis 
(PrEP)  
 
Final Version 5.0  
June 10 , 2013  
 
A Study of the HIV Prevention Trials Network (HPTN)  
 
Sponsored by:  
 
[CONTACT_749398]  
U.S.  National Institute of Mental Health  
U.S.  National Institutes of Health  
 
 
I, the Investigator of Record, agree to conduct this study in full accordance with t he provisions of 
this protocol.  I will comply with all requirements regarding the obligations of investigators as 
outlined in the Statement of Investigator (Form FDA 1572), which I have also signed.  I agree to 
maintain all study documentation for at leas t two years following the date of marketing approval 
for the study product for the indication in which it was studied, unless otherwise specified by [CONTACT_145638] (DAIDS), [COMPANY_009] Sciences, Inc., or the HIV Prevention Trials Network 
(HPTN) Coordinati ng and Operations Center.  If no marketing application is filed, or if the 
application is not approved, the records will be retained for two years after the FDA is notified 
that the Investigational New Drug (IND) application is discontinued.  Publication o f the results 
of this study will be governed by [CONTACT_262273].  Any presentation, abstract, or manuscript will 
be submitted to the HPTN Manuscript Review Committee, DAIDS, and [COMPANY_009] Sciences, Inc.  
for review prior to submission.  
 
I have read and understa nd the information in the Investigator's Brochure(s), including the 
potential risks and side effects of the products under investigation, and will ensure that all 
associates, colleagues, and employees assisting in the conduct of the study are informed abou t 
the obligations incurred by [CONTACT_100388].  
 
__________________________________  
Name [CONTACT_137839]  
 
 
__________________________________   _________________________________  
Signature [CONTACT_137839]   [INVESTIGATOR_749305] 067, Final  Version 5.0 Page xiii June 10 , 2013  
 HPTN 067  
The ADAPT study:  
A Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of the Use of 
Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre -Exposure Prophylaxis 
(PrEP)  
 
SCHEMA  
 
Purpose:  
This is a behavioral study to evaluate the feasibility of intermittent dosing of a pre -exposure 
prophylaxis (PrEP) regimen.  Recommendations for intermittent usage, compared with daily 
usage, may provide comparable coverage of possible exposures with pre - and post -exposure 
dosing, decr eased pi[INVESTIGATOR_749306], and decreased symptoms.  This study is designed to 
optimize and facilitate future efficacy research, to be proposed separately.  The study aims to 
identify dosing regimens that foster healthy sexual practices and pi[INVESTIGATOR_4382] -taking behavi or in people at 
high risk of human immunodeficiency virus (HIV) infection.  The word ADAPT in the study title 
is an acronym for Alternative Dosing to Augment PrEP pi[INVESTIGATOR_4382]-Taking.   
 
Design:  
A Phase II randomized open -label clinical trial of oral Truvada® [ tenofovir disoproxil fumarate 
(TDF) plus emtricitabine (FTC)] PrEP among HIV -uninfected men who have sex with men and 
transgender women (MSM /TGW ) and women who have sex with men (WSM), at high risk of 
acquiring HIV infection.  The study includes a six week  lead-in period which includes directly 
observed therapy (DOT) at Enrollment and Weeks 1 through 4, followed by [CONTACT_749399] (PK).   This will provide the 
opportunity to create a pharmacokinet ic analysis of drug levels to be expected at given rates of 
intake (adherence).  Participants will then be randomly assigned to one of three dosage groups in 
a 1:1:1 ratio: daily dosing, time -driven dosing, and event -driven dosing.  After randomization, 
participants will then complete a 24 -week period of self -administered dosing (Weeks 6 through 
30), with one visit four weeks after the completion of dosing (34 weeks total).  Participants who 
acquire HIV infection during the study discontinue dosing and will  be followed until study 
closure and referred for post -trial care as per local regulations.  A subset of participants in each 
of the study arms will also participate in a qualitative evaluation of the social and behavioral 
aspects of differing dosing strat egies utilizing focus groups after Week 34.  A subset of clinic 
staff who directly interact with participants regarding pi[INVESTIGATOR_4382] -taking and sexual risk behavior, as 
well as a subset of participants identified as particularly informative will participate in key -
informant interviews after Week 34.   
 
Study Population:  
HIV-uninfected MSM /TGW , WSM at high risk of acquiring HIV infection  
 
Study Size:  
540 evaluable participants, including 180 MSM /TGW in Bangkok, 180 MSM /TGW in [LOCATION_001] 
and 180 WSM  in Cape Town.  
HPTN 067, Final  Version 5.0 Page xiv June 10 , 2013  
 Treatment Regimen:  
Oral FTC/TDF in three dosage groups: daily dosing, time -driven dosing, and event -driven 
dosing.  The time -driven dosing group will be asked to take FTC/TDF twice weekly with a post -
exposure boost.  The event -driven dosing group will be a sked to take FTC/TDF before and after 
a potential exposure to HIV infection.  In all three dosing groups, dosing will not exceed two 
doses per day or seven doses per week.  
 
Study Duration:  
The total duration of the study will be less than two years.  Enrol lment  is planned over 8 months.  
Follow -up will include a 30 -week dosing period, with a single (final) visit four weeks after 
completion of dosing.  The 30 -week dosing period includes a 6 -week lead -in period which 
includes once -a-week DOT administered at E nrollment and Weeks 1 through 4, followed by [CONTACT_749400].  The lead -in phase will be followed by 24 weeks of self -administered use, 
a 4 week off -drug period, and a final clinic visit at Week 34.  
 
Primary Objective:  
 To test the hypothesis that recommending intermittent (non -daily) usage of 
oral FTC/TDF chemoprophylaxis, compared with recommending daily usage, 
will be associated with:  
 
 Equivalent coverage of sex events with pre - and post -exposure dosing  
 Lower number of pi[INVESTIGATOR_749307] a nd fewer pi[INVESTIGATOR_544610]  
 Decreased self -reported symptoms/side effects (both severity and 
frequency) during 24 weeks of self -administered use  
 
Secondary Objectives:  
 Develop objective measures of drug exposure by [CONTACT_749401] -
dose “trough” drug co ncentration in several biological matrices for 
participants during a lead -in period of weekly DOT  
 To describe safety outcomes among PrEP users including adverse events 
among all participants and drug resistance and plasma HIV r ibonucleic acid  
(RNA) levels  among participants who seroconvert  
 Assess differences between arms in the acceptability of different PrEP 
regimens and in perceptions of advantages and disadvantages of different 
regimens  
 Assess differences by [CONTACT_749402]  
 Evaluate the potential influ ence of PrEP usage on changes in sexual behavior, 
planning for sex, prediction of risky situations, and recognition of possible 
HIV exposure from baseline to final on -drug assessment in relation to PrEP 
optimism  
 
Study Sites:  
The Thailand Ministry of Public Health –[LOCATION_002] (U.S.) Centers for Disease Control (CDC) 
collaboration (TUC) Silom Community Clinic in Bangkok, Thailand and the Harlem Prevention 
Center in [LOCATION_001], [LOCATION_003] for MSM /TGW , and Emavundleni Centre, The Desmond  Tutu HIV 
Foundation in Cape Town, South Africa for WSM.   
 
HPTN 067, Final  Version 5.0 Page xv June 10 , 2013  
 HPTN 067  
The ADAPT study:  
A Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of the Use of 
Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre -Exposure Prophyl axis 
(PrEP)  
 
OVERVIEW OF STUDY DESIGN AND RANDOMIZATION SCHEME  
 
A) Randomization Scheme  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
300mg TDF/  
200 mg FTC 
Tablets  
(Truvada®)   
DOT  
Week 6  
Randomization   
Arm 3  
Event -driven  
Arm 2  
Time -driven  
Arm 1  
Daily  
120 
MSM/TGW  
120 
MSM/TGW  
120 
MSM/TGW  
60 WSM  
 60 WSM  
 60 WSM  
HPTN 067, Final Version 5.0  Page xvi June 10 , 2013  
 B) Study Design  
            
Week  -10  0 6 10 14 18 22 26 30 34 
            
Screening             
     Day -70 to -1               
            
Directly Observed Therapy             
     Day 0 (Enrollment) up to Week 6/Randomization              
            
Self Administered Therapy             
     Week 6/Randomization up to Week [ADDRESS_1024710] be 
evaluated and made available as “combination intervention” as rapi[INVESTIGATOR_749308].  The “tool box” for prevention of HIV infection shou ld 
include different strategies such as condom usage and male circumcision, as well 
as behavioral, biomedical and structural interventions for HIV -uninfected and 
HIV-infected individuals.  Daily PrEP with oral antiretroviral drugs is currently 
being evalua ted in clinical trials in diverse populations and settings.  However, for 
the majority of the “at -risk” populations, the prevention method of daily PrEP 
dosing may not match patterns of HIV risk -taking, which is unlikely to occur on a 
daily basis.  Further more, daily dosing of PrEP was selected for on -going 
prevention trials based on dosing intervals that are approved for treatment of HIV 
infection.   
 
Less frequent dosing of PrEP  may be sufficient for prevention purposes as well as 
result in decreased drug costs and potentially lower risk of toxicity which may 
increase acceptability and improve utilization.  Studying intermittent dosing can 
contribute critical information regardin g behavioral effects, adherence reporting 
and counseling content.  In addition, this study will be useful even in the setting 
of negative daily dosing trials if it identifies ways to foster pi[INVESTIGATOR_749309].   
 
Therefore, s trategies using intermittent PrEP regimens should be evaluated as an 
alternative tool for HIV prevention.  Establishing the potential benefits and 
feasibility of intermittent regimens in terms of coverage, acceptability, resistance, 
and uptake, as well as potential influence on other risk -management strategies 
(e.g., condom use) is critical in the portfolio of research that will advise the real -
world dissemination and implementation of combination interventions.   
 
In late November 2010, the iPrEx study pub lished results which found that the 
daily use of oral Truvada®  reduced the risk of HIV infection by [ADDRESS_1024711] drug in the blood was associated with higher levels of 
protection.  In July 2011, two separate studies reported that an oral dose of 
Truvada ® can provide additional protection to heterosexual men and women in 
Africa:  HIV risk was reduced by 63% in the TDF2 study and by 73% in the 
Partners PrEP study of serodiscordant  heterosexual couples in Africa. 2,3These 
two trials found efficacy for Tru vada ® in both men and women. These results 
contrasted with the findings of the FEM -PrEP study that was discontinued after an 
interim review found that the study was unlikely to eventually find evidence of 
Truvada ® PrEP efficacy in the high -risk women who h ad been enrolled.[ADDRESS_1024712] confirmed the safety 
of Truvada®  including a lack of clinically significant effects on the kidne ys and 
the liver.  The ADAPT study seeks to find alternative dosing strategies that are 
more convenient, which may increase the consistent use of PrEP.  The ADAPT 
study will also provide important new information about how tests for drug in the 
blood may b e used to monitor use of PrEP, and how to improve the reliability of 
self-reporting of pi[INVESTIGATOR_293273].   
 
Oral Truvada ® is used in the ADAPT study because it has demonstrated efficacy 
in the iPrEx, TDF2, and Partners PrEP  trials.  Furthermore, the prophylactic 
activity of Truvada ®, which contains both emtricitabine and tenofovir disoproxil 
fumarate (TDF), was higher in non -human primates than either drug alone.5  The 
Partners PrEP trial found efficacy of Truvada to be 73% while the efficacy of 
TDF alone was 62% (P=0.18 for the difference in efficacy e stimates).2  The 
Vaginal and Oral Interventions to Control the Epi[INVESTIGATOR_901] (VOICE) trial was not 
able to show  efficacy of oral TDF, oral FTC/TDF, or tenofovir vaginal gel in 
heterosexual A frican women, perhaps because  use of the interventions was low in 
all groups.[ADDRESS_1024713] that the virtues of the “new 
approach” be highlighted to justify considering alterations to the standard of care.  
There is the potential for both negative and positive findings in this study.  
Intermittent dosing may lead to poor coverage of exposure, costs may increase 
because pi[INVESTIGATOR_749310].   
 
The primary measure of pi[INVESTIGATOR_4382] -taking in this study will be based on the adjusted 
Electronic Drug Monitoring (EDM)  device.  The  EDM data is transmitted 
electronically to a database system and this data is used by [CONTACT_749403] -reported pi[INVESTIGATOR_4382] -taking via brief weekly interviews.  
EDM has received considerable support within the antiretroviral drug adher ence 
literature as an objective measure of adherence,8-11 although EDM has also been 
noted as potentially underestimating adherence.12  Accuracy of EDM is dependent 
on case -openings  being indicative of (a proxy for) pi[INVESTIGATOR_660398].  The 
appropriateness of this assumption is increasingly suspect if participants do not 
use the EDM case for pi[INVESTIGATOR_749311], or dispense pi[INVESTIGATOR_749312].  The weekly interviews we re developed to address these 
HPTN 067, Final Version 5.[ADDRESS_1024714] encouraging data suggesting that intermittent PrEP may be a plausible 
prevention strategy comes from a recent study in which monkeys were well -
protected from simian immunodeficiency virus (SIV) infection after receiving one 
dose of TDF plus FTC at either [ADDRESS_1024715] -exposure.13  While encouraging, these 
data cannot be directly extrapolated to humans due to the differences in simian 
anatomy and pharmacok inetics, as well as differences between HIV and the SIV 
challenge strain.  
 
The coformulation  of FTC/TDF is selected for this trial because it was the most 
active in pre -clinical studies of non -human primates.  While TDF or FTC alone 
had some protective activity in animal studies, the combination of both agents 
was associated with higher levels of  protection.  The combination has been co -
formulated as a single pi[INVESTIGATOR_4382], and is available from [COMPANY_009] Sciences, Inc. under the 
trade name “Truvada®”.  
1.3 Human FTC/TDF trials  
The nucleotide reverse transcriptase inhibitors (NRTIs) TDF and FTC were 
licensed b y the U.S.  Food and Drug Administration (FDA) for treatment of HIV -l 
infection in [ADDRESS_1024716] 2004, the FDA licensed 
a fixed dose c o-formulated drug containing 300 mg TDF and 200 mg FTC (trade 
name: [CONTACT_262340]®) .[ADDRESS_1024717] anding safety and 
efficacy in human clinical trials .17,18  TDF has characteristics that make it suitable 
for evaluation as a chemoprophylaxis agent.  These characteristics include: 
prolonged intracellular half -life that allows once -a-day dosing, high levels of 
tolerability, potent antiviral effects, and selectio n of drug -resistant variants that 
have mutations associated with diminished viral replication capacity.   
 
Several clinical trials evaluating the efficacy of FTC/TDF (administered daily) for 
PrEP are ongoing or recently completed .  These multi -site trials are being 
conducted in many countries and in different populations including young women 
(CDC -funded study in Botswana,19 [LOCATION_003]ID -funded FEM -PrEP,20 NIH-funded 
VOICE21), MSM (NIH and Gates funded iPrEX22), intravenous drug users (CDC 
funded study in Thailand19), and discordant heterosexual partners (Gates funded 
Partners study23).  The results from the iPrEx trial indicated that PrEP reduced the 
risk of HIV infection and had no serious safety concerns1. 
1.4 Significance of Determining Pharmacology of Intermittent PrEP  
Assuming dose proportionality is found, this model will be used to estimate 
extracellular and intracellular drug exposure in multiple compartments for any 
HPTN 067, Final Version 5.0  Page 4 of 13 3 June 10 , 2013  
 dose and dosing interv al combination.  This model will be critical to the following 
three areas: 1) developi[INVESTIGATOR_262242] -based adherence intervention 
for future PrEP studies, 2) assessing adherence in ongoing studies with currently 
stored samples, and 3) developin g a pharmacokinetic -pharmacodynamic (PK/PD) 
model to determine target intracellular drug exposures that prevent HIV infection.   
1.5 Drug Concentration as an Adherence Measure  
In clinical trials,  measurement of drug concentrations has been proposed as a 
potential quantitative measure of medication adherence.  In this protocol, we plan 
to use drug concentration of tenofovir in different biological matrices as a 
measure of adherence.  We propose the following model to quantitatively estimate 
the percent adhe rence to the prescribed regimen:  
 
% Adherence = 100 ● (observed concentration / expected concentration) +  +  
where  represents the sources of measurable variability (inter - and intra -
individual variability and drug assay variability) and  is the random unmeasured 
error.  
 
Pre-dose “trough” samples will be collected at Weeks 18 and 30 following 
unwitnessed doses to be used to represent the “observed” drug concentrations and 
taken to reflect two examples of concentration to assess adherence.  This will 
enable estimation of adherence at two times during the study.  (More frequent 
assessments were not planned due to financial and site specific logistical 
constraints.) The “expected” drug concentrations are based on steady -state pre -
dose drug con centrations after, so -called, “directly observed therapy” or DOT 
which is the subject specific reference for 100% adherence.  The ratio of drug 
concentrations (observed/expected) is taken as a rough estimate of the proportion 
of prescribed doses that were actually taken plus other known and unknown 
variability. Any differences between the observed and expected values are 
attributed primarily to adherence, since the expected value estimates (described 
below) control for adherence, and since other significant  sources of variation 
(e.g., assay variability and environmental variables) are reasonably assumed to be 
stable over time.  
Biological matrices and analytes to be sampled include plasma tenofovir (TFVs), 
plasma emtricitabine (FTC), intracellular tenofovir d iphosphate (TFV -DP), 
intracellular emtricitabine triphosphate (FTC -TP), hair tenofovir (TFV), and hair 
HPTN 067, Final Version 5.0  Page 5 of 13 3 June 10 , 2013  
 emtricitabine (FTC).  Dried blood spot (DBS) samples will also be collected at 
one study site  for analysis  of these  drugs in whole blood, which is mainly  
comprised of red blood cells (RBCs). Each of these has different assay variability 
and analyte half -life.  Tenofovir half -lives are generally longer than emtricitabine.  
The half -life of serum analytes is less than a day ; the half -life of intracellular 
analytes in PBMCs can be several days to one week ; the half -life of intracellular 
analytes in RBCs can be several weeks; the half -life of the analyte in hair can be 
more than a month.  It should be noted that these half -life estimates are not well 
establis hed for intracellular phosphates (PBMCs and RBCs) and analytes in hair.  
The method for measuring these analytes in RBCs/DBS is new and further 
validation studies are needed. These characteristics are mentioned because they 
may relate directly to the limit ations of drug concentration as a method of 
adherence.  For example, all things being equal, increasing variability diminishes 
the ability to discriminate between different degrees of adherence.  Due to a larger 
accumulation index, a longer drug half -life allows both greater ability to 
discriminate among adherence levels and less susceptibility to the “white coat 
effect” wherein a subject may appear to be 100% adherent after taking only one 
dose of medication immediately prior to a study visit without havin g taken any 
prior doses.  The long half -life can also require delays until steady -state is 
achieved (five times the drug half -life in the biological matrix) and limit the 
ability to detect poor adherence “holidays” in time frames much shorter than the 
half-life.  For example, the two long half -life measures (cells and hair) can be 
insensitive to a holiday (no drug taking for a week or a few days, respectively) 
when most of an observation period may be associated with very high adherence.  
It is anticipated that a combination of adherence measures ( e.g., 
microelectromechanical systems (MEMS) devices) can help improve sensitivity 
to this type of adherence issue.  The impact of half -life, accumulation index, and 
inter- and intra -subject variability are describe d further below.  Finally, hair color 
and hair treatments ( e.g., dye and perms) can alter assessment of drug 
concentration in hair.  A sexual event dependent drug schedule is a challenge for 
drug concentration as adherence measure, because the standard “ex pected” value 
is not related to DOT steady -state directly, though steady -state DOT data can be 
used to estimate single dose drug kinetics which can, in combination with sexual 
event reporting, be used to estimate expected drug concentrations.  However, thi s 
introduces an undesired subjective variable (sexual activity reporting) that could 
be as inaccurate as pi[INVESTIGATOR_4382] -taking diaries.  
1.6 Development and Validation of Tenofovir Hair Assay  
Methods for the detecting tenofovir (TFV) in hair have been developed and 
valid ated by [INVESTIGATOR_124]. Yong Huang’s laboratory at University of [LOCATION_004] at San 
Francisco (UCSF) and a Women’s Interagency HIV Study (WIHS) investigator 
HPTN 067, Final Version 5.0  Page 6 of 13 3 June 10 , 2013  
 group at UCSF.24  This method using liquid chromatography/mass 
spectroscopy/mass spectroscopy (LC/MS/MS) has been validated fo r the range of 
0.01 to 0.4 ng/mg hair.  Subsequently, the feasibility of hair collection and ability 
to detect TFV in hair were evaluated among HIV -uninfected MSM participating 
in a CDC -sponsored PrEP study in San Francisco.  Single samples of hair were 
collected and tested in a blinded fashion in this placebo -controlled trial.  Overall, 
hair collection was found to be feasible and acceptable among men enrolled in a 
PrEP trial, and hair analysis was highly sensitive and specific for TFV exposure in 
these pa rticipants.  Correlative studies between peripheral blood mononuclear 
cells (PBMC) and hair levels and between different directly -observed dosing 
patterns and TFV hair levels are currently in progress.  
1.7 Drug Concentration Simulation Models  
In computer simul ation models, the “expected” drug concentration is based on the 
PK characteristics of the drug and the prescribed dosing regimen of the study.  To 
facilitate these simulations, PK data are available from several reports in which 
TDF (Viread®) has been admi nistered to human research participants.  From 
these studies, one can make some estimates of the effective intracellular half -life 
for tenofovir diphosphate (TFV -DP), the active moiety of the drug, which appears 
to be approximately ~150 hours.25-27  From these studies, however, the inter -
individual variability for half -life and peak concentration (C max) for TFV -DP is 
relatively large (coefficient of variation around 50% to 65%).  Accordingly, the 
best parameter estimates for such a simulation come from individual study 
participants.  To avoid intensive, frequent PK sampling, which would be 
cumbersome in a clinical trial, one can employ a combination of (1) population -
based estimates from the studies like those cited above, and (2) da ta from a few 
samples from each individual in a prospective study.  This approach substantially 
reduces inter -individual variation, while reducing logistical complexity of the 
study.  To remove the variable of adherence in estimation of individual PK 
param eter estimates, samples collected from the individuals tested should follow 
an observed dose.  With an observed dose, the possibility of variable adherence 
affecting subsequent drug concentrations is removed.  This leaves the following 
variables to conside r: inter -individual PK variability, assay variability, and 
unknown sources of noise that may vary with time in the environment.  Examples 
of simulations of the dosing strategy of TFV -DP in PBMCs and TFV in blood 
serum (Figure 1 -1) are shown below.   
 
HPTN 067, Final Version 5.0  Page 7 of 13 3 June 10 , 2013  
  
Figure 1 -1.   
Simulation of TFV -DP concentration in PBMCs (y -axis-1) and in blood serum (y -
axis-2) versus time (x -axis) anticipated with the weekly regimen planned for this 
study: TDF 300 mg weekly; note the regimen is administered as Truvada® 
(FTC/TDF).  Note the minor increase in C tau and C max between Day [ADDRESS_1024718] to the interaction of drug, parti cipant, and regimen: intra -
individual variability and dose -proportionality.  Knowledge of these variables is 
essential for planning future studies that use estimated PK parameters based on 
individual drug concentrations to evaluate adherence.  
1.[ADDRESS_1024719]: from concentrations associated with 100% adherence  down to 

HPTN 067, Final Version 5.[ADDRESS_1024720] order drug.  Very few drugs 
exhibit mixed or zero order PK in the clinically relevant concentration range ( e.g., 
aspi[INVESTIGATOR_248], phenytoin, and fluoxetine).  For these drugs, a proportional increase in 
dose results in a disproportionately large increase in concentration.  For other 
drugs, a proport ional increase in dose may result in a disproportionately small 
increase in concentration.  This can be seen in drugs with saturable absorption, 
and with drugs that are anabolized to phosphorylated forms within cells, such as 
TFV, FTC, and zidovudine (ZDV) .  For example, because phosphorylation of 
zidovudine (AZT) -monophosphate within cells is the rate -limiting step in AZT -
triphosphate anabolism, increasing the AZT dose can result in disproportionately 
small or no increase in AZT -triphosphate.  For either c ause of disproportionate 
PK, the assumption of proportionate change in adherence (as with expected and 
observed drug concentrations) becomes more complex.   
 
While the dose -proportionality for both TDF and FTC are well -established 28,[ADDRESS_1024721] be established for one to use TFV -DP or FTC -triphosphate 
(FTC -TP) as measures of adherence to a Truvada ® (FTC/TDF) regimen.   
 
Other proportionality factors are dose frequency and the accumulation of drug 
concentration with time – characteristics that are unique to each drug and dosing 
regimen.  Drugs that are dosed at intervals more frequent than their half -life 
accumulate over t ime and achieve concentrations that are higher at steady -state 
than following a single dose.  This accumulation – the so -called “accumulation 
index” or R ac – varies with the ratio of the drug half -life to dose frequency as 
follows:  
 
Rac = 1/(1 – e-k), wh ere k is the elimination rate constant [Ln(2)/half -life] 
and  is the dosing interval.   
 
The greater the drug half -life is, the greater the accumulation index.  The higher 
the accumulation index, the greater the magnitude by [CONTACT_749404] e xceed sources of noise in drug concentration assessment ( e.g., dosing time 
variation, assay variability, assay sensitivity, and inter - and intra -individual 
variability).  When measuring adherence with drug concentration, one is assessing 
the magnitude of d ifference between (1) the expected concentrations of drug at 
prescribed dosing intervals assuming 100% adherence, and (2) the actual drug 
concentrations from an unobserved dosing period.  The difference is attributed to 
less than 100% adherence.  A reducti on in adherence has the equivalent effect on 
HPTN 067, Final Version 5.0  Page 9 of 13 3 June 10 , 2013  
 concentration as a reduction in the frequency of dosing ( i.e., the concentration 
falls).  Drugs with a large accumulation index provide a greater degree of 
detectable difference between 100% adherence and lesser  adherence.  For drugs 
with little accumulation (dose frequency less than their half -life), it may be very 
difficult to discriminate the concentration associated with a single dose (without 
any prior doses) from perfect adherence.  Therefore, a participant  with poor 
adherence can appear to a have high level of adherence with a low accumulation 
index drug and drug regimen combination.  In contrast, large accumulation index 
drug and drug regimen combination is very resistant to “white -coat adherence”, in 
whic h a participant takes one or several doses within the day prior to a scheduled 
research clinic visit.   
 
Table 1 -1.  Accumulation index for parent and phosphorylated moieties of 
TDF and FTC dosed either weekly (168 hours) or daily (24 hours).  Drug 
moieties and regimens are ranked by [CONTACT_749405].  An index of 2 indicates 
a doubling of concentration at steady -state compared to a single dose.  An index 
of 1 indicates no accumulation at steady -state.  For example, the concentration 
observed with 100% adherence can look the same as no adherence if the non -
adherent participant takes a single dose prior to the observed blood collection 
when TDF, FTC or FTC/TDF are used with prescribed weekly dosing regimens.  
By [CONTACT_22242], the concentration expec ted with 100% adherence to FTC/TDF will be 
9.6 (TFV -DP) or 2.7 (FTC -TP) times the concentration observed if a participant 
has taken only a single dose prior to the scheduled observation.   
Table 1 -1.  Accumulation index for parent and phosphorylated moieti es of 
TDF and FTC dosed either weekly (168 hours) or daily (24 hours).  
Drug moiety  Half -life 
(hours)  Dosing 
interval 
(hours, 
tau) Dosing 
interval / 
half-life 
(tau/HL)  Accumulation  
index  
(Rac) 
TFV -DP 150 24 0.2 9.5 
FTC -TP 36 24 0.7 2.7 
TFV -DP 150 168 1.1 1.9 
TFV  17 24 1.4 1.6 
FTC  10 24 2.4 1.2 
FTC -TP 36 168 4.7 1.0 
TFV  17 168 9.9 1.0 
FTC  10 168 16.8 1.0 
 
For this reason, TFV -DP (the intracellular form of TFV) is an excellent candidate 
for drug adherence monitoring, especially with daily dosing (Table 1 -1).  With an 
intracellular half -life of ~[ADDRESS_1024722], TFV concentration (measured in plasma), when TDF is 
dosed daily, would be expected to perform much less well, with a small difference 
in drug accumulation at steady -state during daily dosing when compared to a 
single dose ( e.g., taken on the day of observation).  When using TDF on a weekly 
dosing regimen, there is no anticipated difference between drug concentrations of 
plasma TFV compared to taking a single dose of TDF without any prior doses.  
Contrasting the two lines in Figure [ADDRESS_1024723] one day per w eek. 
1.9 TDF and FTC drug resistance  
If HIV infection occurs during the trial, the participant may be exposed to both 
TDF and FTC before HIV infection is diagnosed.   
 
Participants will be tested for HIV infection at Screening, Enrollment, and Weeks 
4, 6, 10, 14, 18, 22, 26, 30, and 34.  HIV RNA testing will be used in addition to 
serologic testing for HIV infection if a participant has signs or symptoms 
consistent with acute (pre -seroconversion) HIV infection, or expresses a concern 
about recent HIV acquis ition.  Frequent testing for HIV acquisition during the 
study period will allow prompt cessation of study drug in an HIV -infected 
participant, minimizing the risk that resistant virus will emerge.  Recent results of 
a trial of topi[INVESTIGATOR_749313].[ADDRESS_1024724] TDF 
susceptibility.14  Even in the presence of the K65R mutation, HIV isolates are 
partially susceptible to TDF.  The K70E mutation is also associated with TDF 
resistance.  
 
High -level resistance to FTC can develop with a single mutation, M184V or I, 
within weeks with monotherapy.31  The M184V/I mutations also confer high -level 
resistance to lamivudine (3TC), and low -level resistance to abacavir (ABV) and 
didanosine (DDI), but increase susceptibility to ZDV and TDF .[ADDRESS_1024725] a 
replication capacity of 53% compared to wild -type virus; replication capacity is 
further decreased to 24% when the K65R and M184V mutations are both 
present. 14   
 
Among HIV -infected individuals treated with TDF/3TC/efavirenz (EFV) 
combinations for up to three years,32 the K65R mutation occurred in 2.7% (8/299) 
of patients and the M184V mutation occurred in 6% (18/299) of patients.  In  a 
study of treatment -naïve patients,33 patien ts received either TDF/FTC/EFV 
(n=257) or Combivir® (ZDV+3TC)/EFV (n=254) for 48 weeks.  Among the 34 
patients with virologic failure at 48 weeks, 17% (2/12) in the TDF/FTC/EFV  
group and 32% (7/22) in the Combivir/EFV group  had M184V mutations.  No 
patient s developed K65R mutations through 48 weeks of the study.  In a Phase III 
trial that involved adding TDF to a failing regimen, the K65R mutation occurred 
in 3% (n=183) of the patients receiving TDF, and the M184V mutation occurred 
in 1% of all patients on antiretroviral therapy including 3TC (n=274) by [CONTACT_10585] 
24.34  Taken together, these data indicate a substantial barrier to TDF resistance.  
Combined use of FTC/TDF may further increase the barrier to drug resistance.  
 
1.10 Rationale  
1.10.1  Justification for Intermittent PrEP  
All current PrEP trials are evaluating daily dosing of antiretroviral drugs fo r HIV 
prevention.  The daily dosing strategy was selected for prevention trials based on 
dosing intervals that are approved for treatment of HIV infection.  The hypothesis 
for this trial is that daily dosing of FTC/TDF for prevention may be excessive.  
The rationale for this hypothesis is the following:  (a) the intracellular half -lives 
of the TFV -DP and FTC -TP are ~150 hours and ~48 hours respectively, which 
provides substantial drug concentrations to be present for several days after each 
dose,  35 (b) non -human primate models indicate that dosing once a week may be 
sufficient for protection if post -exposure dosing is also used,5,13 (c) the majority 
(>80%) of individuals at high risk of HIV infection are exposed to HIV less often 
than daily, typi[INVESTIGATOR_749314] a week,36 and (d) the amount of virus 
exposing uninfected users of P rEP is substantially less than the amount of virus 
present in individuals with established HIV infection who require treatment.  
Importantly, the dosing interval for treatment has never been optimized; although 
daily dosing was found to be effective for tr eatment of HIV infection in clinical 
trials, less frequent dosing has not been evaluated for HIV treatment or 
prevention.  Doses of TDF higher than [ADDRESS_1024726], less 
frequent dosing is expected to decrease side -effects related to drug exposure.  
Lower doses of PrEP agents may diminish mild side effects, such as crampi[INVESTIGATOR_007], 
diarrhea, flatulence, headache, and dizziness, which cou ld interfere with 
adherence.  Even if these side effects are rarely severe enough to require stoppi[INVESTIGATOR_749315], they may interfere with adherence when 
taken for prophylaxis.  While current PrEP trials will assess overall rates  of 
adverse events (AE), little or no information is being obtained regarding 
interactions between drug dose, non -specific grade [ADDRESS_1024727] of the drug (Truvada®) is a major component of the total program cost of 
PrEP.  In HPTN 067, we will follow the number of pi[INVESTIGATOR_749316].  In addition, we realize that PrEP programs involve a variety of  additional 
costs ( i.e.  HIV counseling and testing) in addition to pi[INVESTIGATOR_4382] -use.  Outside of the aims 
of this study, we will collaborate with experts in this field to inform fully 
developed cost effectiveness modeling to evaluate the cost effectiveness of the  
intervention.  We will work with staff and investigators to identify differences in 
resources associated with different usage groups in all elements including 
counseling, communications, community education, drug importation, drug 
storage, drug dispensati on, drug labeling, medical evaluation, and laboratory 
testing.  
 
Further, in relation to self -administration of PrEP, there is reason to believe that 
intermittent regimens may foster higher rates of adherence if these regimens are 
perceived as being more ac ceptable, feasible, and responsive to one’s specific risk 
reduction needs.  These critical aspects of uptake and acceptability of PrEP are 
essential in preparing for the wide -scale availability of these prevention strategies 
and best supporting their disse mination and implementation, if found efficacious 
in ongoing studies.   
   
The decision about whether a larger efficacy trial of intermittent PrEP should go 
forward is, of course, speculative at this point and will involve results from the 
HPTN [ADDRESS_1024728] are:  
 Equivalency of coverage between daily PrEP and intermi ttent PrEP.  If 
coverage is significantly lower in the intermittent PrEP arm relative to the 
daily arm then this would suggest that intermittent PrEP might have lower 
efficacy for HIV prevention and should move forward only if additional 
information become s available that the missing coverage may not be 
essential for efficacy.  If coverage in the intermittent PrEP arm is equal to 
or better than the daily arm, then this would suggest that intermittent PrEP 
might have equivalent (or better) efficacy for HIV p revention;  
 Significantly decreased drug usage in the intermittent PrEP arm.  If fewer 
pi[INVESTIGATOR_749317].   
 Significantly decreased side effects i n the intermittent PrEP arm relative to 
the daily arm.  A major reason for interest in intermittent PrEP is the 
hypothesis that fewer drug doses will result in fewer side effects.   
 An efficacy trial of intermittent PrEP versus daily PrEP will be warranted  
if current trials show that daily PrEP is sufficiently effective to be 
considered as a viable HIV prevention tool.  An efficacy trial of 
intermittent PrEP versus placebo would be warranted if daily oral PrEP 
fails to demonstrate efficacy relative to place bo, and the failure of daily 
recommendations is found to be attributable to low levels of drug 
exposure that may be improved with intermittent dosing 
recommendations.  
 
Although the results of a recent trial of intermittent topi[INVESTIGATOR_749318], the converse to all of the conditions above may also occur.[ADDRESS_1024729]-exposure prophylaxis (PEP) frequently fails on an intent -to-treat basis 
because individuals fail to recognize significant exposures to HIV, or fail to 
timely initiate prophylaxis  after being exposed.[ADDRESS_1024730] 
communication with partners, lack of information, and substance use all 
contribute to failure to initiate PEP regimens.  These factors may or may not bear  
on use of intermittent PrEP regimens.  Barriers and facilitators will be fully 
characterized and are anticipated to include unintentional factors (periodic 
forgetting, challenges in prospective memory, or planning) and more internally 
HPTN 067, Final Version 5.0  Page 14 of 13 3 June 10 , 2013  
 driven factors (such  as stigma, intentional avoidance, beliefs in negative outcomes 
from pi[INVESTIGATOR_4382] -use, inaccurate information about pi[INVESTIGATOR_749319]) which will be 
generally organized by a theory -based approach to predicting actual patterns of 
pi[INVESTIGATOR_4382]-use across and within the di fferent arms (daily, time -driven, or event -driven).  
 
Event -driven dosing will require specific communication between study 
counselors and participants to promote skills in identifying antecedents of sexual 
risk in order to prepare participants for the cond itionality of taking a tablet prior to 
sexual events.  Thus, it is anticipated that participation in the event -driven arm 
may foster planning for sexual activity, and more explicit recognition of the risks 
of HIV exposure associated with sexual activity.  Such planning and recognition 
may ultimately affect partner choice, the amount and types of sexual activity, the 
patterns of PrEP use, and overall exposure to HIV.  For example, planning for 
sexual activity may include plans for using condoms, disclosure, strategic 
positioning, and other risk reduction strategies.  Pi[INVESTIGATOR_4382] -use is anticipated to be an 
integral part of this planning and thus across arms it is assumed that those in the 
event -driven arm will demonstrate a pattern of pi[INVESTIGATOR_4382] -use most consistent with 
recommendations.  Further, little is presently known about actual preferences 
from a participant or clinic staff perspective for intermittent versus daily dosing.  
End of study questionnaire items will provide information about overall 
preferences for regim ens of varying kinds, and focus group data will inform 
overall perceptions of feasibility of each regimen with qualitative data.  A subset 
of study participants and clinic staff will participate in post -study focus groups 
and key -informant interviews to un derstand the extent and reasons for the 
development of preferences for certain regimens over others.  These multiple 
sources of data will provide much needed characterization of how intermittent 
versus daily PrEP is viewed by [CONTACT_749406].   
1.10.3  Theoretical basis for postulating behavioral effects of intermittent 
dosing  
This research provides a unique opportunity for hypothesis driven, theory -based 
research on PrEP use, and risk behavior in the context of PrEP trials.  An adapted 
Information, Motivation, Behavioral skills (IMB) model of risk reduction and 
health behavior adoption is applied as an organizing explanatory framework for 
the assessment and characterization of core factors influencing both condom -use 
and PrEP use.  The IMB m odel was originally formulated primarily as a theory of 
risk reduction [ADDRESS_1024731] examinations,47 and 
antiretroviral medication adherence.41,42  
 
Essentially, the IMB model proposes that a health behavior is a function of one’s 
fund of accurate information about the behavior, one’s personal and social 
motivation towards the behavior, and one’s set of behavior al skills for 
implementing the behavior across various conditions and one’s associated self -
efficacy for doing so.  We position exploration of important aspects of self -
perception social roles and their impact on PrEP use and sexual and PrEP use 
HPTN 067, Final Version 5.0  Page 15 of 13 3 June 10 , 2013  
 behavior i n the context of PrEP as one of the factors that contribute to one’s 
overall motivation towards desired behaviors.  The core constructs and the 
structural relations among these constructs are specified such that information and 
motivation can co -vary but a re not determinants of each other; information and 
motivation both relate to behavioral skills in positive directions so that the more 
informed one is about a health behavior or the greater one’s personal and social 
motivation towards the health behavior, the greater one’s set of behavioral skills 
for implementing that behavior; one’s set of behavioral skills for implementing a 
health behavior relates directly to the implementation of the health behavior in 
question.  For behaviors that have not become over ly automated, this is a 
mediated model where the direct relations between information and behavior and 
between motivation and behavior are largely mediated by [CONTACT_749407].  
Essentially, this mediation suggests that when behaviors are difficult or com plex, 
being well informed or highly motivated is insufficient to impact on behavior if 
one’s skills in implementing that behavior over diverse situations and over time 
are not also well developed.  
 
The utility of the identified core constructs, as well as their structural relations, 
has been supported by [CONTACT_749408]41 and is the 
basis for a number of risk  reduction (condom use) intervention approaches, 
including prevention protocols for HIV -positive persons in care48 and ART 
adherence interventions.[ADDRESS_1024732] in the present study, an adapted IMB -
model to address condom -use and PrEP use specifically in the context of the 
proposed intermittent PrEP trial was developed (F igure 1 -2).  Drawing from 
previous research, as well as an interest in providing greater specificity in 
identifying and characterizing important aspects of risk reduction behavior in 
relation to PrEP use, each of the core constructs of the IMB -model were 
elaborated to the kinds of facilitators and barriers that are anticipated to be most 
influential to the adoption of PrEP across the study arms (thus resulting in risk 
event coverage via PrEP) and the kinds of information, motivation, and 
behavioral skills f or condom use in the context of PrEP that would be expected to 
predict potential changes in participants’ condom use over the course of their 
participation in the PrEP trial.   
 
Behavior -relevant information includes funds of accurate information, and also  
the extent to which participants believe common pi[INVESTIGATOR_749320].  As indicated in Figure 1 -2, where basic information about 
condoms or about PrEP, PrEP trials, and one’s assigned regimen is important, of 
equal importance is the extent to which participants believe inaccurate “facts” to 
be true (such as, ‘condoms contain HIV or other diseases,’ ‘PrEP drugs cause 
HIV,’ ‘participants are asked to leave the trial if they are not consistently adherent 
to PrEP’).  Specific to this construct, it is likely that without appropriate 
counseling support, participants in the more complex dosing arms (intermittent) 
HPTN 067, Final Version 5.[ADDRESS_1024733] greater difficulty in reaching requisite informational levels about the 
specific requirements of their regimen.  Howev er, given the comprehensive 
counseling approach adopted in this study, significant differences in accurate 
information for condom use or PrEP use are not anticipated.  Because of concerns 
that intermittent doses may be “too complicated” for individuals to negotiate over 
time, establishing a null difference in knowledge of regimen and regimen 
requirements is very important.  Also, differences in misinformation between 
arms are of interest.  
 
Behavior -relevant motivation houses a number of core subconstructs ( Figure 1 -2).  
Within this construct, personal and social beliefs and attitudes towards the 
adoption and non -adoption of the behavior are housed.  To the extent that one has 
strong positive attitudes and beliefs that adoption of the behavior will bring 
positive consequences (personal and social), and non -adoption is not viewed as 
positive, participants are expected to be in a better position to adopt the behavior 
consistently (providing requisite skills are in place).  Individuals experiencing 
personal and s ocial barriers to behavior adoption will be less apt to develop 
requisite skills or, subsequently, practice the behavior consistently.   
 
There is an emphasis on specific variables to the traditional conceptualization of 
motivation  within the IMB -model to allow for better representation of the kinds of 
attitudes and beliefs that are critical in elucidating what has been identified as risk 
compensation.  The theory of risk compensation [ADDRESS_1024734] to include detailed assessment of perceived positive 
consequences of PrEP use and of condom use (particularly in terms of potential 
changes  in condom optimism that may occur as a result of PrEP trial 
involvement) and perceived vulnerability to positive consequences of PrEP and 
condom use and negative consequences of non -use (most specifically, to HIV 
infection in unprotected events), the curr ent study will offer an examination of 
mechanisms by [CONTACT_749409].  Further, because 
of the comprehensive conceptualization of motivation adopted in the model, this 
study will be positioned to be able to speak to risk comp ensation (where 
perceived risk in the context of non -condom use would diminish through adoption 
of an alternative [PrEP use] strategy).  It is important to note, however, that the 
current study’s counseling protocol developed to support pi[INVESTIGATOR_4382] -taking and con dom 
use will not allow for a ‘naturalistic’ characterization of either of these 
phenomenon.  However, this work would build to the growing literature 
evaluating changes in risk -behavior in the context of PrEP when appropriate 
counseling is provided.[ADDRESS_1024735] demonstrated explanatory and predictive power in the field of behavioral 
economics,52-54 particularly in the context of decision -making under conditions of 
uncertainty.  Presently, lit tle is known about the role participants develop in the 
context of PrEP trials or the relation between these roles and risk -prevention 
behaviors.  The exploration of these important aspects of the “PrEP participant 
role” and their impact on PrEP use and se xual behavior in the context of PrEP is 
positioned as one of the factors that contribute to one’s overall motivation towards 
these behaviors.  Like other aspects of motivation, we anticipate that positive self -
beliefs - positive attributes one would use to  describe oneself in their role in the 
trial and as a active contributor to it (prevention activist) - will contribute to 
higher motivation towards PrEP use and condom use and that this will be more 
characteristic of participants in the intermittent than t he daily PrEP arm.   
  
The behavioral skills  construct (Figure 1 -2) includes objective and perceived 
skills in the implementation of the targeted behavior, across diverse and 
challenging circumstances, as well as one’s perceived efficacy in being able to 
implement an attained skill.  As the most proximal construct to behavior, and in 
the context of the structural relations identified by [CONTACT_749410] -model, skills carry the 
direct relation between lead -in (exogenous) constructs (information and 
motivation) and th e behavior itself (condom use, PrEP use).  Essentially, the 
IMB -model proposes that even the highly motivated and well informed will have 
difficulty adopting a behavior if they do not develop or feel comfortable using 
requisite skills to actually perform t he behavior in the situations that typi[INVESTIGATOR_749321].  For example, a woman who is well 
informed about condom use and is highly motivated to use condoms may be 
unable to consistently adopt the behavior if she does not have th e negotiation 
skills needed to convince her partner to use a condom.  A participant who requires 
privacy when taking his PrEP dose may be informed and motivated, but may lack 
the skills needed to take PrEP in privacy ( e.g., planning, use of hiding strategi es).  
To the extent that the targeted behavior becomes increasing difficult in the context 
of one’s life, skills play an increasingly large role in mediating the relation 
between the lead -in constructs and the outcome behavior.   
 
Because assigned PrEP arm  likely will require differing sets of requisite skills for 
consistent and regimen -accurate pi[INVESTIGATOR_4382] -taking, the effects of being in the intermittent 
PrEP arm on the development of and changes in certain skill -sets is of a particular 
interest.  Those assigned to the event -driven arm are asked to take a pre -exposure 
dose prior to and following a sex event.  The unique requirement of pre -exposure 
dose taking is addressed in counseling support for individuals in this arm through 
guidance in the development of sexu al ‘forecasting’ skills - skill sets for 
predicting when a potential event may occur.  Part of this prediction will involve 
exploration of one’s personal patterns of sexual behavior and risk exposures.  As 
such, it is possible that those assigned to this a rm will increase their sexual 
planning skills, as well as their abilities to clearly identify important factors in 
sexual (and prevention -related) decision making.  While all arms participating in 
risk reduction and condom adoption counseling, the repeated  cumulative 
HPTN 067, Final Version 5.0  Page 18 of 13 3 June 10 , 2013  
 exposures to forecasting risk may produce unique skills acquisition and efficacy 
in the event -driven arm.   
 
Outside of the core constructs of the adapted IMB -model, an additional set of 
‘moderating’ variables are typi[INVESTIGATOR_749322] -model s 41which include 
variables that are believed to alter, and at times attenuate IMB -model proposed 
relations.  Severe depression, ac tive substance use, or homelessness were 
identified in the IMB -model of antiretroviral medication adherence as factors that 
limit IMB -model based interventions and would require resolution before changes 
in information, motivation, or behavioral skills cou ld be promoted through 
intervention.55  The ‘moderator hypothesis’ is not adopted in the adaptation of the 
IMB -model for PrEP use.  Instead, these personal and situational variables are 
used to define the context in which PrEP use must be neg otiated, and are 
incorporated in the adherence/PrEP use counseling approach.  As indicated in 
Figure 1 -2, context variables include persistent negative mood,  perceived 
relationship with study staff and providers, disclosure of study participation to 
impor tant others, active drug/alcohol use, and personal history (education, 
participation in other trials) and are used to help to define the  psychological and 
social context in which participation in the trial, experiences of negotiating trial 
participation, and one’s PrEP -related information, motivation, and behavioral 
skills are developed, experienced, and modified.  Context variables will be 
examined to assess for unique contributions in influencing PrEP adherence and 
PrEP related information, motivation, a nd behavioral skills areas.   
 
A specific goal of this study is also to identify potential changes in other 
prevention behaviors (condom use) and, if observed, potential correlates  of 
changes in risk behavior.  If a pattern of reduced condom use is observed in the 
sample from baseline to final on -drug assessment, the data will be examined for 
attitudes, perceived vulnerability to HIV and high optimism about PrEP efficacy.   
Elucidating the relation s between depression, and perceptions of relationships and 
rapport with study team and risk behavior, as well as its core determinants, is a 
unique contribution of the present research.  While depression and substance use 
have been well demonstrated in the ir relation to risk,56-[ADDRESS_1024736] or contextualize core facilitators and barriers to one’s funds 
of information, motivation, and behavioral skills is less well understood, but 
critical in the empi[INVESTIGATOR_749323].  
 
 
HPTN 067, Final Version 5.0  Page 19 of 13 3 June 10, 2013  
  
 
 
 
INFORMATION  about  
 Goals of trial  
 PrEP  
 Specific regimen requirements (when to use, how to use)  
 Accurate information about study -drug, intentions of research, and dosing 
requirements (low  level of misinformation or faulty heuristics)  
 Condom Use  
 Where to obtain, how to use correctly, how condoms protect from STIs 
(HIV), and low funds  of accurate information  
 
MOTIVATION  
Personal Motivation  
 Ownership of study (positive beliefs of perso nal role in answering study 
question)  
 Attitudes/beliefs towards target behavior (pi[INVESTIGATOR_4382] -taking, condom use)  
 Positive consequences of pi[INVESTIGATOR_4382] -taking (condom use)  
 Perceived vulnerability (susceptibility) to positive consequences of pi[INVESTIGATOR_4382] -
taking (condom use)  
 Positi ve beliefs of regimen -daily life fit (condom use -daily life fit)  
 Lower negative consequences of pi[INVESTIGATOR_4382] -taking (condom use)  
 Ownership of regimen (positive beliefs that regimen is responsive to one’s 
personal patterns of risk), condom use adoption (positive beliefs that 
condoms are well matched to one’s personal patterns of risk)  
Social Motivation  
 Commitment to goals of study at community (MSM, WSM) level  
 Perceived role in study (activist vs.  patient role)  
 Attitudes/beliefs that others support behavior (pi[INVESTIGATOR_4382] -taking, condom use)  
 Positive attitudes/beliefs about pi[INVESTIGATOR_4382] -taking (condom use) as a ‘social’ 
contribution  
 Lower levels of attributions of pi[INVESTIGATOR_4382] -taking (condom use) as being done or 
maintained for “others”  
BEHAVIORAL SKILLS  
PrEP -specific objective and perc eived skills and 
confidence in:  
 Pi[INVESTIGATOR_4382]-taking in diverse situations  
 Requiring privacy  
 When schedule changes  
 When feeling depressed, hung -over, anxious  
 Over time  
 When not sexually active  
 Following regimen requirements  
 Planning for sex  
 Pre-exposure pi[INVESTIGATOR_4382] -use 
 Post-exposure pi[INVESTIGATOR_4382] -use 
 Management of potential side -effects  
 Remembering dose -times or pre/post dose  
 Organizing pi[INVESTIGATOR_4382] -taking  
 Managing social consequences (real or 
perceived) of study participation  
Condom use -specific objective and perceived skills 
and confiden ce in appropriate (correct) condom 
use:  
 In diverse situations/contexts  
 With steady partner(s)  
 In casual sex or sex for barter or money  
 With partners preferring not to use a condom 
(skills in negotiation of use)  
 When feeling depressed, anxious, stressed  
 In the context of drugs or alcohol  
 Over time  
 Continued use of condoms in ongoing sexual 
relationships  
 
 
 
BEHAVIOR  
COVERAGE  
(PI[INVESTIGATOR_93601] -TAKING at 
rates that 
provide high 
coverage of risk 
events)  
RATES  OF PI[INVESTIGATOR_93601] -
TAKING as 
recommended  
CONDOM USE 
(continued or 
changes  in) 
 
 
CONTEXT VARIABLES  (variables that may influence levels of motivation and relations between information, motivation, behavioral skills and outco mes)  
 Persistent Negative Mood States ( e.g., depression); Persistent Positive Mood States ( e.g., optimism ) 
 Perceived relationship with clinic providers and study staff  
 Disclosure of study participation to important others  
 Demography (income, education, previous participation in HIV prevention studies, close contact [CONTACT_749411]) a nd active alcohol or drug use  
 Figure 1 -2: Adapted IMB -model of PrEP and Condom Use  
INFORMATION  about  
 Goals of trial  
 PrEP  
 Specific regimen requirements (when to use, how to use)  
 Accurate  information about study -drug, intentions of research, and dosing 
requirements (low level of misinformation or faulty heuristics)  
 Condom Use  
 Where to obtain, how to use correctly, how condoms protect from STIs 
(HIV), and low funds  of accurate information  
MOTIVATION  
Personal Motivation  
 Ownership of study (positive beliefs of personal role in answering study 
question)  
 Attitudes/beliefs towards target behavior (pi[INVESTIGATOR_4382] -taking, condom use)  
 Positive consequences of pi[INVESTIGATOR_4382] -taking (condom use)  
 Perceived vulnerability (susceptibility) to positive consequences of pi[INVESTIGATOR_4382] -
taking (condom use)  
 Positive beliefs of regimen -daily life fit (condom use -daily life fit)  
 Lower negative consequences of pi[INVESTIGATOR_4382] -taking (condom use)  
 Ownership of regimen (positive beliefs that r egimen is responsive to one’s 
personal patterns of risk), condom use adoption (positive beliefs that 
condoms are well matched to one’s personal patterns of risk)  
Social Motivation  
 Commitment to goals of study at community (MSM/TGW, WSM) level  
 Perceived rol e in study (activist vs.  patient role)  
 Attitudes/beliefs that others support behavior (pi[INVESTIGATOR_4382] -taking, condom use)  
 Positive attitudes/beliefs about pi[INVESTIGATOR_4382] -taking (condom use) as a ‘social’ 
contribution  
 Lower levels of attributions of pi[INVESTIGATOR_4382] -taking (condom use) a s being done or 
maintained for “others”  
BEHAVIORAL SKILLS  
PrEP -specific objective and perceived skills and 
confidence in:  
 Pi[INVESTIGATOR_4382]-taking in diverse situations  
 Requiring privacy  
 When schedule changes  
 When feeling depressed, hung -over, anxious  
 Over time  
 When not sexually active  
 Following regimen requirements  
 Planning for sex  
 Pre-exposure pi[INVESTIGATOR_4382] -use 
 Post -exposure pi[INVESTIGATOR_4382] -use 
 Management of potential side -effects  
 Remembering dose -times or pre/post dose  
 Organizing pi[INVESTIGATOR_4382] -taking  
 Managing social consequences (real or 
perceived) of study participation  
Condom use -specific objective and perceived skills 
and confidence in appropriate (correct) condom 
use:  
 In diverse situations/contexts  
 With steady partner(s)  
 In casual sex or sex for barter or money  
 With partners preferring  not to use a condom 
(skills in negotiation of use)  
 When feeling depressed, anxious, stressed  
 In the context of drugs or alcohol  
 Over time  
 Continued use of condoms in ongoing sexual 
relationships  
BEHAVIOR  
COVERAGE  
(PI[INVESTIGATOR_93601] -TAKING at 
rates that 
provide high 
coverage of risk 
events)  
RATES  OF PI[INVESTIGATOR_93601] -
TAKING as 
recommended  
CONDOM USE 
(continued or 
changes in)  
CONTEXT VARIABLES  (variables that may influence levels of motivation and relations between information, motivation, behavioral skills and outco mes)  
 Persistent Negative Mood States ( e.g., depression)  
 Perceived relationship with clinic providers and study staff  
 Disclosure of study participation to important others  
 Demography (income, education, previous participation in HIV prevention studies, close contact [CONTACT_749411]) and active alcohol or drug use  
HPTN 067, Final Version 5.[ADDRESS_1024737] microbicide trial was 
96%, adherence utilizing an objective measure of applicator use was only 44%.[ADDRESS_1024738] 
long intracellu lar half -lives (48 and 150 hours, respectively) such that 
measurements made using specimens collected at clinic visits will reflect pi[INVESTIGATOR_4382] -use 
over the previous days to weeks.  Such measures of long term drug exposure are 
less influenced by “white coat” ef fects, where pi[INVESTIGATOR_749324].  The relationship between drug level and pi[INVESTIGATOR_4382] -
use is complicated by [CONTACT_749412], distribution, and 
clearance of drugs.   
 
In this study, th e relationships between drug exposure and pi[INVESTIGATOR_4382] -taking will be 
calibrated for each participant during a lead -in phase including DOT.  In this 
manner, the study will have an objective measure of pi[INVESTIGATOR_4382] -use and over -reporting of 
pi[INVESTIGATOR_4382]-use for Weeks 10, [ADDRESS_1024739] discontinued all pi[INVESTIGATOR_4382] -use despi[INVESTIGATOR_749325], and to identify the 
extent of over -reporting of pi[INVESTIGATOR_4382] -use in the  three usage groups for the weeks prior to 
these evaluation periods.  Recommendations for intermittent use may be 
associated with less over -reporting of pi[INVESTIGATOR_4382] -taking because intermittent regimens 
require more thoughtful behavior; therefore, social expectati ons for pi[INVESTIGATOR_4382] -use may 
be less.  HPTN [ADDRESS_1024740] a non -inferiority design if daily oral TDF/FTV 
PrEP  were found to be superior to standard interventions in current trials.  
Alternatively, if daily dosing is not found to be efficacious in current trials 
because of dose -related intolerance or poor adherence related to pi[INVESTIGATOR_13551], the 
future efficacy study  would have a superiority design versus standard of care, 
which would remain no use of PrEP.  
 
Regardless of eventual design, a future efficacy study of intermittent PrEP 
requires guidance in terms of patterns of pi[INVESTIGATOR_4382] -taking adherence and a strong signal 
for acceptability and feasibility within the targeted participant groups.  HPTN 067 
will assess the feasibility of different intermittent dosing strategies, identify 
theory -based determinants of sexual and pi[INVESTIGATOR_4382] -taking behavior during PrEP use, 
maintain cohor ts of participants interested in intermittent PrEP, and build 
HPTN 067, Final Version 5.0  Page 22 of 13 3 June 10 , 2013  
 interagency infrastructure that is essential for efficacy evaluation, regardless of 
whether it utilizes superiority or non -inferiority designs.  Because nearly 20,000 
people are expected to fini sh PrEP trials in the next three years, there would be 
ample opportunity to fully power a non -inferiority study of daily versus 
intermittent PrEP.  This study would develop the information, collaborative 
relationships, and infrastructure required to develo p the next generation of PrEP 
research and program development.  
2.0 STUDY OBJECTIVES AND  DESIGN  
2.1 Primary Objective:  
To test the hypothesis that recommending intermittent (non -daily) usage of oral 
FTC/TDF chemoprophylaxis, compared with recommending dail y usage, will be 
associated with:  
 Equivalent coverage of sex events with pre - and post -exposure dosing  
 Lower number of pi[INVESTIGATOR_749326]  
 Decreased self -reported symptoms/side effects (both severity and 
frequency) during 24 wee ks of self -administered use  
2.2 Secondary Objectives:  
 Develop objective measures of drug exposure by [CONTACT_749401] -
dose “trough” drug concentration in several biological matrices for 
participants during a lead -in period of weekly DOT  
 To desc ribe safety outcomes among PrEP users including adverse events 
among all participants and drug resistance and plasma HIV RNA levels 
among participants who seroconvert  
 Assess differences between arms in the acceptability of different PrEP 
regimens and in pe rceptions of advantages and disadvantages of different 
regimens  
 Assess differences by [CONTACT_749402]  
 Evaluate the potential influence of PrEP usage on changes in sexual behavior, 
planning for sex, prediction of risky situations, and recognition of possi ble 
HIV exposure from baseline to final on -drug assessment in relation to PrEP 
optimism  
2.3 Study Design  
HPTN 067 is a Phase II randomized open -label clinical trial of oral FTC/TDF 
PrEP among HIV -uninfected men who have sex with men (MSM) , transgender 
wome n, (TGW)  and women who have sex with men (WSM) at high risk of 
acquiring HIV infection.  The study includes a six weeks lead -in period including 
DOT at Enrollment and Weeks 1 through 4, followed by [CONTACT_749413].  This will provide the 
opportunity to create a pharmacokinetic analysis of drug levels to be expected at 
given rates of intake (adherence) which will be analyzed as part of the secondary 
HPTN 067, Final Version 5.0  Page 23 of 13 3 June 10 , 2013  
 analysis to confirm self -reported data.  Partici pants will then (at Week 6) be 
randomized to one of three dosage groups in a 1:1:1 ratio: daily dosing, time -
driven dosing, and event -driven dosing.  After randomization, participants will 
complete a 24 -week period of self -administered dosing, with one vis it four weeks 
after the completion of dosing (34 weeks total).  Participants who acquire HIV 
infection during the study will discontinue dosing and will be followed until study 
closure and referred for post -trial care as per local regulations.  A subset of  study 
participants in each of the study arms (convenience sample) and clinic staff will 
also participate in a qualitative evaluation of the social and behavioral aspects of 
differing dosing strategies, to include focus groups and key informant interviews 
after Week 34.  
2.4 Description of the intervention  
2.4.1  Once -a-week directly observed dosing lead -in component  
A six week lead -in period consisting of DOT at Enrollment and Weeks 1 through 
4, followed by [CONTACT_749414] s teady -state drug 
levels and accumulation and decay constants for each individual.  The purpose of 
obtaining these estimates is to interpret adherence measurements during the 
subsequent self -administered dosing phase of the study.  During the DOT phase, 
all participants will begin the study by [CONTACT_749415] 5.  During this period, participants will begin learning how to use 
the EDM device prior to beginning the self -administered phase.  At Enrollment 
through Week 4, partic ipants will receive one directly observed dose per week of 
oral FTC/TDF (five doses total).  No drug will be administered during Week 5.  
PBMC specimens will be collected for analyses of drug levels at Weeks 4 and 5.  
These values will be used to estimate the accumulation and decay constants and 
steady state levels of TFV -DP; FTC -TP may also be measured. DBS samples will 
also be collected at one study site for exploratory studies of these analytes in  
whole blood  RBCs .  Blood samples should be collected prio r to dosing.  Plasma 
and hair samples will also be collected prior to dosing and stored at selected study 
visits, which may be used for comparison of PBMC drug levels to drug levels in 
those samples.  These concentrations will be evaluated to test for stea dy-state and 
the “expected” pre -dose concentration for each individual.  Week 4 and Week 5 
data (Week 5 alone if steady -state has not been achieved) will provide a point 
estimate for the expected concentration at steady -state and an estimate of intra -
indiv idual variability in this pre -dose concentration.  Decay will be monitored 
from drug dose concentration data collected at Week 6.  The Study Specific 
Procedures (SSP) Manual will detail acceptable windows for the DOT phase.  
2.4.2  Self-administered dosing c omponent  
After the 6 -week lead -in period including DOT (Enrollment and Weeks 1 through 
4 followed by [CONTACT_749416] 5), participants will be randomly assigned to one 
of three unblinded PrEP usage groups at Week 6: (1) daily usage, (2) time -driven 
usage, and (3) event -driven usage, as described in the Schema.  Individuals will 
participate in theory -based, participant -centered, individual, brief (10 -15 minutes) 
HPTN 067, Final Version 5.0  Page 24 of 13 3 June 10 , 2013  
 counseling sessions optimized for each usage plan at study visits.  This counseling 
approach will  draw from well -established models ( e.g., motivational 
interviewing) and will be based on the IMB model adapted for this research.  This 
counseling will also be informed by [CONTACT_749417] e to antiretroviral therapy (ART).61,62  
 
The adherence support counseling approach used in this protocol, entitled “Next 
Step Counseling”, includes structural, cultural, and personal facilitators and 
barriers to daily, time -driven, and event -driven pi[INVESTIGATOR_4382] -use.  This counseling 
approach seeks to tar get and address adherence -related information, motivation, 
and behavioral skills required to produce optimal rates of adherence.  For 
different arms, the information and skills targeted differ slightly in content 
particularly in early sessions.  All partic ipants will receive regimen -specific 
information during their first counseling session, which will vary between but not 
within the study arms.  Information regarding the mechanisms of FTC/TDF  for 
potential HIV -prevention will be standardized across the arm s, but the added 
messaging that focuses on how one’s specific assigned regimen provides 
protection against infection will be arm (regimen) specific. All participants will be 
counseled about the risks and benefits of PrEP and it will be emphasized that the 
efficacy of intermittent dosing has not been established. Therefore participants 
will be educated about the necessity to use condoms from start to finish of every 
sexual intercourse. Condoms and lubricant will be provided by [CONTACT_30107], as 
appropriate.  
 
Additionally, messaging for preparatory skills needed for one’s specific regimen 
schedule will be explored.  For the daily arm, this exploration includes review of 
commonly used strategies for daily pi[INVESTIGATOR_4382] -taking ( e.g., dose timing, matching dose 
with daily ev ent).  For the time -driven arm, strategies to remember dose -taking 
twice weekly, ways to identify risk events requiring a post exposure dose, and 
‘rules of thumb’ for when a post -exposure dose replaces a weekly dose or a 
weekly dose replaces a post -exposur e dose will be discussed.  For the event 
driven arm, strategies for sexual forecasting, those strategies discussed with the 
time driven arm for post -exposure and ‘rules of thumb’ for not exceeding 
recommended doses per week will be discussed.  These issues  will be re -visited as 
needed at subsequent sessions.   
 
All remaining aspects of the semi -structured counseling approach to support PrEP 
use will be administered identically to participants through targeted discussions of 
pi[INVESTIGATOR_4382]-taking at each study visit.  The exact content and strategies identified in each 
counseling session are individually targeted and tailored, thus the approach is 
intended to have the flexibility to identify and address specific strengths and 
weaknesses in integrating pi[INVESTIGATOR_4382] -taking into the ecology of one’s daily life, which 
will vary at the level of the individual participant.  While the content intentionally 
varies by [CONTACT_4317], the discussion process of the pi[INVESTIGATOR_4382] -taking is standardized 
across participants and all arms.  Exceptions, p reviously noted, are in first session 
in terms of information -delivery and the identification and exploration of 
regimen -specific skills.   
HPTN 067, Final Version 5.[ADDRESS_1024741] themselves in other ways, 
including using condoms during intercourse.  All groups will be informed that 
missed doses should be taken when the person remembers, but no more than two 
pi[INVESTIGATOR_749327] 24 -hour period, or seven pi[INVESTIGATOR_749328] .  
Counseling at each study visit will target increasing the perceived ease of pi[INVESTIGATOR_4382] -
taking and decreasing perceived burden of pi[INVESTIGATOR_4382] -taking, utilizing various client -
centered, motivational interviewing and motivation enhancement strategies.  All 
participants i n each arm will receive identical counseling, although the 
informational content pertinent to pi[INVESTIGATOR_4382] -taking regimen will vary by [INVESTIGATOR_216], as will the 
relative weight of specific skills ( e.g., sexual planning skills development).  All 
participants will receive a sufficient supply of study medication to last until the 
next scheduled visit, accompanied by [CONTACT_749418][INVESTIGATOR_749329] -use.   
 
If individuals in the time - and event -driven arms are having sex frequently and 
taking the pi[INVESTIGATOR_749330], they could end up taking the pi[INVESTIGATOR_36832].  
Although preliminary research has indicated that this behavior is likely to be rare, 
the counseling and behavioral strategies that lead to daily use would remain 
distinct, as d escribed above.  As the participants in the time -driven arms will be 
encouraged to think about possible exposure to HIV in the context of pi[INVESTIGATOR_82959], 
while the participant in daily arms will be encouraged to build pi[INVESTIGATOR_749331].  Migrati on and preferences between arms will be monitored in this 
trial.  In practice, there will undoubtedly be considerable variation in sexual 
frequency in the persons enrolled in this study and understanding the advantages 
and disadvantages of time -driven and event -driven usage strategies across the 
spectrum of sexual activity will be possible.   
 
During this period of self -administered PrEP, participants will be asked to take 
pi[INVESTIGATOR_749332]/case.  The EDM cases electronically transmit the 
date and time of all case openings to a central server, which is then distributed to 
the interviewers conducting the weekly telephone -based assessments of pi[INVESTIGATOR_4382] -
taking and risk behavior.  To assess pi[INVESTIGATOR_4382] -taking, the EDM -collected data will serve 
as a prompt for i nterviewers to query participants.  For each case opening, the 
participant will be asked to describe what happened (number of pi[INVESTIGATOR_749333] (which could be zero if the case was opened with no release of tablets) 
and what happened with each disp ensed tablet (taken or not taken; time/day of 
consumption if taken).  After assessing the outcomes associated with each 
documented case -opening, participants will be asked if they had any additional 
pi[INVESTIGATOR_4382]-events that were not discussed to capture pi[INVESTIGATOR_749334].  Pi[INVESTIGATOR_4382] -taking assessment will be followed by 
[CONTACT_749419] (day/time and type of event) using a timeline follow -
HPTN 067, Final Version 5.0  Page 26 of 13 3 June 10 , 2013  
 back approach, when needed or when time intervals assessed extend beyond one 
week .   
 
Because the current assessment of adherence to PrEP regimens requires the 
collection of highly specific sexual and pi[INVESTIGATOR_4382] -taking behaviors ( e.g., time of sex 
events and times of pi[INVESTIGATOR_4382] -taking), retrospective recall of events and pi[INVESTIGATOR_4382] -taking in 
traditional  one-month or three -month intervals is likely to prohibit the collection 
of the information needed with a reasonable degree of accuracy.  Recent work 
suggests that shorter recall intervals produce more accurate reports of risk 
behavior,63 while daily telephone based (as well as electronic diary and web -based 
diary) assessments have a well demonstrated history.64-67  To balance potential 
sensitization with need for accurate recall, a weekly schedule of telephone -based 
interviews will provide the main vehicle for collection of time and type of sexual 
events, as well as determination of outcomes for each EDM recorded device 
opening.  Telephone interviewers will be trained in neutral assessment 
approaches, with careful  messaging to participants at each call providing 
permission statements and normalization of reporting “risk” events and missed 
pi[INVESTIGATOR_749335] -presentation bias.  Additionally, interviewers will be trained in 
techniques for participants who have diff iculty in recalling events and for use 
when the assessment interval has for whatever reason extended beyond 
approximately the past week.  To assist participants in recall, items such as sexual 
behavior journals and small diary cards will be created for the  purposes of the 
current research and offered to participants for use, although they are not required.  
Participants opting to use these memory aids will be asked to use them when 
conversing with the interviewer on weekly calls.   
 
The data collected via t hese weekly interviews will be used to adjust the EDM -
collected data to produce a continuous measurement of pi[INVESTIGATOR_4382] -taking throughout 
participation in this phase of the project.  These data will also be used to produce 
the longitudinal assessment of risk (con dom use or non -use).  The adjusted EDM 
data and risk behavior data will be combined to calculate PrEP coverage of risk 
events.  Specifically, a sex act will be considered “covered” if at least one pi[INVESTIGATOR_749336] 4 days (96 hours) before the act a nd at least one additional pi[INVESTIGATOR_749337] [ADDRESS_1024742].  See Section 7.2.1 for further details.  
[IP_ADDRESS]  Daily usage  
Those randomized to the daily dosing group will receive recommendations to take 
FTC/TDF  once a day regardless of sexual acti vity.  Details regarding pi[INVESTIGATOR_4382] -taking 
counseling will be provided in the counseling manual.   
 
[IP_ADDRESS] Time -driven usage  
Those randomized to the time -driven dosing group will be asked to take 
FTC/TDF twice weekly with a post -exposure boost.  Specifically, t hey will 
receive recommendations to take one pi[INVESTIGATOR_749338], three to four days 
apart, regardless of sexual activity.  In addition, they will be instructed to take a 
post-exposure booster dose within two hours after sexual intercourse, defined as 
HPTN 067, Final Version 5.[ADDRESS_1024743] will also count as one of the twice -weekly doses if it 
occurs on the prescribed day.  Pi[INVESTIGATOR_4382] -taking counseling in the time -driven arm will 
be the same as in the daily arm, with adjustments in education provided for the 
recommended regimen ( e.g., additional information pertaining to booster doses).   
[IP_ADDRESS]  Event -driven usage  
Those randomized to the event -driven dosing group will be asked to take one 
tablet of FTC/TDF, preferably between [ADDRESS_1024744] that occurs up to 48 hours 
later.  Pi[INVESTIGATOR_4382]-taking counseling in the event -driven arm will be the same as in the 
daily arm, with adjustments in education and skills -building provided for the 
recommended regimen ( e.g., additional information pertaining to booster doses 
and pre -exposure doses, and skills development in forecasting sexual exposures to 
facilitate appropriate pre -event dose taking).   
3.0 STUDY POPULATION  
The study will enroll 540 evaluable HIV -uninfected v olunteers: 180 MSM /TGW at the 
CDC TUC Silom Community Clinic in Bangkok, Thailand, 180 MSM /TGW at the 
Harlem Prevention Center  in [LOCATION_001], [LOCATION_003] and 180 WSM at Emavundleni Centre, 
The Desmond Tutu HIV Foundation in Cape Town, South Africa.  Transgender women  
(male -to-female transgender or TGW) are at higher risk of HIV infection (10.5% in 
Thailand based on unpublished data from 2010, Bureau of Epi[INVESTIGATOR_623], Ministry of 
Public Health).  The route of the HIV infection in this population can be from both anal 
and neovaginal sex (see definition below under section 3.1.1) as some transgender 
women stop anal intercourse after gender reassignment surgery.  The TGW population 
exhibits similar risk behavior and closely interacts with their MSM counterpart 
population th erefore including them in this protocol could extend the coverage and 
benefit of this study to the whole MSM/TGW community. The efficacy of oral Truvada 
PrEPhas been demonstrated for vaginal, penile and anal exposure to HIV; separate 
assessment of efficacy  for neovaginal exposure is not currently planned.  
 
Participants will be selected for the study according to the criteria in Sections 3.1 and 3.2 
(and the guidelines in Section 3.4).  They will be recruited as described in Section 3.3 
(and assigned to a study treatment group as described in Section 7.4).  I ssues related to 
participant retention and withdrawal from the study are described in Sections 3.5 and 3.6, 
respectively.  
HPTN 067, Final Version 5.0  Page 28 of 13 3 June 10 , 2013  
 3.1 Inclusion Criteria  
 At least 18 years old  
 Literacy in one of the study languages (Thai, Xhosa and/or English)  
 Able to provide writ ten informed consent  
 Able to provide weekly telephonic updates  
 Within 70 days of Enrollment:  
o serum creatinine < upper limit of normal (ULN) and calculated 
creatinine clearance of at least 70 mL/min by [CONTACT_16424] -Gault 
formula where:  
 eCcr (female) in mL/min = [(140 – age in years) x (lean 
body weight in kg) x 0.85] / (72 x serum creatinine in 
mg/dL)  
 eCcr (male) in mL/min =  [(140 – age in years) x (lean 
body weight in kg)] / (72 x serum creatinine in mg/dL)  
o Serum phosphate > the lower limit of normal ( LLN)  
o Alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) < [ADDRESS_1024745]  
o Hemoglobin > 10 g/dL  
o Hepatitis B surface antigen (HBsAg) negative  
o Willing and able to provide adequate locator information.   
 
Note: Participants without HBV immunity at screening will be offered vaccination as 
indicated in Section 5.1.   
3.1.1  MSM /TGW 
 Male at birth  
 Reporting anal and/or  receptive  neovaginal intercourse * with at least one man  
or transgender woman  in the past six m onths  
 One or more of the following risk factors for HIV acquisition in the past six 
months according to self -report:  
 Sexual intercourse with more than one man or transgender woman  
 History of an acute sexually transmitted infection (STI)  
 Sex in exchange for money, goods or favors  
 Condomless intercourse (oral, anal , vaginal  or neovaginal ) with a partner 
known to be HIV -infected or of unknown HIV infection status according 
to self -report  
 
*The neo vagina is the surgically constructed organ that has been made  to look like a 
female vaginal sex organ.  It usually involves the removal of the male sex organ (penis) 
and surgically constructing a vagina.  The procedure is formally termed neovaginoplasty 
or se xual reassignment surgery (SRS)  in cases when a vagina did  not previously exist.   
Receptive n eovaginal sex is the act of a male  putting a penis into  a transgender female 's 
neovagina.  
HPTN 067, Final Version 5.0  Page 29 of 13 3 June 10 , 2013  
 3.1.2  WSM  
 Female at birth or self identify as female  
 Not pregnant or breastfeeding  
 Not able or intending to become pregnant during the next year   
 If able to become pregnant, self reported use of an effective method of 
contraception at Enrollment, and intending to use an effective method for the 
next 34 weeks (refer to Section 4.6 for ef fective methods of contraception)  
 One or more of the following risk factors for HIV acquisition in the past six 
months according to self report:  
 Sexual intercourse with more than one man  
 History of an acute STI  
 Sex in exchange for money, goods or favors  
 Condomless intercourse (oral, anal or vaginal) with a partner known to be 
HIV-infected or of unknown HIV infection status  
3.2 Exclusion Criteria  
 Proteinuria 2+ or greater at screening  
 Glucosuria 2+ or greater at screening  
 Serious and active medical or mental  illness  
 One or both HIV rapid tests is reactive at Screening or Enrollment, regardless 
of subsequent HIV diagnostic test results  
 Signs or symptoms suggestive of acute HIV infection  
 Use of hypoglycemic agents for diabetes or agents with known nephrotoxic 
potential  
 Use of ARV therapy (e.g., for PEP or PrEP) in the 90 days prior to study entry  
 Serum phosphate level below site laboratory LLN (lower limit of normal)  
 Current participation (or participation within three months of screening) in 
any HIV prevention  study.   
 Previous or current participation in the active arm of an HIV vaccine trial.   
 Acute or chronic HBV infection * 
 Participant has a psychological or social condition or an addictive disorder 
that would preclude compliance with the protocol  
 Any other  reason or condition that in the opi[INVESTIGATOR_749339], complicate interpretation of study outcome data, 
or otherwise interfere with achieving the study objectives  
 
* Refers to chronic active HBV infection evidenced  by a positive test for hepatitis 
B surface antigen (HBsAg).  
3.2.1  Vulnerable Populations  
Persons under the age of 18 years of age will not be included since the effects of 
antiretroviral therapy on physical development and other growth parameters (e.g., 
effects on bone growth and bone mineral density) in HIV uninfected children and 
HPTN 067, Final Version 5.[ADDRESS_1024746] with prisoners and confidentiality could not be guaranteed.  
 
Pregnant women will not be included or will be discontinued from study drug 
because of the potential risks to the fetus if the m other is taking Truvada®.  
Persons with mental disabilities may be included; however any person who 
cannot provide informed consent will be excluded from participation in the 
project.  Staff conducting enrollment will be trained to identify participants wh o 
cannot provide informed consent . These persons will be given the opportunity to 
reschedule their enrollment appointment as appropriate.  All participants will be 
afforded the same protections.  
3.[ADDRESS_1024747] (IRB) -approved media advertisements, telephone 
scripts, and fliers may be used by [CONTACT_749420], open 
houses, and public events.  
 
MSM /TGW will be recruited from  both the Bangkok MSM Cohort study, an 
ongoing prospective study of HIV infec tion among 1,000 HIV negative 
MSM /TGW at the Silom Community Clinic  and from their voluntary counseling 
and testing (VCT) population.  
 
The community education and recruitment team located at the Emavundleni 
Centre will use their extensive networks in the N yanga District to recruit WSM to 
this study.  They will also utilize the IRB -approved pre -screening protocol at the 
Emavundleni Centre to locate potential recruits who will be invited to participate.  
 
Harlem Prevention Center CRS’ recruitment strategy will combine community -
based outreach, referral from other current and past studies conducted at the CRS, 
and venue -based outreach.  Study staff will meet with stakeholders and 
community members to develop  a comprehensive educational and recruitment 
strategy that is responsive to community needs and concerns.  The resulting 
strategy will be used to create study -specific media advertisements, telephone 
HPTN 067, Final Version 5.[ADDRESS_1024748] (IRB).   IRB -approved materials will 
be used to inform community members, stakeholders, community -based 
organizations, medical providers and potential participants about the study and to 
identify MSM /TGW who may be eligible for study participation.  Harlem site 
staff will collaborate with partner organizations based in [LOCATION_001] City’s diverse 
MSM /TGW communities to engage and recruit study participants.  Interested 
participants from completed  studies at the CRS who have given permission to be 
contact[CONTACT_749421] 067 for prescreening. Similarly, targeted 
venue -based recruitment will be focused on engaging Black and Latino 
MSM /TGW of color, as well as other groups, in HPTN 067. 
 
3.4 Co-Enrollment Guidelines  
Study participants may not enroll in other HIV vaccine or interventional 
prevention trials to reduce participant burden with study visits, to facilitate high 
levels of adherence and retention (including compliance with study med ications), 
to avoid potential unblinding of HIV vaccine trials, and to avoid confounding in 
the interpretation of the primary and secondary endpoint data.  
3.5 Participant Retention  
Once a participant enrolls in this study, the study site will make every ef fort to 
retain him/her for [ADDRESS_1024749] 90% retention at Week 34 (from 
randomization).  Stud y site staff are responsible for developi[INVESTIGATOR_749340] (SOPs) to target this goal.  Components of 
such procedures will include:  
 
 Thorough explanation of the study visit schedule and procedural requirements 
during t he informed consent process and re -emphasis at each study visit  
 Thorough explanation of the importance of all three study treatment groups to 
the overall success of the study  
 Collection of detailed locator information at the Screening visit, and active 
review and updating of this information at each subsequent visit  
 Use of mappi[INVESTIGATOR_749341]  
 Use of appropriate and timely visit reminder mechanisms  
 Immediate and multifaceted follow -up on missed visits  
 Mobilization of trained outreach workers or “tracers” to complete in -person 
contact [CONTACT_749422], other community locations, and 
friends and family  
 Regular communication with the study community at large to increase 
awareness about HIV/AIDS and explain the purpose of HIV prevention 
research and the importance of completing research study visits  
HPTN 067, Final Version 5.[ADDRESS_1024750] their safety and/or if 
they are unwilling or unable to comply with required study procedures after 
consultation with the Protocol Chai r, Division of AIDS (DAIDS) Medical Officer, 
Statistical and Data Management Center (SDMC) Protocol Statistician, and 
Coordinating and Operations Center  (CORE) Protocol Specialist.  Participants 
who withdraw prior to Randomization/Week [ADDRESS_1024751] in continuing.  
Participants who report intentional overdosage of drug (more than 1 tablet in 2 
hours, more than  2 tablets in 24 hours, or more than 7 tablets in 7 days) should 
receive repeated counseling regarding pi[INVESTIGATOR_4382] -use and study medication should be 
withheld in consultation with the Protocol Safety Review Team (PSRT) if 
overdosage is deemed likely to occur agai n despi[INVESTIGATOR_749342].   
 
Participants may be withdrawn if the study sponsor, government or regulatory 
authorities, [including the Office of Human Research Protection (OHRP) and the 
US FDA] or site IRBs/Ethics Committees (ECs) terminate the study p rior to its 
planned end date.   
 
Every reasonable effort will be made to complete a final evaluation (as described 
in Section 5. 6) of participants who terminate from the study prior to Week 30, and 
study staff will record the reason(s) for all withdrawals from the study in 
participants’ study records.  
4.0 STUDY DRUG/INTERVENT ION  
4.1 Study Drug/Intervention Formulation/Content  
FTC/TDF is a fixed dose combination tablet containing 200 mg of FTC and 300 
mg of TDF. It is available as Truvada®, a medication appr oved by [CONTACT_941] U.S. FDA 
for treatment and prevention of HIV -1 infection.68  Further information on 
Truvada® is available in the current package insert.68 
4.2 Study Drug/Intervention Regimen(s) and Administration  
After the 6 -week lead -in period including DOT, participants will be randomly 
assigned  to one of three unblinded PrEP usage groups of oral therapy:  (1) daily 
usage, (2) time -driven usage, and (3) event -driven usage.  During this period of 
HPTN 067, Final Version 5.0  Page 33 of 13 3 June 10 , 2013  
 self-administered therapy, FTC/TDF tablets will be dispensed in an EDM device 
as outlined in the Study  Specific Procedures.  
 
Daily Dosing  
Those randomized to the daily dosing group will receive recommendations to take 
one FTC/TDF tablet once a day with or without food regardless of sexual activity.   
 
Time -Driven Dosing  
Those randomized to the time -driven dosing group will be asked to take one 
FTC/TDF tablet twice weekly with or without food with a post -exposure boost.  
Specifically, they will receive recommendations to take one tablet two days per 
week, three to four days apart, regardless of sexual activi ty.  In addition, they will 
be instructed to take a post -exposure booster dose of one tablet within two hours 
after sexual intercourse, defined as any penile intromission, whether oral, vaginal, 
or anal, and whether or not condoms were used.  The post -expo sure dose should 
be taken after the first penile insertive sex and not repeated if there are multiple 
penile intromissions in a day.  The post -exposure boost will also count as one of 
the twice -weekly doses if it occurs on the prescribed day.  
 
Event -Driven  Dosing  
Those randomized to the event -driven dosing group will be asked to take one 
tablet of FTC/TDF with or without food, preferably between [ADDRESS_1024752] will also count as a pre -exposure dose for sex that occurs up to 48 
hours later.  
 
Note: For all arms, no more than two tablets  per 24 -hour period, or seven tablets  
per week sh ould ever be taken.   
4.3 Study Drug/Intervention Supply and Accountability  
Study Product Supply, Distribution and Accountability  
Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate  (TDF) [ADDRESS_1024753] tablets are manufactured and provided by [CONTACT_10869], Inc. under the 
trade name [CONTACT_262340]®. FTC/TDF tablets must be stored in the pharmacy in the 
original container. Each bottle contains a silica gel desiccant canister to prot ect 
the product from humidity. Store at 25°C. Excursions permitted between 15° to 
30°C.  
 
Study Product Acquisition  
Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) [ADDRESS_1024754] will be supplied by [CONTACT_749423] (CRPMC).  The study site pharmacist can obtain FTC/TDF study products 
HPTN 067, Final Version 5.[ADDRESS_1024755] maintain complete records of all study products received 
from the NIAID Clinical Research Products Management Center (CRPMC) and 
subsequently dispensed to study participants.  All study products must be  stored 
in the pharmacy.  At non - US sites all unused study products must be destroyed in 
accordance with the procedures outlined in the manual Pharmacy Guidelines and 
Instructions for DAIDS Clinical Trials Networks and according to local 
procedures. For t he US site any unused study products must be returned to the 
CRPMC in accordance with the procedures outlined in the manual Pharmacy 
Guidelines and Instructions for DAIDS Clinical Trials Networks.   
4.4 Toxicity Management  
In general, the site investigator has the discretion to hold study drug at any time if 
she or he feels that continued study drug use would be harmful to the participant, 
or interfere with treatment deemed clinically necessary according to the judgment 
of the investigator.  Unless otherwise  specified below, the investigator should 
immediately consult the PSRT for further guidance in restarting study drug or 
progressing to permanent discontinuation.   
4.4.1  Grading System  
The grading system is located in the Division of AIDS Table for Grading  Severity 
of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, 
December 2004 (Clarification August 2009), which can be found on the 
Regulatory Support Center (RSC) Web site:  
http://rsc.tech -res.com/safetyandpharmacovigilance/ . 
4.4.2 Discontinuation of Study Drug in the Presence of Toxicity  
Grades 1 or 2  
In general, participants who develop a Grade 1 or 2 AE regardless of relatedness to 
study drug, and that is not specifically addressed below, may continue use of the 
study drug per p rotocol.   
 
Grade 3  
Participants who develop a Grade 3 AE or toxicity that is not specifically 
addressed below and is judged to be related to study drug by [CONTACT_625122]/designee, 
study drug use should be temporarily discontinued in consultation with the PSRT.  
In general, and unless otherwise decided in consultation with the PSRT, the 
investigator should re -evaluate the participant at least weekly for up to 2 weeks 
HPTN 067, Final Version 5.0  Page 35 of 13 3 June 10 , 2013  
 (or for 2 weeks following the receipt of the results for lab toxicities) to document 
resolution of  toxicity to less than Grade 2.  The study drug should be permanently 
discontinued if improvement to severity ≤ Grade 2 cannot be documented within 
4 weeks of receipt of the initial result.  If study drug use is resumed and the same 
Grade 3 AE recurs at an y time, the IoR/designee must consult the PSRT for 
further guidance on holding of study drug, frequency of reevaluation or 
progression to permanent discontinuation of the study drug.  
 
Grade 4  
Participants who develop a Grade 4 AE or toxicity that is not sp ecifically 
addressed below (regardless of relationship to study drug) should have the study 
drug temporarily discontinued.  The IoR/designee must consult the PSRT and 
continue the temporary study drug hold until a recommendation is obtained from 
the PSRT.  In general, study drug use will not be resumed if the Grade [ADDRESS_1024756] query the PSRT for review.  The PSRT will provide a written response to the 
site indicating their recommendation based on careful review of all relevant data.  
 
A participant will be permanently discont inued from drug use by [CONTACT_625122]/designee 
for any of the following reasons:  
 HIV-[ADDRESS_1024757] or positive  GenAptima HIV RNA assay.  The 
IoR/designee must permanently discontinue study drug if HIV infection is 
confirmed.  A decision to resume study drug in participants who are 
subsequently confirmed to be HIV -uninfected requires approval of the 
Protocol Chair,  PSRT and HPTN NL.  
 Viral hepatitis.  Such participants will not resume study drug use at any time.  
 Pregnancy.  A participant who becomes pregnant must not resume study drug 
use.   
 Breastfeeding.  Study drug use may not resume for participants who report 
breastfeeding at any time after enrollment.  
 
Any participant who prematurely discontinues study drug should be followed 
according to the procedures in the Schedule of Evaluations in Appendix I, with the 
HPTN 067, Final Version 5.0  Page 36 of 13 3 June 10 , 2013  
 exception of study drug dispensation, counseling, and a dherence measurements.  
Weekly calls to determine sexual risk exposure should continue for all HIV 
seronegative participants.  
 
Study drug will be temporarily withheld from a participant for any of the following 
reasons:  
 Report of use of prohibited concomi tant medications described in Section 4.8.  
Study drug use may resume when the participant reports that s/he is no longer 
taking the prohibited medication, provided other reasons for temporary study 
drug hold/permanent discontinuation do not apply.  
 The par ticipant is unable or unwilling to comply with required study 
procedures, or otherwise might be put at undue risk to their safety and well -
being by [CONTACT_749424], according to the judgment of the 
IoR/designee.  The IoR/designee must consult the  PSRT on all temporary study 
drug holds instituted for this reason for further guidance on resuming study drug 
use, continuing the temporary hold, or progressing to permanent 
discontinuation.  If study drug use is temporarily held/permanently discontinued 
for this reason, but the underlying reason for the temporary hold later resolves, 
the IoR/designee should consult the PSRT to resume study drug use at that time.  
 
Participants who temporarily or permanently discontinue study drug will be 
instructed to retu rn all study drug as soon as possible.  
 
4.[ADDRESS_1024758] hold is also noted here, as it pertains to the 
clinical management of toxicities.  
4.5.1  Nausea, Vomiting, and Diarrhea  
Participants with Grad e 1 or 2 nausea, vomiting, or diarrhea may be treated 
symptomatically with hydration, oral antiemetic therapi[INVESTIGATOR_749343].  The site investigator should 
order any clinically relevant laboratory a nalyses (per judgment of the 
IoR/designee).   
 
Participants with Grade  [ADDRESS_1024759] discontinue the study drug temporarily until 
grade 2 or lower and be treated symptomatically .  Should condition(s) not 
improve to Grade <2 within 7 days, the IoR/designee should consult the PSRT for 
guidance on continuing the temporary discontinuation or progressing to 
permanent discontinuation of study drug.   
 
HPTN 067, Final Version 5.[ADDRESS_1024760]/ALT Elevations  
Careful assessments should be done to rule out the use of alcohol, lactic acidosis 
syndrome, non -study medication -related drug t oxicity, herbal 
medications/supplements, or viral hepatitis as the cause of elevation in AST or 
ALT of any grade.  The participant must be carefully assessed for any symptoms 
or signs of hepatotoxicity, including fatigue, malaise, anorexia and nausea, 
jaundice, acholic stools, right upper quadrant pain, or hepatomegaly.  If the 
AST/ALT elevation is considered most likely to be due to concomitant illness or 
medication, standard management, including discontinuation of the likely 
causative agent, if possible,  should be undertaken.  If symptoms or signs of 
clinical hepatitis are present, study drug must be held or discontinued (see below).  
 
Grade [ADDRESS_1024761] be repeated as soon as possible (at most within 1 week of the 
receipt of the results).  Study drug may be continued while repeating AST and 
ALT at the discretion of the investigator provi ded the participant is asymptomatic.  
Should the repeat AST and ALT testing indicate a continuation of Grade 1, the 
PSRT should be immediately consulted.  
 
In the case of symptomatic participants, study drug will be held temporarily, and 
management (includi ng resumption of study drug) should be arranged in 
consultation with the PSRT.  
 
Grade [ADDRESS_1024762]/ALT re -checked as soon as possible (at most within 
1 week of the receipt of the results) and then be followed weekly until levels are 
Grade  < 1.  The frequency of follow up may be altered at the discretion of the site 
investigator following consultation with the PSRT.  Study drug may continue at 
the discretion of the investigator provided the participant is asymptomatic.  
 
In the case of sympt omatic participants, study drug will be held temporarily, and 
management (including resumption of study drug) should be arranged in 
consultation with the PSRT.  
HPTN 067, Final Version 5.[ADDRESS_1024763]/ALT re -checked as soon as possible (at most within 1 week of 
the receipt of the results).  Participants should then be followed weekly until 
levels are Grade < 1.  Resumption of study drug should be arranged in 
consultation with the PSRT.  If imp rovement to Grade <[ADDRESS_1024764] be 
permanently discontinued.  
 
If following a Grade >3 event(s) the participant is permitted to resume study drug, 
but has an additional event (AS T and/or ALT) at a Grade 3 level, the 
IoR/designee must temporarily hold the study drug, offer symptomatic treatment 
(if appropriate), and order any clinically relevant laboratory analyses (per 
judgment of the IoR/designee).  The PSRT should be consulted f or further 
guidance on continuing the temporary hold, clinical management of the 
participants, or progressing to permanent discontinuation of the study drug.  
 
Grade [ADDRESS_1024765]/ALT re -
checked as soon as possible (at most within 1 week  of the receipt of the results).  
Participants should then be followed weekly until levels are Grade  1 unless 
indicated by [CONTACT_111153].   
 
Note for all Grades  
If the investigator has determined in consultation with the PSRT that the case has 
stabilized, it may be possible to decrease the frequency of follow -up laboratory 
testing in addition to resumption of study drug.   
4.5.3  Calculated Cre atinine Clearance  
If the calculated creatinine clearance is <50mL/min, study drug should be 
temporarily held and it should be confirmed within 1 week of the receipt of the 
results, and the PSRT should be consulted.  If the calculated creatinine clearance i s 
confirmed to be <50mL/min, the study drug must be permanently discontinued.  
Participants who fail to have a confirmed test within 7 days of receiving the initial 
result, should be permanently discontinued from use of the study drug.   
 
If re-testing yie lds a result >50mL/min, the IoR/designee must consult the PSRT 
for further guidance on resuming study drug use, continuing the hold temporarily, 
or progressing to permanent discontinuation.  
HPTN 067, Final Version 5.0  Page 39 of 13 3 June 10 , 2013  
  
By [CONTACT_749425], it may be possible to decrease the frequency of follow -up 
laboratory testing in addition to resumption of study drug.   
4.5.4  Hypophosphatemia  
Grades 1 and 2  
The phosphate should be repeated within 2 weeks of the receipt  of any initially 
abnormal results.  Supplemental phosphate should be given with phosphate -rich 
food or fluid with or without neutral phosphate solution.  Other causes of 
phosphate loss should be evaluated.  Unless other temporary study drug hold 
requireme nts apply, study drug need not be held.  
 
Grade 3  
The phosphate should be repeated within 1 week of receipt of any initially 
abnormal results, and should be accompanied by [CONTACT_749426]/glucose.  Supplemental phosp hate should be given with 
phosphate -rich food or fluid with or without neutral phosphate solution, and other 
causes of low phosphate should be investigated.  Participants with any of the 
following results (of tests accompanying the repeat phosphate test) w ill have study 
drug held:  
 Proteinuria >3+  
 Glycosuria >3+  
 Creatinine >1.[ADDRESS_1024766]  
 Creatinine clearance <50 mL/min  
 
Participants may continue study drug provided that:  
 Study drug hold is not otherwise indicated ( e.g., due to the results of creatinine, 
creatinine clearance, urine protein, and/or urine glucose)  
 Phosphate levels will be retested approximately weekly until return to <Grade 
2, unless other retesting schedule has been advised by [CONTACT_749427] 4  
The phosphate should be repeated within 1 week  of the receipt of any initially 
abnormal results, and should be accompanied by [CONTACT_749426]/glucose.  Supplemental phosphate should be given with 
phosphate -rich food or fluid with or without neutral phosphate sol ution.  Other 
causes of low phosphate should be investigated.  
 
HPTN 067, Final Version 5.[ADDRESS_1024767] be immediately 
contact[INVESTIGATOR_530].  Phosphate levels will be retested approximately weekly until return to 
<Grade 2, unless another retesting sc heduled has been advised by [CONTACT_111153].  
Participants may resume study drug, provided that:  
 Study drug hold is not otherwise indicated ( e.g., due to the results of serum 
creatinine, creatinine clearance, urine protein, and/or urine glucose)  
 The phosphate lev el has returned to  <Grade 2  
 A request to resume study drug is approved by [CONTACT_749428] >Grade 2 for protein or glucose 
measured by [CONTACT_749429] a 
phosphate level.  
4.5.5 Proteinuria  
Proteinuria will be assessed by [CONTACT_72502].  A finding of 1+ proteinuria should 
be confirmed with a second urine dipstick performed no earlier than one week but 
no later than [ADDRESS_1024768] 1+ proteinuria.  Protei nuria of 2+ 
or greater does not need to be confirmed at a separate visit.  
 
The IoR/designee should temporarily hold study drug in the following 
circumstances:  
 Detection of 3+ or greater proteinuria at any visit.  Study drug should be held 
regardless of serum creatinine or phosphorus results obtained at the time of 
proteinuria detection.  Urine dipstick testing and serum creatinine and 
phosphate should then be pe rformed monthly for at least three months.  The 
PSRT should be consulted for permission to resume study product based on 
repeat urine dipstick testing.  
 
 Detection of 2+ proteinuria.  Study drug should be held until results of serum 
creatinine and phosphorus  results obtained at the time of proteinuria detection 
are available.  Study drug hold should continue if hold criteria outlined for 
serum creatinine and/or phosphorus are met.  If neither value meets criteria for 
study product hold, study drug should be r esumed.  
 
 Detection of 1+ proteinuria confirmed on two separate visits.  Study drug 
should be held only if serum creatinine or phosphorus results obtained at the 
time of detection of proteinuria meet hold criteria (Sections 4.5.3 and 4.5.4).  
 
HPTN 067, Final Version 5.0  Page 41 of 13 3 June 10 , 2013  
 4.5.6  Glycosur ia 
Glycosuria will be assessed by [CONTACT_72502].  A finding of 1+ glycosuria should 
be confirmed with a second urine dipstick performed no earlier than one week but 
no later than [ADDRESS_1024769] 1+ glycosuria.  Glycosuria of 2+ or 
greater does not need to be confirmed at a separate visit.  Note:  The severity of 
glycosuria is graded using the same grading scale as for proteinuria.  
 
The IoR/designee should temporarily hold study drug in the following 
circumstances:  
 Detection of 3+ or gr eater glycosuria at any visit.  Study drug should be held 
regardless of serum creatinine or phosphorus results obtained at the time of 
glycosuria detection.  Urine dipstick testing and serum creatinine and 
phosphorus should then be performed monthly for at  least three months.  The 
PSRT should be consulted for permission to resume study product based on 
repeat urine dipstick testing.  
 
 Detection of 2+ glycosuria.  Study drug should be held until results of serum 
creatinine  and phosphorus results obtained at the time of glycosuria detection 
are available.  Study drug hold should continue if hold criteria outlined for 
serum creatinine and/or phosphorus are met (Sections 4.5.3 and 4.5.4).  If 
neither of these values meets crit eria for study drug hold, study drug should be 
resumed.  
 
 Detection of 1+ glycosuria confirmed on two separate visits.  Study drug 
should be held only if serum creatinine or phosphorus results obtained at the 
time of detection of glycosuria meet hold criter ia. 
 
4.5.7  HIV Infection  
Frequent testing for HIV acquisition during the study period will allow prompt 
cessation of study drug in an HIV -infected participant, minimizing the risk that 
resistant virus will emerge.  Therefore, HIV testing will be performed at 
Screening, Enrollment,  and Weeks 4, 6, 10, 14, 18, 22, 26, 30 and 34, and also (1) 
at any visit during which signs or symptoms of a viral syndrome are present, (2) at 
any visit where a participant expresses concerns about recent acquisition of HIV 
infection, or (3) at the discr etion of the site investigator.  If a recent infection is 
suspected, a GenAptima HIV RNA test for acute HIV infection will be 
performed.  At the Screening and Enrollment visits, individuals will be deferred 
and referred for evaluation and care if they have  any signs or symptoms consistent 
with acute (pre -seroconversion) HIV infection, or if they express a concern about 
HPTN 067, Final Version 5.0  Page 42 of 13 3 June 10 , 2013  
 recent HIV infection.  Signs and symptoms consistent with acute HIV infection 
include fever (temperature > 38° C), pharyngitis, or a new ras h.  Evaluation of 
possible acute HIV infection prior to enrollment will be performed outside of the 
study, according to local testing guidelines.  If an individual is confirmed to be 
HIV-uninfected after evaluation, they may resume the Screening and Enroll ment 
process.  
 
Any enrolled participants who acquire HIV infection during the study will 
permanently discontinue study product and will be followed after Enrollment at 
Weeks 4, 6, [ADDRESS_1024770]  study participant completes follow -up at the study site.   
Appendix 1B notes the additional laboratory tests to be completed at time of 
diagnosis and follow -up visits. All protocol procedures will be completed with the 
following exceptions:   
 Study drug su pply and associated counseling  
 Weekly telephone or personal contact  
o Review of EDM and sexual intercourse events  
 HIV rapid testing, with confirmation if one or both HIV rapid tests is 
reactive  
 Behavioral Assessment (CASI)  
 Specimen collection related to drug  tolerance (serum creatinine, serum 
phosphate, AST/ALT, protein and glucose) and/or adherence (lysed 
PMBCs, urine and hair for storage)  
 
HIV-infected participants will be followed to contribute information regarding 
HIV outcomes after PrEP exposure, to ma intain confidentiality, and to comply 
with expectations of communities.  These participants will receive counseling and 
referrals for HIV treatment and care according to local guidelines.  Participants 
who test positive for HIV during the DOT phase will be  replaced, but will be 
continued to be followed.   
4.6 Clinical Management of Pregnancy  
Receipt of study medication by [CONTACT_749430], including an intrauterine device (IUD), 
horm onal contraception, or sterilization.  All participants should also use male or 
female condoms for prevention of HIV and other STIs.  As needed, study staff 
will provide contraceptive counseling to enrolled participants throughout the 
duration of study par ticipation and will facilitate access to contraceptive services 
through direct service delivery and/or active referrals to local service providers.  
HPTN 067, Final Version 5.0  Page 43 of 13 3 June 10 , 2013  
 Study staff also will provide participants with male and/or female condoms and 
counseling on use of condoms .   
 
Pregnancy testing will be performed at Screening, Enrollment and at Weeks 4, 6, 
10, 14, 18, 22, 26, and 30.  Participants will be encouraged to report all signs or 
symptoms of pregnancy to study staff.  Participants who are pregnant will stop 
study dr ug but will continue to be followed according to the schedule of visits.  
All protocol procedures will be completed with the following exceptions:   
 Study drug supply and associated counseling  
 Urine specimen for pregnancy testing for women with reproductiv e 
potential  
 Specimen collection related to drug tolerance (serum creatinine, serum 
phosphate, AST/ALT, p rotein and glucose) and/or adherence (lysed 
PMBCs, urine and hair for storage)  
 
Weekly interviews for participants who are on permanent product hold due to a 
positive pregnancy test may only cover sexual events.  
 
The site IoR or designee will counsel any participants who become pregnant 
regarding possible risks to the fetus according  to site -specific SOPs.  Participants 
may not enroll if they are currently breastfeeding and study drug should be 
discontinued if any participant identifies that she is breastfeeding after enrollment.  
The IoR or designee also will refer the participant to  all applicable services; 
however, sites will not be responsible for paying for pregnancy -related care.   
 
Participants who are pregnant at the Week 30 visit will continue to be followed 
until the pregnancy outcome is ascertained (or, in consultation with the PSRT, it 
is determined that the pregnancy outcome cannot be ascertained).  Pregnancy 
outcomes will be reported on relevant Case Report Forms (CRFs).  Outcomes 
meeting criteria for expedited adverse event reporting also will be reported. 
Participants wh o become pregnant during the DOT phase will be replaced, but 
will be continued to be followed.   
4.[ADDRESS_1024771] their safety.  Participants who withdraw 
prior to Randomization/Week 6 will not be randomized.  Participants also may be 
withdrawn if the study sponsors, go vernment or regulatory authorities (including 
the OHRP or US FDA), or site IRBs/ECs terminate the study prior to its planned 
end date.  Site investigators are required to consult the Protocol Chair and 
HPTN 067, Final Version 5.[ADDRESS_1024772] the reason(s) for all withdrawals in participants’ study records.  
 
Any participant who wishes to discontinue study participation prematurely for any 
reason should undergo the evaluations regularly scheduled fo r Weeks 30 prior to  
discontinuation and dismissal from the study, provided that the participant is 
willing to do this.   
4.8 Concomitant Medications  
With the exception of medications listed as prohibited (see below, this section), 
enrolled study participan ts may use concomitant medications during study 
participation.  All concomitant medications, including prescribed and over -the-
counter preparations, vitamins and nutritional supplements, recreational drugs, 
and herbal preparations reported within the 70 da ys prior to study enrollment and 
throughout the course of the study will be recorded on the Case Report Forms 
(CRF) designated for that purpose.  Medications used for the treatment of AEs 
that occur during study participation also will be recorded on appli cable study 
case report forms.  
 
Should participants report use of any of the following medications, they will be 
required to discontinue use of study drug: interleukin therapy, medications with 
significant nephrotoxic potential (including but not limited t o amphotericin B, 
aminoglycosides, cidofovir, foscarnet and systemic chemotherapy), and 
medications that may inhibit or compete for elimination via active renal tubular 
secretion (including but not limited to probenecid).  In addition, if a participant 
requests post -exposure prophylaxis (PEP) for HIV exposure, they will be referred 
to a health care provider for evaluation. If a  participant starts ARV therapy for 
PEP, they should hold study medications until completion of the course of PEP.  
 
5.0 STUDY PROCEDURES  
An overview of the study visit and procedures schedule is presented in Appendix 
I.  Study visits will occur at Screening, Enrollment, at Weeks 1, 2, 3, 4 and 5 
during the DOT lead -in phase, at Week 6 (randomization), and at Weeks 10, 14, 
18, 22,  26, and 30 during the self -administered PrEP phase; a final visit will be 
conducted four weeks after completion of the dosing phase (at Week 34).   
Presented below is additional information on visit -specific study procedures.  
Detailed instructions to gui de and standardize all study procedures across sites 
will be provided in the SSP Manual.  
HPTN 067, Final Version 5.[ADDRESS_1024773] 
provide written informed consent for screening before completing any other  
procedures.  Participants who fail screening for any reason may rescreen one 
additional time.   
 
The following procedures will occur as part of screening:  
 
Administrative, Behavioral, and Regulatory Procedures  
 Informed consent  
 Assign participant ID  
 Collection of locator information  
 Demographics information  
 Behavioral Assessment (Computer Assisted Self Interview [ CASI])  
 
Clinical/Counseling Procedures  
 Medical history (including concomitant medications)  
 HIV risk reduction counseling  
 
Laboratory Procedu res 
 Urine specimen for pregnancy testing for women with reproductive 
potential  
 Urine dipstick for protein and glucose  
 Blood specimen for the following:  
o HIV rapid testing, with confirmatory testing if one or both tests is 
reactive  
o Complete blood count (CBC)  
o Serum creatinine (for estimated creatinine clearance)  
o Serum phosphate  
o AST/ALT  
o HepBsAg  
o HepBsAb and HepBCore Ab testing (if HepBsAg is negative)  
o Plasma for storage  
 
 
Participants who are susceptible to HBV infection will be offered HBV 
vaccination.   
 
Screening may be discontinued at any time if a participant is found to be 
ineligible.  HIV counseling and testing will be offered to everyone who consents 
to screening.  Sites will follow the HIV testing algorithm for screening included in 
the SSP Manual.  If a reactive result is obtained for one or both of the HIV rapid 
tests, the person is not eligible for the study.  Additional testing to confirm HIV 
infection will be performed in accordance with local guidelines.  If HIV infection 
is confirmed, particip ants will receive counseling and be referred for appropriate 
care.   
HPTN 067, Final Version 5.0  Page 46 of 13 3 June 10 , 2013  
  
If all laboratory tests and interview screening indicate that an individual is eligible 
for the study, s/he will be asked to return to the site to complete enrollment.  
Those who are not  eligible will be informed that they do not meet the 
requirements of the study and, if necessary, will be referred for appropriate 
medical care.  There must be no more than 70 days between Screening and 
Enrollment.  
5.2 Enrollment  
If all Inclusion/Exclusion  Criteria are met, then the participant may enroll.  
Participants with one or more reactive HIV rapid test results will not be eligible 
for the study.  Final eligibility determination and enrollment must be completed 
within [ADDRESS_1024774] be present at th e study site for enrollment.  
 
The following procedures will occur as part of enrollment:  
 
Administrative, Behavioral, and Regulatory Procedures  
 Confirm locator information  
 Confirm eligibility  
 
Clinical/Counseling Procedures  
 Administer study drug (DOT)  
 HIV risk reduction counseling  
 Interim medical history including concomitant medications  
 Full physical examination  including baseline symptoms and side effects 
assessment  
 Complete baseline family planning assessment  for women and sex 
hormones assessment for men.   
 Complete vaginal practices assessment for women (including use of 
lubricants and vaginal cleansing practices)  
 Orientation to the EDM device  
 
Laboratory Procedures*  
 Urine specimen for pregnancy testing for wo men with reproductive 
potential  
 Blood specimen for the following:   
o HIV rapid testing, with confirmatory testing if one or both tests is 
reactive.  Note: if one or both HIV rapid tests are reactive, the 
participant is ineligible to enroll in this study (sho uld not receive study 
drug).   
o Plasma for storage  
 
HPTN 067, Final Version 5.0  Page 47 of 13 3 June 10 , 2013  
 *All HIV rapid testing and specimen collection should be completed prior to 
administration of study medication . 
5.3 Weeks 1 -5 
A period of DOT will be used to estimate steady -state drug levels and 
accumulat ion and decay constants for each individual.  During the DOT phase, all 
participants will begin the study by [CONTACT_749431] 5.  At Enrollment through Week 4, participants will receive one directly 
observed dose per week o f oral FTC/TDF (five doses total).  No drug will be 
administered during Week 5.     
 
The following procedures will occur during Weeks 1 through 5:  
 
Administrative, Behavioral, and Regulatory Procedures  
 Confirm locator information  
 Social Harms Assessment  
 
Clinical/Counseling Procedures  
 HIV risk reduction counseling (Week 4 only)  
 Administer study drug (DOT) at Weeks 1 through 4  
 Interim medical history including concomitant medications  
 AE Assessment  
 Complete follow -up family planning assessment  for women and sex 
hormones assessment for men (Week 4 only)  
 
Laboratory Procedures*  
 Specimens collected at Week 4 only (not collected at Weeks 1, 2, 3, or 5):  
o Urine specimen for pregnancy testing for women with reproductive 
potential  
o Blood specimen for the following:  
 HIV rapid testing, with confirmatory testing if one or both tests 
is reactive  
 DBS for storage  for host genetic testing ** 
 AST/ALT  
 Serum Creatinine (for estimated creatinine clearance)  
 
 Specimens collected at Weeks 4 and 5 only (not collected at Weeks 1, 2, 
or 3): 
o Blood draw for the following:  
 Plasma for storage  
 Lysed PBMCs for storage  
 DBS for storage for drug levels (Harlem Only)  
o Hair for storage  
o Urine for storage  
No medication administered at Week 5.  
 
HPTN 067, Final Version 5.0  Page 48 of 13 3 June 10 , 2013  
 *All HIV rapid testing and specimen collection should be c ompleted prior to 
redosing of study medication.  
**DBS are stored for genetic testing related to drug metabolism and/or HIV 
infection, provided that the participant provided consent for this testing.  Consent 
for genetic testing is optional and will not affect study participation.  See Section 
9.5 for mo re details.  
5.4 Week 6/Randomization  
After the 6 -week lead -in period including DOT, participants will be randomly 
assigned to one of three unblinded PrEP usage groups:  (1) daily usage, (2) time -
driven usage, and (3) event -driven usage.  Participants will  receive counseling 
optimized for each usage plan.  Participants must be present at the study site for 
randomization.   
 
The following procedures will occur during Week 6:  
 
Administrative, Behavioral, and Regulatory Procedures  
 Confirm locator information  
 Randomization  
 Social harms assessment  
 Behavioral Assessment ( CASI)  
 
Clinical/Counseling Procedures  
 Adherence orientation  
 HIV risk reduction counseling  
 AE assessment  
 Study drug supply and associated counseling  
 Symptom driven physical examination including s ymptoms and side 
effects assessment  
 Complete follow -up family planning assessment  for women  
 Interim medical history including concomitant medications  
 
Laboratory Procedures*  
 Urine specimen for pregnancy testing for women with reproductive 
potential  
 Blood s pecimen for the following:  
o HIV rapid testing, with confirmation if one or both HIV rapid tests is 
reactive  
o Plasma for storage  
o Lysed PBMCs for storage  
o DBS for storage for drug levels (Harlem Only)  
 Hair for storage  
 Urine for storage  
 Urine dipstick for protein and glucose  
 
HPTN 067, Final Version 5.0  Page 49 of 13 3 June 10 , 2013  
 *All rapid testing and specimen collection should be completed prior to redosing 
of study medication . 
5.5 Weeks 7 through 29  
The following procedures will occur during Weeks 7 through 29 (Visits 
conducted at Weeks 10, 14, 18, 22, and 2 6): 
 
Administrative, Behavioral, and Regulatory Procedures  
 Weekly telephone or personal contact  
o Review of EDM and sexual intercourse events  
 Confirm locator information  
 Social Harms Assessment  
 
The following additional procedures will occur at Week 18:  
 Beha vioral Assessment ( CASI)  
 
Clinical/Counseling Procedures  
 HIV risk reduction counseling  
 AE assessment  
 Study drug supply, pi[INVESTIGATOR_749344]  
 Symptom driven physical examination including symptoms and side 
effects assessment  
 Complete follow -up family planning assessment  for women  
 Interim medical history including concomitant medications  
 
Laboratory Procedures*  
All Visits:  
 Urine specimen for pregnancy testing for women with reproductive 
potential  
 Blood specimen for the following:  
o HIV ra pid testing, with confirmation if one or both tests is reactive  
o Plasma for storage  
Weeks 10 and 18 only:  
 Blood specimen for the following:  
o CBC  
o Serum creatinine (for estimated creatinine clearance)  
o Serum phosphate  
o AST/ALT  
o Lysed PBMCs for storage  
o DBS for s torage  for drug levels (Harlem Only)  
 Hair for storage  
 Urine for storage  
 Urine dipstick for protein and glucose  
 
HPTN 067, Final Version 5.0  Page 50 of 13 3 June 10 , 2013  
 *All HIV rapid testing and specimen collection should be completed prior to 
redosing of study medication . 
5.6 Week 30  
The following procedures will occur during Week 30:  
 
Administrative, Behavioral, and Regulatory Procedures  
 Confirm locator information  
 Social harms assessment  
 Behavioral Assessment ( CASI)  
 
Clinical/Counseling Procedures  
 HIV risk reduction counseling  
 AE assessment  
 Return of EDM de vice and pi[INVESTIGATOR_692]  
 Symptom driven physical examination including symptoms and side 
effects assessment  
 Complete follow -up family planning assessment  for women and sex 
hormones assessment for men.  
 Complete vaginal practices assessment for women (including u se of 
lubricants and vaginal cleansing practices) Interim medical history 
including concomitant medications  
 
Laboratory Procedures*  
 Urine specimen for pregnancy testing for women with reproductive 
potential  
 Blood specimen for the following:  
o HIV rapid testin g, with confirmation if one or both tests is reactive  
o CBC  
o Serum creatinine (for estimated creatinine clearance)  
o Serum phosphate  
o AST/ALT  
o Plasma for storage  
o Lysed PBMCs for storage  
o DBS for storage  for drug levels (Harlem Only)  
 Hair for storage  
 Urine for storage  
 Urine dipstick for protein and glucose  
 
5.7 Week 34  
The following procedures will occur during or after Week 34 (post study follow -
up visit):  
 
HPTN 067, Final Version 5.0  Page 51 of 13 3 June 10 , 2013  
 Administrative, Behavioral, and Regulatory Procedures  
 Social harms assessment  
 Focus groups and key inform ant interviews with selected study 
participants and site staff are to be conducted after Week 34 *  
 
Clinical/Counseling Procedures  
 HIV risk reduction counseling  
 AE assessment  
 
Laboratory Procedures  
 HIV rapid testing, with confirmation if one or both tests  is reactive  
o Plasma for storage if one or both HIV rapid tests is reactive  
 Urine dipstick for protein and glucose  
 
*Note:  The focus groups and key informant interviews with selected participants and site 
staff may be done at any time within a [ADDRESS_1024775] suspected or documented HIV infection during the 
study  
The FDA -cleared Amplified Probe by [CONTACT_749432] 
(APTIMA) HIV -1 RNA Qualitative Assay (Gen -Probe, Inc, referred to as the 
GenAptima  HIV RNA test) may be used to confirm HIV infection in enrolled 
participants who have one or more reactive HIV rapid tests.  This assay will also 
be used at follow -up visits to resolve the HIV infection status of participants 
whose HIV status is not clear (e.g., newly reactive HIV rapid test(s) with a 
negative or indeterminate Western blot) and to confirm or rule out acute HIV 
infection in participants who have signs or symptoms of acute HIV infection or 
express a concern that they might be newly HIV -infect ed.  Rapid diagnosis of 
HIV infection in participants who become HIV -infected during the study will 
allow prompt cessation of study drug (to minimize the risk of resistance) and 
appropriate counseling.  
 
If any enrolled participant has one or more reactive HIV rapid tests or a positive 
GenAptima HIV RNA test, study drug must be discontinued immediately and the 
Site IoR   and the HPTN NL must be notified.  If HIV infection is subsequently 
confirmed, the site should notify the  Protocol Safety Review Team (PSRT) . A 
decision to resume study drug in participants who are subsequently confirmed to 
be HIV -uninfected requires approval of the Protocol Chair, PSRT and HPTN NL.  
 
Any participant who is found to have confirmed HIV infection after Enrollment 
will be followed  at all scheduled visits and also every [ADDRESS_1024776] participant at that study sites completes his or her final study 
visit.  HIV -infected participants will be followed to contribute information 
regarding HIV outcomes af ter PrEP exposure (including viral set point), to 
maintain confidentiality, and to comply with expectations of communities.  See 
HPTN 067, Final Version 5.[ADDRESS_1024777] areas, and perceptions of acceptability; (1) EDM 
data indicating the dates/times that the EDM case was opened (adj usted by [CONTACT_6270] -
report data as described below), (2) weekly incentivized telephone -based brief 
interviews to record risk events, (3) CASI collected self -report measures, (4) 
qualitative focus group and key informant interviews with study participants and 
clinic staff who directly interact with participants regarding their pi[INVESTIGATOR_4382] -taking and 
sexual risk behavior; and (5) data collected on CRFs during regular visits.   
5.10.1  Quantitative Behavioral Component  
 
[IP_ADDRESS]  Coverage and Sexual Behavior  
The primary measure of pi[INVESTIGATOR_4382] -taking will be based on the adjusted EDM data.  The 
EDM data is transmitted electronically to a database system and this data is used 
by [CONTACT_749433] -reported pi[INVESTIGATOR_4382] -taking via brief 
weekly intervie ws, as in Section 2.4.2.  Further, several steps will be taken to 
reinforce participant use of the EDM case.  At Enrollment, all participants will be 
instructed to use the EDM case for each pi[INVESTIGATOR_4382] -taking event, provided with an 
explanation of why the EDM cas e is needed to achieve the scientific aims of the 
study, and trained on its use.  Staff will also explore any difficulties with EDM 
case use.  Finally, to minimize curiosity openings during the study, clinic staff 
will work to familiarize the participant w ith the EDM device, and will provide the 
participant with an EDM device and a one month supply of multivitamin pi[INVESTIGATOR_749345].   
 
Because the timing of sexual events is critical to establishing coverage in the 
intermittent arms, sexual behavior  will be assessed during weekly interviews to 
minimize difficulties with recall.  During weekly telephone interviews, the 
interviewer will also ask the participant if a sex event occurred during this time 
period and the day(s) of the event(s) will be recor ded.  For each event -day, the 
general start time of the event/session/or round, event type(s), and number of 
partners involved, as well as if condoms were used during all insertions for that 
round/session, will be collected.  This will be repeated until al l days/events are 
characterized.  Interviewers will be staff or contractors otherwise unknown to the 
participant, and trained in neutral assessment and timeline follow -back techniques 
HPTN 067, Final Version 5.0  Page 53 of 13 3 June 10 , 2013  
 to facilitate brevity and minimization of social -desirability (or self -presentation) 
bias.  In the event that a participant is not contact[CONTACT_5365] a given assessment week, 
additional attempts will be made to contact [CONTACT_749434].  Where no conta ct has 
been made and the participant comes to a monthly clinic visit, the telephone based 
interview data will be replaced with an in -person interview from a trained staff 
member.  Alternative data collection method will be noted in the participant’s 
data.   
 
In addition to the weekly interview risk -data collected, a more general risk 
assessment will be included as a brief measure in the CASI assessments including 
safer sexual practices such as serosorting, sexual positioning, etc..  While it is 
improbable t hat participants will be able to recall the timing of events occurring 
during this longer time period, the assessment of risk behavior occurring over the 
last one to three months is not uncommon.69-[ADDRESS_1024778] been used in some manner in previous research within different 
communities.  All questionnaires w ill be administered via CASI in the local 
language at the study site.  
 
If a participant needs assistance with CASI, a study staff member will help him or 
her and this help will be noted in the CASI data.  The administration of 
questionnaires will take appr oximately thirty minutes.  Non -literate participants 
will not be eligible for this study.   
5.10.2  Qualitative Behavioral Component  
 
[IP_ADDRESS]  Focus groups and key informant interviews  
We will explore differences between arms in the acceptability of differe nt PrEP 
regimens using qualitative research methods, including focus groups and key 
informant interviews.  Two focus groups will be performed per study arm at each 
site.  Each focus group will include approximately 6 -8 study participants per 
study arm grou p per site per focus group. These groups will include 
approximately 108-144 participants total.  Two key informant interviews will be 
performed per study arm per site with selected study participants identified by 
[CONTACT_43588] a total of 18 participant key informants.  In addition, a total of 9-12 
key informant (site staff who interacted directly with participants during the 
HPTN 067, Final Version 5.0  Page 54 of 13 3 June 10 , 2013  
 study) interviews will be conducted of 3 -4 staff members per site.  Key informant 
interviews will be conducted after the on -drug pe riod (after Week 34).  
Participants who discontinue study drug early for reasons not related to AEs or 
symptoms/side effects will be specifically targeted for the focus groups and key 
informant interviews, as their participation will provide information on  why some 
high-risk individuals who have access to PrEP elect not to use it.  Focus groups 
and key informant interview are each anticipated to last approximately 2 hours.   
 
Focus groups: For participant focus groups, participants will be recruited from 
clinic through advertisement of the focus groups approximately 6 weeks prior to 
conducting the groups; participants not attending the clinic during this enrollment 
period will be contact[INVESTIGATOR_530] t o be made aware of these groups.  Convenience 
sampling will be used, where interested participants are enrolled until each focus 
group is “filled”.  Enrollment ends when all groups are filled.  Note that results of 
focus groups will be interpreted and pres ented with this limitation in mind.  
Adequate reminders will be used to ensure participants attend the event at the 
appropriate date and time.  Focus group participants will be encouraged to select a 
pseudonym or nickname [CONTACT_169561] w ithin the group.  Focus 
groups will be held in a private space in the clinic or off -site in a space where 
responses cannot be overheard by [CONTACT_749435].  Focus groups will be 
conducted by [CONTACT_749436] . All focus groups will be administered, recorded and transcribed 
in the native language of the site.  Analysis will be completed at each site and 
then transcripts will be translated.  General themes will be identified acr oss sites.  
Recordings and transcripts will be maintained in a secure location and destroyed 
after analysis according to DAIDS guidelines for data retention.   
 
A focus group guide will be developed that has queries posed to each group 
regarding;  
 their pe rceptions of feasibility, acceptability and ease of uptake for their 
assigned regimen  
 if they altered the regimen to better ‘fit’ their daily life or risk behavior  
 whether they would switch to a different regimen if available  
 what the ideal regimen woul d be 
 common barriers and facilitators to following their regimen  
 whether important others knew the participant was enrolled in the study  
 feelings towards the project, project -staff, and how pi[INVESTIGATOR_4382] -taking and 
condom use was supported  
 perceptions  of the support provided for pi[INVESTIGATOR_4382] -taking and for condom use, 
how they would change it, and what frequency or type of support would 
be most acceptable to them if they were taking PrEP outside of the 
context of research.  
 
Additionally, to further guide theo ry and intervention development, self -perceived 
attributes defining “PrEP participant”, “consistent PrEP user” and “consistent 
condom user” will be qualitatively explored.  Discussion from focus groups will 
HPTN 067, Final Version 5.0  Page 55 of 13 3 June 10 , 2013  
 be transcribed and coding will be approached with  a two -phase analytic method 
(fully detailed in Section 7.5.6), including both theory -grounded and content 
analyses.  Rigorous qualitative methods will be used to identify the emerging 
themes, primarily surrounding pi[INVESTIGATOR_4382] -taking and condom use in the context  of PrEP.  
Coding will focus on the adapted IMB model of pi[INVESTIGATOR_4382] -taking and condom use 
through focused identification of content within the core determinants of the IMB 
model and content related to barriers and facilitators of each behavior that cannot 
be cod ed with the model constructs.  Data gathered from focus groups are 
intended to supplement and inform the quantitative results obtained regarding 
perceptions of dosing schedule, feelings about group assignment, perceptions of 
HIV risk, disclosure of study p articipation and pi[INVESTIGATOR_4382] -use to sexual partner(s), 
housemates and family, relationships with study staff, perceptions of social role, 
and factors influencing use of pi[INVESTIGATOR_3353].  Data collected through qualitative focus 
groups may be combined with qualitative data collected in sub -studies targeting 
ADAPT participants and their experiences on -study if appropriate.  
 
Key informant interviews: Direct -care clinic staff will have had extended 
cumulative interactions with participants in each of the study arms by [CONTACT_749437] -drug phase.  Therefore, each of these staff is considered to be a key 
informant with valuable knowledge of and experience with each of the regimens 
and how participants interacted with the study and the regimen demands.  
Selected study participa nts, such as those who crossed over study arms, 
discontinued study drug, or withdrew from the study, will also be considered key -
informants.  Semi -structured interview guides will be developed that query 
interviewees along similar themes listed above.  Bec ause of the structured nature 
of these interviews, content analysis will be the primary analytic strategy focused 
on coding main content of responses to queries.  Data will supplement participant -
based responses to quantitatively and qualitatively assess a cceptability and 
feasibility and to refine the adapted model developed for the present research.  
Key informant interviews for participants will be completed by [CONTACT_749438].  Key informant interviews with staff will be complete d by 
[CONTACT_749439] a supervisory role for the interviewee.  All key 
informant interviews will be held in a private space in the clinic or off -site in a 
space where responses cannot be overheard by [CONTACT_749435].  Data 
collected through qualitative interviews  may be combined with qualitative data 
collected in sub -studies targeting ADAPT participants and their experiences on -
study if appropriate.  
HPTN 067, Final Version 5.0  Page 56 of 13 3 June 10 , 2013  
 6.0 SAFETY MONITORING AN D ADVERSE EVENT REPO RTING  
6.1 Safety Monitoring  
Close c ooperation between the Protocol Chair(s), study site Investigator(s), 
NIAID Medical/Program Officer, CORE Protocol Coordinator, SDMC 
Biostatistician, HPTN NL, and other study team members will be necessary in 
order to monitor participant safety and to resp ond to occurrences of toxicity in a 
timely manner.  The team will have regularly scheduled conference calls during 
the period of study implementation, and additional ad hoc  calls will be convened 
if required.  
 
The study site Investigators are responsible f or continuous close monitoring of all 
AEs that occur among study participants after enrollment, and for alerting the 
PSRT if unexpected concerns arise.   
 
A sub -group of the Protocol Team, including the Protocol Chair, DAIDS Medical 
Officer, one or more si te clinicians, and the SDMC Clinical Affairs Safety 
Associate will serve as the PSRT to be chaired by [CONTACT_36476].  The HPTN 
SDMC will prepare routine safety data reports for review by [CONTACT_111153], which 
will meet via conference call approximately once  per month or as needed 
throughout the period of study implementation to review safety data, discuss 
product use management and address any potential safety concerns.  The content, 
format and frequency of safety data reports will be agreed upon by [CONTACT_749440].  
6.2 Clinical Data Safety Review  
A multi -tiered safety review process will be followed for the duration of this 
study.  The study site investigators are responsible for the initial evaluation and 
reporting o f safety information  at the participant level, and for alerting the PSRT 
if unexpected concerns arise.  Participant safety is also monitored at the Network 
level through a series of routine reviews organized and led by [CONTACT_749441] (Stud y Monitoring Committee (SMC) reviews), the PSRT and study 
sponsors.  In addition, the study will be overseen by [CONTACT_749442] 
a NIAID Data and Safety Monitoring Board ( DSMB ). Additional reviews may be 
conducted at each of these levels as dic tated by [CONTACT_625114].   
 
HPTN SDMC Clinical Affairs staff will review incoming safety data on an 
ongoing basis.  Events identified as questionable, inconsistent, or unexplained 
will be queried for verification.  AE reports submitted in  an expedited manner to 
HPTN 067, Final Version 5.0  Page 57 of 13 3 June 10 , 2013  
 the DAIDS Safety Office will be forwarded to the DAIDS Medical Officer for 
review.  
 
The PSRT will meet regularly via conference call to review clinical data reports 
generated by [CONTACT_132766].  The content, format and frequency of t he clinical 
data reports will be agreed upon by [CONTACT_658186].  In addition to the routine safety data reviews, the PSRT will 
convene on an ad hoc  basis to make decisions regarding the handling of any 
significant safety concerns.  If necessary, experts external to the HPTN 
representing expertise in the fields of ART, biostatistics, HIV transmission and 
medical ethics may be invited to join the PSRT safety review.  A recommendation 
to stop the trial may be made by t he PSRT at any such time that the team agrees 
that an unacceptable type and/or frequency of AEs has been observed.  
 
Recommendations regarding permanent discontinuation of study product may 
involve sponsor consultation with the U.S. FDA.  
 
In the unlikely ev ent that the protocol team or PSRT has serious safety concerns 
that lead to a decision to permanently discontinue the study product for all 
participants and stop accrual into the study, the protocol team or PSRT will 
request a review of the data by [CONTACT_749443] N SMC before recommending that the 
study be stopped.  If at any time, a decision is made to discontinue the study 
product in all participants, DAIDS will notify the U.S. FDA and the site 
Investigators of Record will notify the responsible IRBs/ECs expediti ously.  
6.3 Adverse Event definition and reporting to DAIDS  
Requirements, definitions and methods for expedited reporting of AEs are 
outlined in Version 2.0 of the DAIDS Expedited Adverse Events (EAE) Manual, 
which is available on the Regulatory Support Ce nter (RSC) website at  
http://rsc.tech -res.com/safetyandpharmacovigilance/ .  This information is also 
available in Section 14.4 of the HPTN Manual of Operations at 
http://www.hptn.org/netw ork_information/policy_procedure/HPTNMOP2010.ht
m. 
6.3.[ADDRESS_1024779].  As 
such, an AE can be an unfavorable or unintended sign (including an abnormal 
laboratory finding, for example), symptom or disease temporally associated with 
the use of an investigational product, whether or  not considered related to the 
HPTN 067, Final Version 5.[ADDRESS_1024780].  The term “investigational product” for this study refers to the oral 
medication Truvada®  (emtricitabine/ tenofovir disoproxil fumarate).  
 
Study participants will be provided instructions for contact[CONTACT_749444] e to 
report any untoward medical occurrences they may experience, except for 
possible life -threatening events, for which they will be instructed to seek 
immediate emergency care.  Where feasible and medically appropriate, 
participants will be encouraged to  seek evaluation where a study clinician is 
based, and to request that the clinician be contact[CONTACT_18110].  With 
appropriate permission of the participant, whenever possible, records from all 
non-study medical providers related to untoward medic al occurrences will be 
obtained, and required data elements will be recorded on study CRFs.  All 
participants reporting an untoward medical occurrence will be followed clinically 
until the occurrence resolves (returns to baseline) or stabilizes.  
 
Study sit e staff will document in source documents and the appropriate AE Log 
CRF all AEs reported by [CONTACT_749445].  AE severity will be graded 
per the DAIDS Table for G rading Adult and Pediatric Adverse Events, Version 
1.0, December 2004 (Clarification dated August 2009).  
6.3.2  Serious Adverse Events  
Serious AEs (SAEs) will be defined per International Conference on 
Harmonisation (ICH) guidance, as specified in Version 2.0 of the Manual for 
Expedited Adverse Events to DAIDS, dated January 2010.   
[IP_ADDRESS]  AE Reporting to DAIDS  
The SAE Reporting Category, as defined in Version 2.0 of the DAIDS EAE 
Manual, will be used for this study.    
 
According to the SAEs reporting cat egory in the manual, all SAEs occurring 
during the study reporting period (defined below) will be reported to the DAIDS 
RSC Safety Office in an expedited manner, within three reporting days of site 
awareness of the events (see definition in Appendix D of t he manual).   
 
The DAIDS Adverse Experience Reporting System (DAERS), an internet -based 
reporting system, must be used for expedited AE reporting to DAIDS.  In the 
event of system outages or technical difficulties, expedited AEs may be submitted 
via the DA IDS EAE Form.  For questions about DAERS, please contact [CONTACT_106898] -
ES at DAIDS -[EMAIL_2683].  Site queries may also be sent from 
within the DAERS application itself.  
 
 
The study agent for which expedited reporting is required is Truvada® 
(emtricitabine/ tenofovir disoproxil fumarate).  For each trial participant, the AE 
reporting period begins at Enrollment and ends when the participant completes 
the Week 34 or exit Visit.  If the study is still enrolling or in follow -up when a 
HPTN 067, Final Version 5.0  Page 59 of 13 3 June 10 , 2013  
 participant has completed their Week 34 or exit visit, any EAEs that study staff 
become aware of on a passive basis should be reported to DAIDS in an expedited 
manner.  
 
After study closure, only suspected, unexpected, serious adverse drug reactions 
(S[LOCATION_003]Rs; defined i n Version 2.0 of the DAIDS EAE Manual) that study staff 
become aware of on a passive basis will be reported to DAIDS in an expedited 
manner.  
[IP_ADDRESS]  Grading severity of adverse events  
The severity of all AEs will be graded according to the current Division  of AIDS 
Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 
1.0, dated December 2004 (with Clarification dated August 2009), which is 
available on the RSC website at  
http://rsc.tech -res.com/safetyandpharmacovigilance /.      
6.3.[ADDRESS_1024781] 
will be assessed as specified in Version 2.0 of t he DAIDS EAE Reporting 
Manual.   
6.4 Pregnancy Outcomes  
Pregnancy outcomes will be collected for all applicable study participants.  After 
the participant’s final study contact, any pregnancy outcomes that meet criteria for 
SAE reporting ( e.g., congenital  anomalies) occurring among participants will 
continue to be expeditiously reported.  
6.5 Regulatory Requirements  
Information on all reported AEs will be recorded on CRFs and included in reports 
to the FDA and other applicable government and regulatory aut horities.  The site 
IoR/designee will submit AE information in accordance with local regulatory 
agencies’ or other local authorities’ requirements.  The site IoR/designee also will 
submit AE information and any other relevant safety information to the 
IRB/ Ethics Committee (EC) in accordance with IRB/EC requirements.  
6.[ADDRESS_1024782] participant privacy and 
confidentiality, it is possible that participants' involvement in the study could 
become  known to others, and that social harms may result ( i.e., because 
participants could be perceived as being HIV -infected or at "high risk" for HIV 
infection).  For example, participants could be treated unfairly, or could have 
problems being accepted by [CONTACT_578995]/or communities.  Social harms that 
are judged by [CONTACT_625122]/designee to be serious or unexpected will be reported to the 
HPTN 067, Final Version 5.0  Page 60 of 13 3 June 10 , 2013  
 responsible site’s IRBs/ECs at least annually, or according to their individual 
requirements.  Social harms will be collec ted and reported on CRFs during 
regular visits.  In the event that a participant reports social harm, every effort will 
be made by [CONTACT_634016], and/or referral to appropriate resources for the s afety of the 
participant.  Each site will provide such care and counseling in accordance with 
standardized guidance in the SSP Manual.  While maintaining participant 
confidentiality, study sites may engage their Community Advisory Boards in 
exploring the s ocial context surrounding instances of social harm, to minimize the 
potential occurrence of such harm.  
 
7.0 STATISTICAL CONSIDER ATIONS  
7.1 Review of Study Design  
This is a Phase II randomized open -label clinical trial of oral Truvada® 
(FTC/TDF) PrEP among HIV-uninfected MSM /TGW and WSM at high risk for 
acquiring HIV infection.   
 
The study will randomize 540 people, 180 MSMTGW at the TUC Silom 
Community Clinic in Bangkok, Thailand , 180 MSM /TGW at the Harlem 
Prevention Center in [LOCATION_001], [LOCATION_003] and 180 WSM at Emavundleni Centre, The 
Desmond Tutu HIV Foundation in Cape Town, South Africa.  The study includes 
a lead -in period of 6 weeks including DOT to determine individual steady state 
PK, and a 24 -week self -administered PrEP phase to assess adherence, sexual 
behaviors, tolerance, and acceptability.  At Week 6, participants will be 
randomized and assigned to one of three dosage groups in a 1:1:1 ratio: daily 
dosing, time -driven dosing, and event -driven dosing.  During the self -
administered PrEP phase, all partici pants will engage in PrEP adherence 
counseling during all study visits and once per week telephone contacts will be 
used to query each participant regarding sexual exposure and pi[INVESTIGATOR_4382] -use.  If a 
participant cannot be reached for a given week or weeks of tele phone -based 
assessment, an interview based timeline follow -back approach administered at the 
next clinic visit will be used to complete missing information and will be denoted 
as having been collected via this alternative method.  Focus groups (selected 
participants) and key informant interviews (selected participants and clinic staff) 
will occur within three months after Week 34.   
7.[ADDRESS_1024783] the hypothesis that 
recommendi ng intermittent (non -daily) use of oral FTC/TDF chemoprophylaxis, 
compared with recommending daily usage, will be associated with:   
 
HPTN 067, Final Version 5.[ADDRESS_1024784] -exposure dosing   
o Lower number of pi[INVESTIGATOR_749326]  
o Decreased self -reported symptoms/side effects (both severity and 
frequency) during 24 weeks of self -administered use, the following 
endpoint(s) will be assessed:  
 The proportion of sexual expos ures covered by [CONTACT_094] - and post -exposure dosing.  
Coverage will be determined based on the adjusted electronic and self -
reported pi[INVESTIGATOR_4382] -use data.  Specifically, a sex act will be considered “covered” if 
the following two conditions are met:  
i. At least one pi[INVESTIGATOR_4382] i s taken during the 4 days (96 hours) before the act or 
prior to the act on the day of the act ( e.g., if a sex act occurs on Friday, 
that act would be covered if a pi[INVESTIGATOR_749346], Tuesday, 
Wednesday, Thursday, or Friday prior to the act) and:  
ii. At least one additional pi[INVESTIGATOR_749347] [ADDRESS_1024785] ( e.g., if a 
sex act occurs on Friday at [ADDRESS_1024786] would be covered if the second 
pi[INVESTIGATOR_749348] 11 pm and Saturday 11 pm).  
Note that the same pi[INVESTIGATOR_749349] a pre -exposure  dose and a post -exposure 
dose if events are closely spaced.  At no time should a participant in the 
intermittent arm be taking more pi[INVESTIGATOR_749350].   
 The (minimum) total number of pi[INVESTIGATOR_749351] 100% coverage over the 
follow -up period (based o n randomization arm and self -reported sexual 
history in the weekly interviews) (after Week 6 up until about the Week 30 
visit).   
 The total pi[INVESTIGATOR_749352] -up period, based on the adjusted 
electronic and self -reported pi[INVESTIGATOR_4382] -use data (aft er Week 6 through Week 30)  
 The self -reported symptom/side effect scores (to be developed) for common 
symptoms/side effects including headache, dizziness, crampi[INVESTIGATOR_007], abdominal 
pain, and flatulence.  Collected during clinic visits.   
7.2.2  Secondary Endpoint s 
Consistent with the secondary study objective to develop objective measures of 
drug exposure among PrEP users by [CONTACT_749446] -dose “trough” drug 
concentration in several biological matrices for participants enrolled during a 
lead-in period of weekly DOT , the following endpoint(s) will be assessed:  
 
 Measurement of TFV -DP in PBMCs.  Samples will also be collected and 
stored for possible future substudies comparing the level of TFV -DP in 
PBMCs to the levels of extracellular TFV in plasma , of intracellular a nalytes 
in whole blood (Harlem only),  and of TFV - in hair.  FTC and its 
phosphorylated derivative, FTC -TP, may also be measured.  
 
HPTN 067, Final Version 5.0  Page 62 of 13 3 June 10 , 2013  
 Consistent with the secondary objective to describe safety outcomes among PrEP  
users, including AEs among all participants and drug resistance, and plasma HIV 
RNA levels among participants who seroconvert, the following will be provided:  
 
 A listing of all AEs (see Sections 6.3.1 and 6.3.2) by [CONTACT_479], relationship to 
study product, an d arm  
 A listing, by [INVESTIGATOR_216], of drug resistance test results and plasma HIV RNA levels 
among all participants who seroconvert while on study  
 
Consistent with the secondary study objective to assess the acceptability of 
different PrEP regimens and perceptions o f advantages and disadvantages of 
different regimens , the following endpoint(s) will be assessed:  
 The proportion of participants in each of the study arms who self -report 
acceptability of assigned study arm collected on CASI assessment   
 Perceptions of adv antages and disadvantages of different regimens as reported 
by [CONTACT_749447], PrEP use, and related inf ormation, motivation and behavioral skills, 
the following endpoints will be assessed:  
 The percentage adherence (number of pi[INVESTIGATOR_38947]/number of pi[INVESTIGATOR_749353]) and percentage of correctly timed adherence 
(number of pi[INVESTIGATOR_749354] t he recommended timeframe/number of pi[INVESTIGATOR_749355]) during 24 weeks of follow -up based on 
weekly interviews and adjusted EDM data  
 The percentage adherence (number of pi[INVESTIGATOR_38947]/number of pi[INVESTIGATOR_749353]) during 2 4 weeks of follow -up based on pi[INVESTIGATOR_10705]  
 The proportion of participants who discontinue all PrEP use based on self -
report via CASI or weekly interviews  
 Information related to PrEP use, motivation, and behavioral skills  based on 
self-report via CASI  
Consis tent with the secondary study objective to evaluate the potential influence 
of PrEP usage on changes in sexual behavior, planning for sex, prediction of risky 
situations, and recognition of possible HIV exposure in relation to PrEP optimism, 
and other demo graphic variables, the following endpoints will be assessed:  
 The frequency of unprotected sex acts via CASI  
 Planning for sex assessed via CASI  
 Safer sex planning survey assessed via CASI  
 Perceived vulnerability assessed via CASI  
 PrEP optimism assessed via  CASI  
HPTN 067, Final Version 5.0  Page 63 of 13 3 June 10 , 2013  
  Demographic measures assessed at enrollment  
 7.3 Accrual, Follow -up, and Sample Size  
The study is mainly powered to assess and compare the proportion of HIV 
exposures covered by [CONTACT_21173][INVESTIGATOR_4382] -use (coverage) in the different populations and usage 
groups.  The study will randomize [ADDRESS_1024787], we are 
interested in the non -inferiority hypothesis that the selected intermittent arm is not 
markedly inferior to the daily arm in the percentage of sex acts covered by [CONTACT_21173][INVESTIGATOR_4382] -
use:  
 
(1) 
Ho: pd – pi >δ 
Ha: pd – pi <δ 
 
Where pi [INVESTIGATOR_749356], pd 
is the corresponding quantity for the daily arm and δ represents an “indifference 
region” ( i.e., if the average proportion of covered sex acts for the intermittent arm 
is within at least δ of the daily arm we will consider them to be equivalent).  The 
second hypothesis is that one intermittent arm has a higher proportion of covered 
sex acts compared to the other intermittent arm:  
 
(2) 
  Ho: pi 1= pi 2 
  Ha: pi 1≠ pi 2 
 
Where pi 1 is the proportion of covered sex acts in one intermittent arm and pi 2 is 
the proportion in the other intermittent arm.   
   
The following are assumed in the sample size calculations: each person will 
report, on average, 50 sex acts over the 24 week self -administered follow -up 
period.  This will vary from person to person an d in the final analysis we will 
account for variable numbers of sex acts across participants.  For simplicity, we 
ignore that variability here.  It is assumed that 90% of sex acts in the daily arm 
will be covered (10% uncovered).  Further, it is assumed th at the proportion of 
HPTN 067, Final Version 5.0  Page 64 of 13 3 June 10 , 2013  
 uncovered acts will vary across participants with a c oefficient of variation  (CV) of 
40% - 80% (a relatively large variance).  The sample size calculations of Hayes 
and Bennett 74 are used directly  to assess the power for the superiority hypothesis 
(2) and we adapt their approach for the non -inferiority hypothesis (1).  
  
HPTN 067, Final Version 5.0  Page 65 of 13 3 June 10 , 2013  
 Table 7.1  Non -inferiority region (δ) for hypothesis (1) 
assuming 60 participants/arm, 50 acts per participant, α =0.05 
(one-tailed).  Power is computed against the alternative that 
coverage is exactly equal in the two arms ( i.e. δ = 0).  
CV Power  % ``uncovered’’ 
sex in daily arm 
(1 – pd) null δ  
  n=60  
.4 .9 .1 0.031  
.4 .95 .1 0.035  
.6 .9 .1 0.040  
.6 .95 .1 0.045  
.8 .9 .1 0.049  
.8 .95 .1 0.055  
 
 
 
Table 7.2  Minimum detectable difference between the rate of 
covered sex acts in one intermittent treatment arm as 
compared to the other intermittent arm (hypothesis 2), 
assuming 60 participants/arm, 50 acts per participant, α = 0.05 
(two-tailed).  
CV Power  The rate of 
uncovered sex 
acts in 
intermittent arm 
1 (1 – pi1) Minimum 
detectable rate of 
uncovered sex in 
intermittent arm 
2  (1 – pi2) 
n=[ADDRESS_1024788] that the rate of 
``uncovered’’ sex acts in the intermittent arm is not different from that in the daily 
arm.  The smaller the equivalence region is, the better power to test the non -
inferiority hypothesis will be achieved.  For a fairly large CV (0.4 -0.6), Table 7.1 
shows that the targeted sample size provides a rather small equivalence margin,  
around 0.03 -0.05, when the daily arm has 10% sex not ``covered’’ by [CONTACT_21173][INVESTIGATOR_4382] -use.  
Table 7.2 shows the minimum detectable rate of covered sex in one intermittent 
arm when the other inte rmittent arm has 10% covered sex acts.  The closer the 
minimum detectable rate is to 0.1, the better power to detect small differences.  
For a CV between 0.[ADDRESS_1024789] (0.8~0.95) on the min imal 
detectable difference (see tables in Appendix II).  Similar power performances 
were observed for the range of rates.  
 
Table 7.3 The sample size needed to achieve a fixed power level (0.8 or 0.9) to a 
detect difference in tolerance scores (based on Ver tigo symptom scale for 
dizziness) between the daily arm and one intermittent arm, given a range of CV, 
assuming tolerance scores are collected twice in the study, the average tolerance 
score in the daily arm is 15, the standard deviation within subject is 5, α = 0.05 
(two-tailed).  
CV Power  The average tolerance 
scores in the intermittent 
arm  Sample size 
needed per arm  
.[ADDRESS_1024790] 
differences in the tolerance scores between the daily arm and one intermittent 
arm, corresponding to the hypotheses  
 
(3) 
  Ho: ud= ui  
Ha: ud≠ ui  
 
where ud is the mean tolerance score in the daily arm and ui  is the mean tolerance 
score in the intermittent arm.   The Vertigo symptom scale for dizziness is used for 
illustration.  This scale will be measured twice in this study.  Based on literature 
on validation of this scale [ADDRESS_1024791] 1/[ADDRESS_1024792] (α = 
0.05) are shown in Table 7.3.  The sample size calculation is based on formula in 
Hayes and Bennett.[ADDRESS_1024793] similar decrease provided the CV is 0.6 or less 
(which we believe is likely).  
 
Table 7.[ADDRESS_1024794] the difference of the number of pi[INVESTIGATOR_749357], corresponding to the 
hypotheses  
HPTN 067, Final Version 5.0  Page 67 of 13 3 June 10 , 2013  
  
(4) 
  Ho: ud= ui  
Ha: ud≠ ui  
 
where ud is the mean number of pi[INVESTIGATOR_749358]. The table gives the power for a range 
of differences and standard deviations, assuming the average number of pi[INVESTIGATOR_749359] [ADDRESS_1024795] (α = 0.05).  The targeted sample  size 
will provide adequate power to detect approximately 15 -20% decrease in number 
of pi[INVESTIGATOR_544610].  A much larger difference is expected so the trial is very well 
powered for this endpoint.  In addition, we do not want to be powered to detect 
smaller diffe rences in pi[INVESTIGATOR_749360] -use do not represent a meaningful benefit of the 
intermittent arm.   
 
Table 7.[ADDRESS_1024796] deviations and the differences, assuming the average number of pi[INVESTIGATOR_749361] 120, n = 60/arm and α = 0.05 (two -tailed).  
Difference between 
Daily arm and the 
intermittent arm   Standard 
Deviation 
(SD) of pi[INVESTIGATOR_749362]  
[ADDRESS_1024797] of a comparison of the proportion of sex acts 
covered by [CONTACT_21173][INVESTIGATOR_4382] -use, percentage of pi[INVESTIGATOR_749363]/her assigned regimen and reported side effects/symptoms between 
the three randomization arms.  All the analyses described here will be intent -to-
treat (in this context, intent to treat means that all sex acts will be included in the 
analysis while the participant is HIV -uninfected, regardless of whether or not the 
participant is on a product -hold) .  All analyses in this section will be conducted 
separately for different social grou ps, defined as women, Thai MSM /TGW, and 
US MSM /TGW in each risk group . Analyses involving pi[INVESTIGATOR_4382] -use data will be 
carried out using the adjusted electronic and self -reported pi[INVESTIGATOR_4382] -use data.  EDM 
pi[INVESTIGATOR_4382]-use data will be adjusted based on weekly interviews to tak e into account 
openings of the device not associated with pi[INVESTIGATOR_749364] ( i.e. when more than one pi[INVESTIGATOR_749365], or pocket dosing).  Information collected after HIV seroconversion, if  
any, will not be included in the analyses.  
 
H1: Study -drug coverage of risk events across the 24 -week monitoring period will 
be statistically equivalent between the non -daily dosing arms and the daily dosing 
arm. 
The sex and pi[INVESTIGATOR_4382] -use data collected weekly  will be summarized for each 
participant as total number of sex acts and the total number of sex acts “covered’’ 
by [CONTACT_21173][INVESTIGATOR_4382] -use during the self -administer study period.  Logistic regression will be 
used to compare the proportion of covered acts between random ized arms.  The 
standard errors of parameter estimates will be scaled by [CONTACT_749448].   
 
H2: Non-daily arms will have fewer reported side -effects.  
Symptom/S ide-effects scores will be collected at regular intervals.  They will be 
treated as ordinal repeated measures, or continuous measures depending on the 
type of tolerance score.  For ordinal measures, a proportional odds model will be 
used for generalized es timating equation (GEE) analysis based on the cumulative 
logit function.  For continuous scores, a linear model will be used for GEE 
analysis.  In both cases, robust standard errors (GEE) will be used to correct for 
correlation between repeated measures on  the same individual.  Pre -
randomization scores will be used as covariates in the analysis to adjust for 
heterogeneity between participants.  Pairwise comparison will be conducted for 
three randomization arms.  Nominal p -values will be provided and a permu tation 
procedure will be used to provide comparisons between the arms that are 
corrected for multiple testing.  
 
H3a: Fewer total pi[INVESTIGATOR_749366] -daily arms.  
The minimum total number of pi[INVESTIGATOR_749367]-
administered period will be computed for each subject using the self -reported 
sexual history data.  The (mean of the) logarithm of the total numbers of pi[INVESTIGATOR_749368] 067, Final Version 5.0  Page 69 of 13 3 June 10 , 2013  
 the dura tion of follow -up will be included in the model as an offset term to 
account for (potentially) different follow -up periods for each participant  
 
H3b: Fewer total pi[INVESTIGATOR_749369] -daily arms.  
The total number of pi[INVESTIGATOR_749370] -administ ered period will be 
computed for each subject using the adjusted EDM data.  The (mean of the) 
logarithm of the total numbers of pi[INVESTIGATOR_749371] -up will be 
included in the model as an offset term to account for (potentially) different 
follow -up periods for each participant.   
7.5.2  Secondary analyses on coverage, pi[INVESTIGATOR_4382] -use and side effects/symptoms  
Differences in effects between the risk groups  will be tested alt hough it is 
acknowledged that tests for effect modification usually have low power.  
 
Another secondary analysis will consider 4 categories of coverage: not covered, 
pre-dose only taken, post -dose only taken, pre and post -dose taken ( i.e., covered).  
A [ADDRESS_1024798] and will use a randomization procedure (randomizing by 
[CONTACT_3445]) to test for differences between arms.  
 
Exploratory secondary analyses using weekly collected  pi[INVESTIGATOR_749372] (defined as 
receptive vaginal or receptive or insertive anal intercourse events where no 
condom use was reported). Methods identical to those outlined for hypothesis  H1 
in section 7.5.1 will be used.  
7.5.3  Secondary analyses on adherence, acceptability  and sexual behavioral 
data  
H1: Time - and event -driven arm participants will report greater preference for their 
assigned study arm at the Week [ADDRESS_1024799].   
 
H2: At Week 30 assessments, participants assigned to time - and event -driven arms 
will report higher levels of PrEP use related information, motivation, and behavioral 
skills, in comparison to those in the daily arm.  
 
A score for PrEP use will be computed ba sed on IMB (see Table 1, Section 5.10) for 
each participant and a Wilcoxon rank sum test will be used to compare the scores 
between treatment arms.  
 
H3: Across all 24 weeks of on -drug monitoring, rates of adherence to one’s assigned 
regimen will be higher in the time - and event -driven arms.  
HPTN 067, Final Version 5.0  Page 70 of 13 3 June 10 , 2013  
  
Self-reported adherence (SR adherence) will be calculated for each participant as 
the percentage of pi[INVESTIGATOR_749373]/her 
assigned regimen and (in the case of the intermittent  arms) self -reported sex 
events.  Logistic regression will be used to compare the adherence rates between 
randomized arms.  The standard errors of parameter estimates will be scaled by 
[CONTACT_749449].  Analyses will be done with and without the 
unvalidated pi[INVESTIGATOR_4382] -use data, as described in Section 7.5.1.   
 
We will also calculate adherence by [CONTACT_21173][INVESTIGATOR_749374] 4 
week follow -up period.  Adheren ce by [CONTACT_21173][INVESTIGATOR_749375].  A scatterplot of the two measures of adherence will be 
presented and the concordance correlation 76 will be computed for these two 
measures of adherence.  
 
H4: Across all [ADDRESS_1024800].   
 
H5: PrEP  use will not uniquely contribute to increases in risk (non -condom use risk 
events) from baseline to final Week 30 assessment (null disinhibition hypothesis).  
The self -reported data on sex acts will be summarized for each subject to create 
the total number  of sex acts and the number of sex acts with and without condom 
use.  Rates of condom use relative to total sex acts, for those with at least one act 
reported throughout the [ADDRESS_1024801] errors of parameter 
estimates will be scaled by [CONTACT_749450].   
 
H6: A relationsh ip between intervention arm and coverage can be explained by [CONTACT_749451].  
 
Here we illustrate just one set of analyses that we will do to explore th is 
hypothes is.  It is likely that additional analyses will be suggested by [CONTACT_749452] r elated analyses.  
 
Suppose we find that coverage (for example) differs significantly by [CONTACT_468138].  We may hypothesize that the observed effect of arm on coverage can be 
explained by [CONTACT_749453].   
 
 Arm  Coverage  
 
              PrEP Optimism  
HPTN 067, Final Version 5.[ADDRESS_1024802] and the dashed arrow 
indicates a univariate (unadjusted) association that is not significant in the 
adjusted model.  To investigate this we would run the follo wing models (here, Y 
is the outcome, A is intervention arm, OP is optimism about PrEP):  
 
 Y ~ A  
 Y ~ A + OP  
 OP ~ A  
 
If optimism about PrEP mediates the effect of arm on the outcome, then we would 
expect to see a strong relationship between the outcome and  arm in the first 
model, a weak relationship between the outcome and arm after controlling for 
PrEP optimism in the second model, and a strong relationship between optimism 
about PrEP and arm in the third model.   
 
H7: Planning for sexual events, predictio n of risk events, and recognition of risk 
events will be superior at last on -drug assessment within time and event -driven arms 
compared to the daily PrEP arm.  
7.5.[ADDRESS_1024803] being 
TFV -DP.  While drug concentration dat a collected during this period may allow 
estimation of PK parameters (clearance, volume of distribution, half -life), the 
sparse weekly sampling and fixed pre -dose schedule of blood collection will limit 
the precision of these estimates.  The primary readou t from this period is the pre -
dose drug concentration at Weeks [ADDRESS_1024804] for steady -state and the “expected” pre -dose concentration for 
each individual.  Week 4 and Week 5 data (Week 5 alone if steady -state ha s not 
been achieved) will provide a point estimate for the expected concentration at 
steady -state and an estimate of intra -individual variability in this pre -dose 
concentration.  Decay will be monitored from drug dose concentration data 
collected at Week 6 .   
 
All of the assays used will be validated and approved for use in NIH network 
studies by [CONTACT_579020] (CPQA) Program 
consistent with FDA standards for drug development.  All of these assays use 
LC/MS methods for analyte q uantitation.  
HPTN 067, Final Version 5.0  Page 72 of 13 3 June 10 , 2013  
  
These data will be used to compute laboratory verified adherence (LV adherence) 
for participants in the unobserved dosing phase of the study.  In contrast to self -
report adjusted EDM -based adherence (defined in Section 7.5.3), LV adherence is  
computed as the ratio of observed and expected concentrations (where the 
expected concentration is based on the reported dosing) and can be greater than 
1.0 due to random variability.  Random error can be attributed to intra -individual 
variability and ass ay variability in the laboratory (<15% CV) with the validated 
assay used at the HPTN NL.   
 
With scheduled dosing, the expectation of drug concentration can be estimated 
based on observed drug concentrations at the end of the DOT period by a simple 
simulation of drug concentration over time according to the prescribed regimen.  
The regimen itself  is simply an invariant scalar that predicts the expected 
concentration.  Event -driven dosing introduces an additional variability that 
decreases the precision of any LV adherence estimates.  With sexual event 
dependent dosing, a similar simulation can be performed, using the time of sex 
and the PK parameters derived from the DOT period.   
 
Based on available information, it is predicted that participants who take [ADDRESS_1024805] detectable TFV -DP in their PBMCs, 
as measure d at Weeks 10, 18 and 30.  Undetectable drug levels in persons 
reporting using 4 or more pi[INVESTIGATOR_749376] -reporting.  In a secondary, 
exploratory analysis, we will repeat the analyses of coverage (Section 7.5.1) and 
adherence (Section 7.5.3) and data from periods of over -reporting will be 
censored from the analysis.  Persons reporting use of fewer than [ADDRESS_1024806] 
2 weeks will be included in the analysis regardless of drug level.  We will 
evaluate the amount of data censored by [CONTACT_749454] -reporting 
periods.  Drug levels may also be assessed in whole blood (Harlem site only).  
7.5.[ADDRESS_1024807] appropriate unit to code (utterance, table turn, complete sentence, 
or some other integral).  Once units are defined, transcripts will undergo two 
phases of qualitative analysis.  The first phase utilizes grounded theory analysis or 
a site selected valid alternative methodology (e.g., framework analysis).[ADDRESS_1024808].79  The methodology recommended for grounded 
theory includes a phase of open -coding where transcripts are iteratively 
HPTN 067, Final Version 5.0  Page 73 of 13 3 June 10 , 2013  
 reviewed by [CONTACT_749455] ( e.g., pi[INVESTIGATOR_4382] -taking, PrEP ) enough to provide an adequate level of 
theoretical sensitivity in the development of coding schemes.  These reviews 
produce a set of general global categories which describe the concepts and 
properties of the phenomenon under study.  Given the intended c ontent of the 
focus group queries, it is anticipated that a priori phenomenon will include 
pi[INVESTIGATOR_4382]-taking, participating in a PrEP trial, risk reduction behavior (condom use), 
PrEP regimens, and social roles.  However, additional phenomenon that 
emerge from f ocus group data will also be included.  Open -coding can be 
further qualified by [CONTACT_749456], defined as not only a comprehensive 
description of the phenomenon but also identification of the context in which it 
occurs (moderating content), intervening cond itions for it to occur (mediating 
conditions), action strategies (activities done surrounding or in response to the 
phenomenon), and consequences (outcomes of activities).  With adequate 
characterization of the data with open codes, consolidation of codes will lead 
to a final coding system that will be used to quantify the data.  It is assumed 
that using this process, the focus groups will be characterized in terms of the 
main content describing discussions of critical aspects of pi[INVESTIGATOR_4382] -taking and PrEP 
partic ipation defined both a priori and through the identification of emerging 
phenomenon that may not have been anticipated.  Note that while constant 
comparison methods are used, we are also interested in applying principles of 
classic content analyses in that  the relative frequencies of variable aspects of 
the axial codes are also of interest.80  Because of this, we will evaluate 
agreement on a minimum of 10% of the coded units via double -coding.   
 
Focus group data will also be used to inform the adapted IMB model employed 
in this research and to identify the relative type and frequency of theory -
related barriers and facilitators via content (structural) analysis.[ADDRESS_1024809], core content categories for 
summary ( e.g., frequencies, relative proportions).  It is anticipated that after 
completion of the grounded theory coding, coders will review content of the 
focus groups for references to barriers and facilitators of pi[INVESTIGATOR_4382] -taking and of 
prevention behaviors ( e.g., condom use).  Each identified barrier and 
facilitator will be further coded for content that is informational, motivational 
or behavioral skills related.  These non -orthoganol codes will characterize the 
kinds of barriers and  facilitators reported in focus group discussions.  
Importantly, any barrier or facilitator not  coded by [CONTACT_749457] (content) that will 
be used in future applications of the model and to provide guidance for targets 
of pi[INVESTIGATOR_4382] -taking and condom use support strategies.  Similar to the classical 
content analysis portion of the grounded theory approach, at least 10% of the 
units will be double coded to determine agreement.  It is anticipated that data 
from focus groups will provide nuanced information about acceptability and 
feasibility of the various PrEP regimens and will characterize the factors that 
HPTN 067, Final Version 5.[ADDRESS_1024810] influential to focus group participants in maintaining pi[INVESTIGATOR_4382] -use, as 
well as con dom use in the context of PrEP.   
 
Key informant interviews: Semi -structured interviews will be conducted after 
Week 34.  The one -on-one interviews with selected participants and study staff 
will use an interview guide and responses will be recorded and tr anscribed.  
Responses will be reviewed by [CONTACT_749458] ( e.g. by [CONTACT_749459], by [CONTACT_749460]) and inductive generation of 
main content themes.  Qualitative analytic strategies similar to those used in 
analyzing focus group data will be adopted for the key informant interview data 
as well.  
Analysis for both qualitative components will be completed using CDC EZ Text 
or another simil ar qualitative software program.   
 
7.6 Safety Monitoring for HIV Seroconversions  
HIV seroconversions are not the primary outcome in HPTN 067 because they are 
expected to be rare.  However, if an unexpectedly large number of serconversions 
were to occur in  the trial, and if these were all concentrated in one arm, then this 
information would overshadow results from the pre -specified primary outcome of 
coverage.  Therefore, it makes sense to devise a monitoring plan for HIV 
seroconversions.   
 
Daily Truvada® is the “standard of care” condition in this trial, with proven 
efficacy in MSM based on iPrEx and in WSM based on the Partners  PrEP trial . 2  
The intermittent arms are the “experimental” co nditions.  Thus, our concern is 
that the HIV seroconversion rate may be higher in the intermittent arms compared 
to the daily arm.  To evaluate this concern, we will compare the combined number 
of HIV events in the intermittent arms with the number of even ts in the daily arm.  
 
The following table gives the probability (p -value) for various distributions of 
HIV seroconversion events between the daily and intermittent arms under the null 
hypothesis assumption of no difference in HIV seroconversion rates betwe en the 
[ADDRESS_1024811] e looks at 
the data (“multiple testing”).   Such adjustments typi[INVESTIGATOR_749377], which is difficult to predict here (in 
fact, in the two original HPTN 067 sites – South Africa and Thailand – we expect 
fewer than 8 total events).  This suggests, however, that one should be 
conservative in using these probabilities for modifying the trial (i.e. only stop 
when the probability is quite small).  In addition, these probabilities depend on the 
total number of events in the intermittent arms and do not distinguish between all 
events in one arm (say, event -driven) and a mix of events in the two intermittent 
arms.  The rationale for t his is that we would be equally “alarmed” in either case.  
Finally, the probabilities given in the table are “one -sided” in the sense that we 
would not consider stoppi[INVESTIGATOR_749378] (if this 
HPTN 067, Final Version 5.0  Page 75 of 13 3 June 10 , 2013  
 possibility were included, the probabilities in the table would be larger and the 
number of events to consider stoppi[INVESTIGATOR_749379]).  
 
Number in daily arm  Number in intermittent arms  Probability1 
0 3 .30 
0 4 .20 
0 5 .13 
0 6 .088 
0 7 .059 
0 8 .039 
0 9 .026 
1 9 .10 
1 10 .075 
1 11 .054 
1Computed as a one -tailed p -value under the null assumption that 2/3 of the HIV events will occur 
in the intermittent arms and 1/[ADDRESS_1024812] one could possibly reach a one sided p <  0.[ADDRESS_1024813] occurred, the 
data will be immediately forwarded to the DSMB for prompt consideration.  The 
DSMB  and SDMC  will monitor the total number of events.  The study team and 
DSMB will agree upo n a monitoring plan for HIV seroconversion events.  
 
8.0 HUMAN SUBJECTS CONSI DERATIONS  
8.1 Ethical Review  
This protocol and the template informed consent forms contained in Appendix III 
— and any subsequent modifications — will be reviewed and approved by t he 
HPTN Scientific Review Committee (SRC) and DAIDS Protocol Safety Review 
Committee (PSRC) with respect to scientific content and compliance with 
applicable research and human subjects regulations.   
 
The protocol, site -specific informed consent forms, participant education and 
recruitment materials, and other requested documents — and any subsequent 
modifications — also will be reviewed and approved by [CONTACT_749461] t of research conducted at the study site.  The University 
of Cape Town in Cape Town is the IRB of record for the Cape Town site. The 
Institutional Review Board, Human Research Protection Office, US Centers for 
Disease Control and Prevention and the Ethica l Review Committee for Research 
in Human Subjects, Department of Medical Sciences, Ministry of Public Health, 
Thailand are the IRBs of record for the Bangkok site. Columbia University 
Medical Center Institutional Review Board in [LOCATION_001] is the IRB of reco rd for 
the [LOCATION_001] site.  
 
HPTN 067, Final Version 5.0  Page 76 of 13 3 June 10 , 2013  
 Subsequent to initial review and approval, the responsible IRBs/ECs will review 
the protocol at least annually.  The Investigator will make safety and progress 
reports to the IRBs/ECs at least annually, and within three months o f study 
termination or completion.  These reports will include the total number of 
participants enrolled in the study, the number of participants who completed the 
study, all changes in the research activity, and all unanticipated problems 
involving risks to human subjects or others.  IRBs and participants will also be 
informed of important new findings related to the effectiveness of PrEP.  Study 
sites will submit documentation of continuing review to the DAIDS Protocol 
Registration Office, via the HPTN CO RE, in accordance with the current DAIDS 
Protocol Registration Policy and Procedure Manual.  
8.2 Informed Consent  
Written informed consent will be obtained from each study participant.  Each 
study site is responsible for developi[INVESTIGATOR_007] a study informed consent form for local 
use, based on the template in Appendix III that describes the purpose of the study, 
the procedures to be followed, and the risks and benefits of participation, in 
accordance with all applicable regulations.  The study site also is responsibl e for 
translating the template form into local languages and verifying the accuracy of 
the translation.   
 
Participants will document their provision of informed consent by [CONTACT_749462].  Non -literate participants will not be eligib le for the 
study.  (Further details regarding DAIDS requirements for documenting the 
informed consent process are provided in the DAIDS s tandard operating 
procedure  (SOP) for Source Documentation.)  
 
Participants will be provided with a copy of their inform ed consent forms if they 
are willing to receive them.  
  
HPTN 067, Final Version 5.[ADDRESS_1024814] acute HIV infection, or 
other acu te viral infections such as H1N1 influenza.  Persons with acute viral 
syndromes will not be enrolled.  They can be enrolled after signs and symptoms 
resolve if they remain eligible in all other respects, including negative HIV 
antibody status.  Persons sus pected of acute HIV infection will be evaluated using 
HIV RNA testing.   
 
Phlebotomy  
Phlebotomy may lead to discomfort, feelings of dizziness or faintness, and/or 
bruising, swelling and/or infection.   
 
Confidentiality  
Although study sites make every effort to protect participant privacy and 
confidentiality, it is possible that participants' involvement in the study could 
become known to others, and that social harms may result.   
 
Study Medications  
TDF .   
More than 12,[ADDRESS_1024815] been treated with Viread®  alone or in 
combination with other antiretroviral medicines for [ADDRESS_1024816] common side effects 
(occurring in 10% or more of patients) identified from any of the 3 large 
controlled clinical trials include rash, diarrhea, headache, pain, depression, 
asthenia (weakness) and nausea.  
 
About 5 to 10 out of 100 people with HIV  taking Viread® tablets in Studies 903, 
934 and 907 (clinical studies of Viread® in combination with other antiretroviral 
agents) have experienced these side effects:   
 Headache  
 Pain, including abdominal, back or joint pain  
 Fever  
 Weakness or fatigue  
 Diarrh ea 
 Nausea or vomiting  
 Depression  
HPTN 067, Final Version 5.0  Page 78 of 13 3 June 10 , 2013  
  Insomnia (inability to sleep)  
 Headache  
 Dizziness  
 Sinus inflammation, respi[INVESTIGATOR_696] (chest) infection  
 Anxiety  
 Rash  
 Increased cholesterol  
 Increased creatine  kinase (an enzyme found in tissues and cells of the body), 
which could mean muscle damage  
 Increased amylase (an enzyme made by [CONTACT_749463])  
 
The following additional side effects have been reported in patients taking 
Viread® outsid e of clinical trials. It is not always possible to estimate how 
frequently these events occur or know if they result from taking tenofovir 
disoproxil fumarate.  
 Immune system problems (allergic reaction, including swelling of face, lips 
and/or tongue)  
 Nutri tion problems (buildup of lactic acidosis, low potassium in the blood, 
low phosphate levels in the blood)  
 Shortness of breath  
 Stomach problems (swelling of the pancreas, increased amylase, and stomach 
pain)  
 Liver problems (fat in the liver, swelling of the  liver, increased liver enzymes)  
 Rash  
 Muscle and tissue problems (breakdown of muscle fibers, softening of the 
bones, weakness, muscle pain)  
 Kidney problems (kidney failure, decline in kidney function, increase 
creatinine [a marker of kidney function], pro tein in the urine, increase 
urination)  
 Weakness  
 
Viread® may cause the following serious side effects:  
 Lactic acidosis (buildup of acid in the blood)  
 Serious liver problems (hepatotoxicity) with liver enlargement 
(hepatomegaly) and fat in the liver (steat osis)  
 “Flare -ups” of hepatitis B virus (HBV) infection, in which the disease 
suddenly returns in a worse way than before, can occur if Viread®  is stopped  
 Kidney problems  
 Changes in bone mineral density (thinning bones)  
 Changes in body fat  
HPTN 067, Final Version 5.0  Page 79 of 13 3 June 10 , 2013  
  Changes in the HIV -positive patient’s immune system (Immune 
Reconstitution Syndrome)  
 
The side effects listed above were reported in people with HIV infection. They 
used Viread® for HIV treatment. The side effects of Viread® when taken by 
[CONTACT_749464] .  
 
TDF is a pregnancy category B medication.  A controlled human study of TDF 
among pregnant women has been conducted, but results are not currently 
available (HPTN 057: http://www.hptn.org/research_studies/hptn057.as p).   
 
FTC .  More than 2,[ADDRESS_1024817] been treated with Emtriva ® alone or 
in combination with other antiretroviral medicines for [ADDRESS_1024818] common side effects (occurring in 10% or more of 
patients) identified from any of the 3 large controlled clinical trials include 
headache, diarrhea, nausea, fatigue, dizziness, depr ession, insomnia, abnormal 
dreams, rash, abdominal pain, asthenia (muscle weakness), increased cough, and 
rhinitis (runny nose). Skin discoloration (darkening of the palms and/or soles) 
may also happen with Emtriva®.  
 
About 5 to 10 out of 100 people with H IV taking Emtriva® capsules in Studies 
301, 303 and 934 (clinical studies of Emtriva® in combination with other 
antiretroviral agents) have experienced these side effects:   
 Headache  
 Pain, including abdominal or joint pain  
 Weakness or fatigue  
 Paresthesia ( tingling)  
 Diarrhea  
 Nausea or vomiting  
 Depression  
 Insomnia (inability to sleep) or abnormal dreams  
 Headache  
 Dizziness  
 Cough  
 Sinus inflammation, respi[INVESTIGATOR_696] (chest) infection  
 Rash  
 Increased cholesterol or triglycerides  
 Increased creatine  kinase (an enzyme found in tissues and cells of the body), 
which could mean muscle damage  
 Increased amylase (an enzyme made by [CONTACT_749463])  
HPTN 067, Final Version 5.0  Page 80 of 13 3 June 10 , 2013  
  
Emtriva® may cause the following serious side effects:  
 Lactic acidosis (buildup of acid in  the blood)  
 Serious liver problems (hepatotoxicity) with liver enlargement 
(hepatomegaly) and fat in the liver (steatosis)  
 “Flare -ups” of hepatitis B virus (HBV) infection, in which the disease 
suddenly returns in a worse way than before, can occur if Emt riva®  is stopped  
 Changes in body fat  
 
The side effects listed above were reported in people with HIV infection. They 
used Emtriva® for HIV treatment. The side effects of Emtriva® when taken by 
[CONTACT_749465] .  
 
 
FTC is a pregnancy category B medication.  No controlled human studies of FTC 
among pregnant women have been conducted.   
 
FTC/TDF combination tablet .   
About 5 to 10 out of 100 people with HIV taking Truvada ® tablets in Study 934, 
a clinical study of Truvada ® and efavirenz, have experienced these side effects .16 
 Diarrhea or nausea  
 Fatigue or lack of energy  
 Sinus inflammation, respi[INVESTIGATOR_696] (chest) infection  
 Dizziness or headache  
 Depression or insomnia  
 Rash  
 Increased cholesterol  
 Increased creatine phosphokinase (CPK; an enzyme found in tissues and cells 
of the body), which could mean muscle damage  
 Increased amylase (an enzyme made by [CONTACT_749463])  
 
Other side effects that have occurred in at least 5 out of 100 patients receiving the 
components of Truvada®, emtricitabine15 or tenofovir disoproxil fumarate14, with 
other HIV medications in clinical trials include:  
 Anxiety  
 Joint pain (arthralgia)  
 Increased cough  
 Upset stomach or indigestion (dyspepsia)  
 Fever  
 Muscle pain (myalgia)  
HPTN 067, Final Version 5.0  Page 81 of 13 3 June 10 , 2013  
  Pain  
 Abdominal pain  
 Numbness or tingling of the skin (paresthesia)  
 Problem with the nerves that can cause weakness, changes in sensation, or 
pain (peripheral neuropathy)  
 Pneumonia  
 Runny nose (rhinitis)  
 
The following additional side effects have been reported in patients taking 
tenofovir disoproxil fumarate14, a component of Truvada®, outside of clinical 
trials. It is not always possible to estimate how frequently these events occur or 
know if they result from taking tenofovir disoproxil fumarate.  
 Immun e system problems (allergic reaction)  
 Nutrition problems (buildup of lactic acidosis, low potassium in the blood, 
low phosphate levels in the blood)  
 Shortness of breath  
 Stomach problems (swelling of the pancreas, increased amylase, and stomach 
pain)  
 Liver problems (fat in the liver, swelling of the liver, increased liver enzymes)  
 Rash  
 Muscle and tissue problems (breakdown of muscle fibers, softening of the 
bones, weakness, muscle pain)  
 Kidney problems (kidney failure, decline in kidney function, increase 
creatinine [a marker of kidney function], protein in the urine, increase 
urination)  
 Weakness  
 
Truvada® may cause the following serious side effects:  
 Lactic acidosis (buildup of acid in the blood)  
 Serious liver problems (hepatotoxicity) with liver enlargemen t 
(hepatomegaly) and fat in the liver (steatosis)  
 “Flare -ups” of hepatitis B virus (HBV) infection, in which the disease 
suddenly returns in a worse way than before, can occur if the patient stops 
taking  Truvada®.   
 Kidney problems  
 Changes in bone mineral  density (thinning bones)  
 
Other side effects with Truvada® when used with other anti -HIV-1 medications 
include .16 
HPTN 067, Final Version 5.0  Page 82 of 13 3 June 10 , 2013  
  Changes in body fat have been seen in some patients taking Truvada® and 
other anti -HIV-1 medicines. These changes may include increased amount of 
fat in the upper back and neck (“buffalo hump”), breast, and around the main 
part of the patient’s  body (trunk).  Loss of fat (wasting) from the legs, arms 
and face may also happen.  
 In some patients with advanced HIV infection (AIDS), signs and symptoms of 
inflammation from previous infections may occur soon after anti -HIV 
treatment is started.  
 
The side effects listed above were reported in people with HIV infection. They 
used Truvada® for HIV treatment. The side effects of Truvada ® when taken by 
[CONTACT_749466], 
Partners PrEP, and TDF2 studies.  Truvada ® was well tolerated with no reported 
side effects by [CONTACT_749467].  Less than [ADDRESS_1024819] 4 weeks of Truvada ® use.  The 
iPrEx study found that bone mineral density was less in those taking Truvada ® 
compared with people taking placebo.  The difference in bone mineral density 
was less than 1% on average, and did not progress after the first 24 weeks, and 
was not associated the bone fractures.1-3_  For the daily arm, the FTC/TDF dosing 
regimens are consistent with package insert recommendations.  Most participants 
in the time -driven and event -driven arms are anticipated to utilize FTC/TDF at a 
less frequent rate th an package insert recommendations.  
 
Nucleotide Analogues .  Lactic acidosis (elevated lactic acid levels in the blood) 
and severe hepatomegaly (enlarged liver) with steatosis (fatty liver) that may 
result in liver failure, other complications or death have been reported with the 
use of antiretroviral nucleoside analogues alone or in combination.  The liver 
complications and death have been seen more often in women on these drug 
regimens.  Some nonspecific symptoms that might indicate lactic acidosis 
include:  unexplained weight loss, stomach discomfort, nausea, vomiting, fatigue, 
cramps, muscle pain, weakness, dizziness, and shortness of breath.  These effects 
are not expected in this study involving a brief exposure to antiretroviral drug.  
 
Antiretroviral dru gs.  Redistribution/accumulation of body fat including central 
obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial 
wasting, breast enlargement, and "cushingoid appearance" have been observed in 
persons receiving antiretroviral  drugs.  The mechanism and long -term 
consequences of these events are currently unknown.  A causal relationship has 
not been established.  These effects are not expected in this study involving a 
brief exposure to antiretroviral drug.  
HPTN 067, Final Version 5.[ADDRESS_1024820] acute HIV infection will defer enrollment and be 
referred for evaluation of acute infection.  If acute HIV infection is suspected after 
enrollment, the participant will undergo evaluation  using rapid HIV antibody 
testing and GenAptima HIV RNA testing, as indicated.  These steps should 
minimize the risk of drug resistance occurrence by [CONTACT_749468][INVESTIGATOR_11743].  If any participant in HPTN 067 bec omes 
HIV-infected during the study and develops TDF or FTC resistance, an alternative 
treatment regimen could be used that includes a non -nucleoside reverse 
transcriptase inhibitor (NNRTI), a protease inhibitor, and an NRTI that is not 
affected by [CONTACT_941] M184 V or K65R mutations.   
8.4 Benefits  
Several clinical trials evaluating the efficacy of FTC/TDF (administered daily) for 
PrEP are ongoing or have already been completed as described in Section 1.3.  
The results of these studies will be shared with participa nts as they are made 
available.   
Participants in this study will benefit from HIV education and prevention 
messages.  They will receive free HIV and HBV serologic testing.  Participants 
found to be susceptible to HBV will be offered standard HBV vaccinati ons.  The 
services to be provided for HIV seroconverters include: laboratory testing for 
drug resistance, plasma HIV RNA level, and CD4 cell count.  Participants who 
acquire HIV infection during the study will be provided with referral for HIV 
services and  evaluation of whether ART is needed and will continue to be 
followed in this study.  
8.5 Incentives  
Pending IRB/EC approval, participants will be compensated for their time and 
effort in this study, and/or be reimbursed for travel to study visits and time away 
from work.  Incentives for responses to weekly telephone contacts will be 
provided via payment at the next clinic visit.  Site-specific reimbursement 
amounts will be specified in the study informed consent forms.  
HPTN 067, Final Version 5.[ADDRESS_1024821] -protected access systems.   
 
Participant’s study information will not be released without the written permission 
of the partici pant, except as necessary for monitoring by [CONTACT_941] U.S. CDC, NIAID 
and/or its contractors; [COMPANY_009] Sciences, Inc. representatives of the HPTN CORE, 
SDMC, and/or NL, the U.S. FDA, other government and regulatory authorities, 
and/or site IRBs/ECs.   
8.7 Communic able Disease Reporting Requirements  
Study staff will comply with all applicable local requirements to report 
communicable diseases identified among study participants to local health 
authorities.  Participants will be made aware of all reporting requirements during 
the study informed consent process.  
8.8 Study Discontinuation  
The study may be discontinued at any time by [CONTACT_18127], the HPTN, the National 
Institutes of Mental Health (NIMH), [COMPANY_009] Sciences, Inc., OHRP, the U.S. FDA, 
the US CDC, the Thai land Ministry of Public Health, the South African 
Medicines Control Council, and/or site IRBs/ECs.  
9.[ADDRESS_1024822] ed for 
testing at the local laboratory (LL):  
 Urine specimen for the following:  
o Pregnancy testing for women with reproductive capacity  
HPTN 067, Final Version 5.0  Page 85 of 13 3 June 10 , 2013  
 o Dipstick for protein and glucose  
o Storage  
 Blood specimen for the following:  
o HIV rapid testing  (See SSP for protocol algori thm) 
o HIV confirmatory testing with a Western blot and/or with the 
GenAptima HIV RNA test  
o Quantitative HIV RNA testing in any participant with confirmed 
HIV infection  
o CD4 cell count in any participant with confirmed HIV infection  
o HepBsAg  
o HepBCoreAb (if the test for HepBsAg is negative)  
o HepBsAb (if the test for HepBsAg is negative)  
o CBC  
o Serum creatinine (for estimated creatinine clearance)  
o Serum phosphate  
o AST/ALT  
o Plasma for storage  
o Lysed PBMCs for storage  
o DBS for storage  for host genetic testing  (see section 9.5)  
o DBS for storage for drug levels  (Harlem site only)  
 Hair specimen for storage  
 
Local laboratories will perform  testing such as Chemistry, Hematology, and 
pregnancy tests as indicated in Appendix I.  International Laboratories performing 
these tests will be monitored by [CONTACT_749469] (pSMILE) and must demonstrate successful participation 
in the relevant External Quality Assurance (EQA) programs.  US sites should 
send the tests to CLIA -certified laboratories and must participate in EQA 
programs.  
 
Local laboratories may also perform CD4 cell count testing and quantitative HIV 
RNA (viral load) testing as indicated in Appendix I.  Laboratories performing 
these tests will be monitored by [CONTACT_592911] 
(IQA) and /or Virology Quality Assurance (VQA) programs and must 
demonstrate successful participation in the relevant EQA programs.  US site s must 
use CLIA -certified laboratories; participation in the IQA and / or VQA program  is 
recommended.  
 
Each study site will adhere to standards of good laboratory practice, the HPTN 
Network Laboratory Manual, and local SOPs for proper collection, processing, 
labeling, transport, and storage of specimens to the LL.  Specimen collection, 
testing, and storage at the LL will be documented using the HPTN Laboratory 
Data Management System (LDMS) as described in the SSP Manual.  
 
All specimens will be shipped in accordance with International Air Transport 
Association (IATA) specimen shippi[INVESTIGATOR_749380].  All shipments will be 
documented using the HPTN LDMS as described in the SSP Manual.  
HPTN 067, Final Version 5.0  Page 86 of 13 3 June 10 , 2013  
 9.2 Network Laboratory Specimens  
As described in Section 5, the following types of specimens will be collected for 
testing at the HPTN NL:  
 
Virology  
 
The HPTN NL will perform testing to determine HIV infection status in selected 
cases ( e.g., indeterminate Western blot) and may also perform specialized assays 
to characterize HIV viruses and the immune response to HIV infection in 
participants who become HIV -infected  during the study.  This may include testing 
with assays used for analysis of HIV incidence.  Additional assays may be 
performed at the HPTN NL or at an outside laboratory designated by [CONTACT_749470].  This testing may include HIV genotypi[INVESTIGATOR_007], HIV phenotypi[INVESTIGATOR_007] , HIV subtypi[INVESTIGATOR_007], 
minority variants assays, or other tests to characterize HIV viruses and/or the host 
response to HIV infection.  Results from those tests will not be returned to study 
sites or study participants.  
 
Pharmacology  
 
Retrospective analysis of drug levels will provide an objective measure of 
adherence.  Estimation of PK for each participant allows for drug concentrations 
to be used as objective measures of drug exposure and allows for an estimation of 
pi[INVESTIGATOR_4382]-use during the self -administered dosing  phase of the study.  
 
The level of TFV -DP in PBMCs will be monitored after directly observed doses 
during Weeks 4 and 5.  Decay will be monitored at Week 6 .  If results from that 
testing indicate that PBMC testing will be informative (if sufficient levels of 
TFV -DP are detected in PBMCs) , levels of TFV -DP will be monitored in PBMCs 
at Weeks 10, 18, and 30.  PBMC drug levels will be measured using assays that 
are validated and approved by [CONTACT_749471] (CPQA).  FTC -TP may also be measured.  Aggregate results that do 
not identify individual study participants may be made available to study sites 
during the trial to provide information on adherence of participants to the study 
regimen s.  Data from individual study participants will not be returned to study 
sites or study participants.  Stored plasma may be tested at the HPTN NL to 
measure extracellular drug levels of TFV and FTC, for comparison.   Initial 
testing  of DBS samples (Harlem site only) will be performed u sing a subset of 
the samples to obtain data about the accumulation of drug to steady state; results 
from that testing will be used to evaluate whether the DBS testing should be 
expanded to include additional DBS samples from that site.  
 
 
Hair will be colle cted and stored for possible measurement of drug levels at 
Weeks 4, 5, 6, 10, 18, and 30.  Testing of hair for drug concentrations may be 
performed either at the HPTN NL or at an outside laboratory designated by [CONTACT_749472].  If an outside laboratory is us ed, protocols for drug measurement must 
HPTN 067, Final Version 5.[ADDRESS_1024823] be approved by [CONTACT_749473] 067 specimens are tested.  Hair 
samples that are not destroyed during analysis will be destr oyed once all hair 
analysis is completed.  
 
Urine will be stored for possible future studies analyzing the relationship between 
TFV drug level and dose and the occurrence of renal proximal tubulopathy.  
Those laboratory studies would be funded separately if  daily PrEP trials show that 
proximal tubulopathy occurs among HIV -uninfected persons at a higher rate after 
TDF exposure than among HIV -uninfected persons exposed to placebo.  The 
testing would include fractional excretion of uric acid and phosphate (invo lving 
parallel testing of these analytes in plasma and urine), urine protein, urine 
glucose, urine creatinine, and urine calcium.  
 
Drug Resistance Testing Performed at a Commercial Laboratory  
 
Samples from participants who become HIV -infected during the st udy will be 
shipped to the HPTN NL.  A sample collected at the time of HIV diagnosis will 
be sent to a commercial laboratory ( e.g., Monogram Biosciences, South San 
Francisco, CA) for HIV resistance testing.  Results from that testing will be made 
available  to study sites at study closure.  Results may be provided to study sites 
prior to study closure upon request, with approval of the HTPN NL and the 
Protocol Chair.  Results from any other resistance testing ( e.g., minority variants 
analysis, if performed, see above) will not be returned to study sites.  
9.[ADDRESS_1024824] of 1988 (CLIA -certified) an d/or 
participate in DAIDS sponsored EQA programs.  NL staff will conduct periodic 
visits to each site to assess the implementation of on -site laboratory quality 
control (QC) procedures, including proper maintenance of laboratory testing 
equipment and use o f appropriate reagents.  NL staff will follow up directly with 
site staff to resolve any QC or quality assurance (QA) problems identified through 
proficiency testing and/or on -site assessments.  Throughout the course of the 
study, the HPTN NL will select a  random sample of stored specimens to test for 
QA purposes.  NL staff will follow -up directly with site staff to resolve any QA 
problems identified through this process.  
 
All of the assays to be used in this study have been approved for use in HPTN 
studies  by [CONTACT_730387] -network CPQA program.  The quality of the assays is also 
continuously evaluated by a twice yearly proficiency testing program 
administered by [CONTACT_749474].  Satisfactory scores are required for the laboratory to 
be able to continue to use assays in support of HPTN studies.  The Pharmacology 
Core Lab will adhere to Good Laboratory Practice (GLP) for processing all 
samples.  
HPTN 067, Final Version 5.[ADDRESS_1024825] use two FDA -cleared rapid tests.  Preference is given to FDA -cleared 
OraSure Oraquick HIV½, Clearview HIV½ Stat Pak, Clearview Complete HIV½ 
, Trinity Unigold Recombigen or OraSure Oraquick HIV 1/[ADDRESS_1024826] approve the testing algorithm  at each site prior to study 
activation and/or when a site needs to change a kit .  Participants with one or two 
reactive HIV rapid test results at Screening or Enrollment will not be eligible for 
enrollment, r egardless of subsequent test results.  In those cases, HIV infection 
status will be confirmed using local HIV testing guidelines.  Participants who 
have one or two reactive HIV rapid test results at any other study visit will be 
further tested using an FDA -cleared Western blot or the GenAptima HIV RNA 
test.  Further testing will be based on the results of the confirmatory testing, as 
described in the SSP Manual.  In addition, if a participant has signs or symptoms 
consistent with acute HIV infection, or exp resses a concern about recent HIV 
acquisition, testing will be performed using the GenAptima HIV RNA test.  
Regardless of whether HIV RNA testing is used for diagnostic testing, HIV 
infection must be confirmed in all cases using two independent samples.    
 
9.3.2  QC for HIV RNA monitoring  
Quantitative HIV RNA (viral load) testing will be performed at local laboratories 
to monitor HIV infection in any subject with confirmed HIV infection.  Viral load 
testing will be performed in HIV -infected participants at the visit when HIV 
infection is confirmed, and at subsequent study visits.  Note that this is distinct 
from use of qualitative HIV RNA testing that is performed to determine HIV 
infection status (see above).  Local laboratories must participate in the DAID S 
Virology QA (VQA) program, with EQA results that are deemed satisfactory by 
[CONTACT_262312].  US site s must use a CLIA -certified laboratory participating in 
EQA program; VQA program participation recommended.  
9.3.[ADDRESS_1024827] be enrolled in the [LOCATION_008] National External Quality Assessment 
Service ([LOCATION_006] NEQAS) program through the DAIDS IQA program.  US site s must 
use a CLIA -certified laboratory participating in EQA program; IQA program 
participation recommended.  
9.[ADDRESS_1024828] with contaminated needles, blood, and blood products, appropriate blood 
and secretion precautions will be employed by [CONTACT_749475][INVESTIGATOR_122505], as currently 
recommended by [CONTACT_941] U.S. CDC.  All infectious specimens will be transported in 
accordance with U.S. regulations [42 Code of Federal Regulations (CFR) 72].  
9.[ADDRESS_1024829] the protocol and the protocol consent form(s) 
approved, as appropriate, by [CONTACT_108298] (IRB)/ethics 
committee (EC) and any o ther applicable regulatory entity (RE).  Upon receiving 
final approval, sites will submit all required protocol registration documents to the 
DAIDS Protocol Registration Office (DAIDS PRO) at the Regulatory Support 
Center (RSC).  The DAIDS PRO will review the submitted protocol registration 
packet to ensure that all of the required documents have been received.   
HPTN 067, Final Version 5.0  Page 90 of 13 3 June 10 , 2013  
  
Pending successful protocol registration and submission of all required 
documents, CORE staff will “activate” the site to begin study operations.   Study 
implementation may not be initiated until a study activation notice is provided to 
the site.  
 
Site-specific informed consent forms (ICFs) will be reviewed and approved by [CONTACT_749476] m the 
DAIDS PRO that indicates successful completion of the protocol registration 
process.  A copy of the Initial Registration Notification should be retained in the 
site's regulatory files.  
 
Upon receiving final IRB/EC and any other applicable RE approval (s) for an 
amendment, sites should implement the amendment immediately.  Sites are 
required to submit an amendment registration packet to the DAIDS PRO at the 
RSC.  The DAIDS PRO will review the submitted protocol registration packet to 
ensure that all the  required documents have been received. Site -specific ICF(s) 
WILL NOT be reviewed and approved by [CONTACT_262314] a 
complete registration packet. A copy of the Amendmen t Registration Notification 
should be retained in the site's regulatory files.  
 
For additional information on the protocol registration process and specific 
documents required for initial and amendment registrations, refer to the current 
version of the DAI DS Protocol Registration Manual.  
10.2 Study Coordination  
DAIDS holds the Investigational New Drug (IND) application for this study 
(#71,859).   Copi[INVESTIGATOR_749381], Inc.  Ass ignment of all sponsor 
responsibilities for this study will be specified in a Clinical Trials Agreement 
executed by [CONTACT_749477], Inc.  
 
Study implementation will be directed by [CONTACT_132796].  
The SSP Manual — which w ill contain reference copi[INVESTIGATOR_749382], as well as the DAIDS Manual 
for Expedited Reporting of Adverse Events to DAIDS, Version 2.0, dated January 
2010 and the DAIDS Toxicity Tables — will outline pr ocedures for conducting 
study visits, data and forms processing, AE assessment, management and 
reporting, dispensing study products and documenting product accountability, and 
other study operations.   
 
Study case report forms and other study instruments ( e.g., CASI) will be 
developed by [CONTACT_132797].  Data will be transferred to the 
HPTN SDMC, processed, and cleaned.  Quality Control reports and data queries 
HPTN 067, Final Version 5.[ADDRESS_1024830] will address issues related to study eligibility and AE 
management and repor ting as needed to assure consistent case management, 
documentation, and information -sharing across sites.  
10.3 Study Monitoring  
On-site study monitoring will be performed in accordance with DAIDS policies.  
Study monitors will visit the site to:  
 
 verify co mpliance with human subjects and other research regulations and 
guidelines  
 assess adherence to the study protocol, study -specific procedures manual, and 
local counseling practices  
 confirm the quality and accuracy of information collected at the study site and 
entered into the study database  
 
Site investigators will allow study monitors to inspect study facilities and 
documentation ( e.g., informed consent forms, clinic and laboratory records, other 
source documents, and CRFs), as well as observe the perform ance of study 
procedures.  Investigators also will allow inspection of all study -related 
documentation by [CONTACT_749478], SDMC, NL, 
NIH, [COMPANY_009] Sciences, Inc., and U.S. and in -country government and regulatory 
authorities inclu ding relevant IRBs/ECs.  A site visit log will be maintained at the 
study site to document all visits.  
10.[ADDRESS_1024831] be submitted to and 
approved by [CONTACT_56335](s)/EC(s) and the DAIDS RSC prior to 
implementing the amendment.  
10.5 Investigator's Records  
The IoR will maintain, and store in a secure manner, complete, accurate, and 
current study records throughout the study.  In accordance with Federal 
regulations, for each of the two investigational products tested, the IoR will retain 
all study records for at least two years following the  date of marketing approval 
for the study product for the indication in which it was studied.  If no marketing 
HPTN 067, Final Version 5.[ADDRESS_1024832] be 
retained for two years after the FDA is notified that the IND is  discontinued.  
Study records include administrative documentation — including protocol 
registration documents and all reports and correspondence relating to the study — 
as well as documentation related to each participant screened and/or enrolled in 
the study — including informed consent forms, locator forms, case report forms, 
notations of all contacts with the participant, and all other source documents.  
10.[ADDRESS_1024833] sex with men. N Engl J Med. Dec 30 2010;363(27):2587 -2599.  
2. Baeten J. Antiretroviral Pre -Exposure Prophylaxis for HIV -1 prevention among 
heterosexual African men and women: the Partners PrEP Study. 6th IAS Conference on HIV 
Pathogenesis, Treatment and Prevention (IAS 2011) . Rome, Italy2011.  
3. Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the 
prevention of HIV infection in heterosexually active young adults in Botswana: results from the 
TDF2 study. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) . 
Rome, Italy2011.  
4. MTN Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a 
Major HIV Prevention Study in Women. 2011; http://www.mtnstopshiv.org/node/3619 . 
Accesse d October 12, 2011.  
5. Garcia -Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in 
macaques by [CONTACT_749479]. PLoS Med. Feb 
2008;5(2):e28.  
6. Marrazzo J, Ramjee G, Nair G, et al.  Pre-exposure Prophylaxis for HIV in Women: Daily 
Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study 
(MTN 003) Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; 
3-6 March 2013; Atlanta,  GA. 
7. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection 
among African women. N Engl J Med. Aug 2 2012;367(5):[ADDRESS_1024834], Hecht FM, Charlebois ED, Chesney M, Moss A. Comparing objective 
measures of adherence t o HIV antiretroviral therapy: Electronic medication monitors and 
unannounced pi[INVESTIGATOR_10685]. AIDS & Behavior. 2001;5(3):[ADDRESS_1024835] 2002;14(5):367 -378. 
10. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of 
adherence to HIV protease inhibitors. Ann Intern Med. May 15 2001;134(10):[ADDRESS_1024836]. Dec 1 2006;[ADDRESS_1024837] 1:S79 -87. 
HPTN 067, Final Version 5.0  Page 94 of 13 3 June 10 , 2013  
 12. Bova CA, Fennie KP, Knafl GJ, Dieckhaus KD, Watrous E, Williams AB. Use of 
electronic monitoring devices to measure antiretroviral adherence: practical considerations. 
AIDS Behav. Mar 2005;9(1):103 -110. 
13. Garcia -Lerma G , Cong M -E MJ , al. e. Prevention of Rectal Simian HIV Transmission in 
Macaques by [CONTACT_262317] -exposure Prophylaxis with Oral Truvada . 16th Conference on Retroviruses 
and Opportunistic Infections . Montreal, Canada 2009.  
14. [COMPANY_009] Sciences . VIREAD Full Prescribing Information . 2001; 
http://www.gilead.com/pdf/viread_ pi.pdf , 2009.  
15. [COMPANY_009] Sciences . EMTRIVA Full Prescribing Information . 2005; 
http://www.gilead.com/pdf/emtriva_pi.pdf , 2009.  
16. [COMPANY_009] Sciences . Truvada Full Prescribing Information . 2006; 
http://www.gilead.com/pdf/truvada_pi.pdf , 2009.  
17. Gallant J , DeJesus E , Arribas J , et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, 
lamivudine, and efavirenz for HIV . N Engl J Med . 2006;354((3)):251-260. 
18. Gallant J , Staszewski S , Pozniak A , et al. Efficacy and safety of tenofovir DF vs stavudine in 
combination therapy in antiretroviral -naive patients: a 3 -year randomized trial . JAMA . 
2004;292((2)):191-201. 
19. Centers for Disease Control (CDC). CDC trials of pre -exposure prophylaxis for HIV 
prevention. 2009; http://www.cdc.gov/hiv/prep/resources/factsheets/index.htm , 2009.  
20. Van Damme L , al. e. FemPrep Trial Update.  
http://www.fhi.org/NR/rdonlyres/edywdorajmfn3cvuiwuwgykzgrtemyhvh3qqnylvr wjwxp7b2w
7livbc7lpsh6pjlj4vc5kzzumfum/FEMPrEPupdateIssue2.pdf , 2009.  
21. Chirenje Z, Marrazzo J, al. e. Phase 2B Safety and Effectiveness Study of Tenofovir 1% 
Gel, Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate 
Tablet  for the Prevention of HIV Infection in Women  
 http://www.mtnstopshiv.org/node/70 , 2009.  
22. Grant RM, Lama JR, et al. Chemoprophylaxis for HIV prevention in Men. 2009; 
http://www.globaliprex.net/web/index.do , 2009.  
23. Celum C, Baeten J, al. e. Pre-exposure prophylaxis to prevent HIV -1 acquisition 
within HIV -1 discordant couples (Partners PrEP) . 2009; 
http://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED] . 
24. Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis 
of anti -HIV drugs, efavirenz, lopi[INVESTIGATOR_14475], in hum an hair by [CONTACT_749480]. Rapid Commun Mass Spectrom. Nov 
2008;22(21):[ADDRESS_1024838]. Aug 1 
2005;39(4):[ADDRESS_1024839] A, Negredo E, Benech H, et al. Measurement of intracellular didanosine and 
tenofovir phosphorylated metabolites and possible interaction of the two drugs in human 
immunodeficiency virus -infected patients. Antimicrob Agents Chemother. May 
2005;49(5):[ADDRESS_1024840] A, Negredo E, Theodoro F, et al. Pi[INVESTIGATOR_749383] -infected patients receiving tenofovir disoproxil fumarate (TDF): 
investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, 
or lopi[INVESTIGATOR_054] -ritonavir. Antimicrob Agents Chemother. May 2009;53(5):1937 -1943.  
28. Barditch -Crovo P, Deeks S, al. e. Phase I/II Trial of the Pharmacokinetics, Safety, and 
Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus -
Infected Adults. Antimicrobial Agents and Chemotherapy. October 2001 ;45(10):2733 -2739.  
29. Gish RG, Leung NW, Wright TL, et al. Dose range study of pharmacokinetics, safety, 
and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. 
Antimicrob Agents Chemother. Jun 2002;46(6):1734 -1740.  
30. Karim QA, Karim SSA, Frohlich JA, et al. Effectiveness and Safety of Tenofovir Gel, an 
Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science. July 19, 
2010:science.1193748.  
31. [COMPANY_009] Sciences Inc. EMTRIVA Full Prescribing Information. 2005; 
http://www.gilead.com/pdf/emtriva_pi.pdf , 2009.  
32. Margot NA, Lu B, Cheng A, Miller MD. Resistance development over [ADDRESS_1024841] 2006;7(7):442 -450. 
33. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ. Development of HIV -1 Drug 
Resistance Through 144 Weeks in Antiretroviral -Naive Subjects on Emt ricitabine, Tenofovir 
Disoproxil Fumarate, and Efavirenz Compared With Lamivudine/Zidovudine and Efavirenz in 
Study GS -01-934. J Acquir Immune Defic Syndr. Jul [ADDRESS_1024842]. Nov 1 
2004;37(3):1340 -1350.  
35. Rodriguez NS, Labarga P, Soriano V, al. e. Predictors of K idney Tubulopathy in HIV 
Patients Treated with Tenofovir: A Pharmacogenetic Study. 16th Conference on Retroviruses 
and Opportunistic Infections . Montreal, Canada2009.  
HPTN 067, Final Version 5.0  Page 96 of 13 3 June 10 , 2013  
 36. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United 
States: impact on lifetime infection risk, clinical outcomes, and cost -effectiveness. Clin Infect 
Dis. Mar 15 2009;48(6):[ADDRESS_1024843] of antiretroviral 
chemoprophylaxis on HIV -1 transmission in resource -limited settings. PLoS One. 
2007;2(9):875.  
38. Grant RM, Buchbinder S, Cates W, Jr., et al. AIDS. Promote HIV chemoprophylaxis 
research, don't prevent it. Science. Sep 30 2 005;309(5744):[ADDRESS_1024844]. Apr 15 
2004;35(5):519 -525. 
40. Fisher JD, Fisher WA. Changing AIDS -risk behavior. Psychol Bull. 1992 May 
1992;111(3):455 -474. 
41. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information -motivation -behavioral 
skills model of adherence to antiretrovi ral therapy. Health Psychol. Jul 2006;25(4):462 -473. 
42. Starace F, Massa A, Amico KR, Fisher JD. Adherence to antiretroviral therapy: an 
empi[INVESTIGATOR_63610] -motivation -behavioral skills model. Health Psychol. Mar 
2006;25(2):153 -162. 
43. Ande rson ES, Wagstaff DA, Heckman TG, et al. Information -Motivation -Behavioral 
Skills (IMB) Model: testing direct and mediated treatment effects on condom use among women 
in low -income housing. Ann Behav Med. Feb 2006;31(1):[ADDRESS_1024845]-Thomas C. Gender differences in the prediction of 
condom use among incarcerated juvenile offenders: testing the Information -Motivation -
Behavior Skills (IMB) model. J Adolesc Health. Jan 2006;38(1):18 -25. 
45. Kalichman SC, Amaral CM, Cherry C, et al. M onitoring medication adherence by 
[CONTACT_113237][INVESTIGATOR_456978]: reliability and criterion -related validity. HIV 
Clin Trials. Sep-Oct 2008;9(5):[ADDRESS_1024846] of information, motivation and behavioural skills (IM B) 
intervention in changing AIDS risk behaviour in female university students. AIDS Care. Feb 
2003;15(1):[ADDRESS_1024847] self - 
examination: A test of the Information --Motivation -- Behavioral Skills model. Journal of 
Applied Social Psychology. 2003(33):[ADDRESS_1024848] of the information, motivation 
and behavioral skills model of antiretroviral therapy adherence. AIDS Care. Aug 
2005;17 (6):661 -673. 
HPTN 067, Final Version 5.0  Page 97 of 13 3 June 10 , 2013  
 49. Amico KR, Barta W, Konkle -Parker DJ, et al. The information -motivation -behavioral 
skills model of ART adherence in a Deep South HIV+ clinic sample. AIDS Behav. Feb 
2009;13(1):66 -75. 
50. Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel 
of innovations in HIV prevention? BMJ. Mar 11 2006;332(7541):[ADDRESS_1024849] G, Shattuck D, Johnson L, et al. Changes in sexual risk behavior among 
participants in a PrEP HIV prevention trial. Sex Transm Dis. Dec 2008;35 (12):1002 -1008.  
52. Simon HA. Models of man: social and rational; mathematical essays on rational human 
behavior in a social setting . [LOCATION_001],: Wiley; 1957.  
53. Tversky A, Kahneman D. Judgment under Uncertainty: Heuristics and Biases. Science. 
Sep 27 1974;185(4157):[ADDRESS_1024850] theory: An analysis of decisions under risk. 
Econometrica. 1979;47:313 -327. 
55. Fisher WA, Fisher JD, Harman J. The information -motivation -behavioraI skills model: A 
general social psychological  approach to understanding and promoting health behavior.  
. In Suls, J. & Wallston, K. A. 2003.  
56. Hutton HE, Lyketsos CG, Zenilman JM, Thompson RE, Erbelding EJ. Depression and 
HIV risk behaviors among patients in a sexually transmitted disease clinic. Am J Psychiatry. 
May 2004;161(5):912 -914. 
57. Smit J, Myer L, Middelkoop K, et al. Mental health and sexual risk behaviours in a South 
African township: a community -based cross -sectional study. Public Health. Jun 
2006;120(6):[ADDRESS_1024851] Dis Clin North 
Am. Mar 2007;21(1):[ADDRESS_1024852] for prevention of 
HIV infection in women in South Africa: a randomised, double -blind, placebo -controlled trial. 
Lancet. Dec 6 2008;372(9654):[ADDRESS_1024853] sex with men: a randomised, double -
blind, plac ebo-controlled trial. Lancet. 2008 Jun 21 2008;371(9630):2109 -2119.  
61. Amico KR, Fisher WA, Cornman DH, et al. Visual analog scale of ART adherence: 
association with [ADDRESS_1024854]. Aug 1 
2006;42(4):4 55-459. 
62. Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to 
antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. Nov 2008;10(6):515 -521. 
HPTN 067, Final Version 5.0  Page 98 of 13 3 June 10 , 2013  
 63. Napper LE, Fisher DG, Reynolds GL, Johnson ME. HIV risk behavio r self -report 
reliability at different recall periods. AIDS Behav. Feb 2010;14(1):152 -161. 
64. Barta WD, Kiene SM, Tennen H, Abu -Hasaballah KS, Ferrer R. The idiographic study of 
inconsistent condom use behavior of persons living with HIV. AIDS Care. Sep 
2007;19(8):[ADDRESS_1024855] sex with men: comparisons with a retrospective recall survey. AIDS Behav. Jul 
2007;11(4):537 -548. 
66. Kiene SM, Simbayi LC, Abrams A, Cl oete A, Tennen H, Fisher JD. High rates of 
unprotected sex occurring among HIV -positive individuals in a daily diary study in South 
Africa: the role of alcohol use. J Acquir Immune Defic Syndr. Oct 1 2008;49(2):219 -226. 
67. McAuliffe TL, Di[LOCATION_009]isco W, Re ed BR. Effects of question format and collection 
mode on the accuracy of retrospective surveys of health risk behavior: a comparison with daily 
sexual activity diaries. Health Psychol. Jan 2007;26(1):60 -67. 
68. [COMPANY_009] Sciences Inc. Truvada® (emtricitabine and tenofovir disoproxil fumarate) tablets 
Package Insert 2012.  
69. Weinhardt LS, Forsyth AD, Carey MP, Jaworski BC, Durant LE. Reliability and validity 
of self -report measures of HIV -related sexual behavior: progress since 1990 and 
recommendations for rese arch and practice. Arch Sex Behav. Apr 1998;27(2):155 -180. 
70. Ostrow D, Kalichman S. Handbook of HIV prevention. In: Peterson JL, DiClemente RJ, 
eds. AIDS prevention and mental health . [LOCATION_001]: Kluwer/Plenum; 2000:67 -80. 
71. Schroder KE, Carey MP, Vanabl e PA. Methodological challenges in research on sexual 
risk behavior: I. Item content, scaling, and data analytical options. Ann Behav Med. [ADDRESS_1024856] 
2003;26(2):76 -103. 
72. Metzger DS, Koblin B, Turner C, et al. Randomized controlled trial of audio computer -
assisted self -interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine 
Preparedness Study Protocol Team. Am J Epi[INVESTIGATOR_5541]. Jul 15 2000;152(2):99 -106. 
73. Crepaz N, Lyles CM, Wolitski RJ, et al. Do prevention interventions reduce HIV ri sk 
behaviours among people living with HIV? A meta -analytic review of controlled trials. AIDS. 
2006 Jan 9 2006;20(2):143 -157. 
74. Hayes R, Bennett S. Simple sample size calculation for cluster -randomized trials. Int J 
Epi[INVESTIGATOR_5541]. April 1999 (2)(28):[ADDRESS_1024857]. 2008;8:2.  
76. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometr ics. 
Mar 1989;45(1):255 -268. 
HPTN 067, Final Version 5.0  Page 99 of 13 3 June 10 , 2013  
 77. Glaser BG, Strauss AL. The discovery of grounded theory; strategies for qualitative 
research . Chicago,: Aldine Pub. Co.; 1967.  
78. Strauss A, Corbin J, eds. Basics of qualitative research: Techniques and procedures for 
developi[INVESTIGATOR_749384], CA: Sage; 1998; No. 2nd edition.  
79. Madill A, Gough B. Qualitative research and its place in psychological science. Psychol 
Methods. Sep 2008;13(3):254 -271. 
80. Leech A, Onwuegbuzie AJ. Development and Initial Validat ion of a Scale to Measure 
Instructors’ Attitudes toward Concept -Based Teaching of Introductory Statistics in the Health 
and Behavioral Science International Statistical Institute, 56th Session 2007.  
 
 
 
  
HPTN 067, Final Version 5.0  Page 100 of 13 3 June 10 , 2013  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES  
HPTN 067, Final Version 5.0  Page 101 of 13 3 June 10 , 2013  
 APPENDICES  
Appendix I: Schedule of Study Visits and Procedures  
 
Appendix IA.  All study participants   
 
 
Screening (up to 
–Day 70)  
Week [ADDRESS_1024858]-Study 
Follow -up Visit  
Administrative, Behavioral, and Regulatory Procedures         
Screening/Enrollment informed consent  X       
Locator information  X X X X X X X 
Demographic information  X       
Social harms assessment    X X X X X 
Randomization to a treatment arm     X    
Behavioral assessment (CASI)  X   X X2 X  
Adherence/ behavioral monitoring (telephonic weekly)      X X  
Focus groups and key informant interviews        X3 
Clinical/Counseling Procedures         
Adherence and EDM orientation/ counseling and pi[INVESTIGATOR_10685]   X  X X4 X4  
Complete medical history including medications  X       
Interim medical history including concomitant medications   X X X X X  
Adverse event (AE) assessment    X X X X X 
Vaginal practices assessment for women   X    X  
Sex hormones assessment for men   X X6   X  
Family planning assessment for women   X X6 X X X  
Full physical exam (symptoms/side effects assessment)   X      
Symptom -driven physical exam (symptoms/side effects 
assessment)     X X X  
Once per week directly observed dosing   X X5     
Study drug supply and associated counseling     X X   
HIV pre -test, risk reduction, and post -test counseling  X X X6 X X7 X X 
Laboratory Procedures *         
Sample testing:         
Urine for pregnancy8 X X X6 X X X  
Urine dipstick for protein and glucose  X   X X9 X X 
Blood collection for:         
HIV rapid testing (with confirmation if indicated)10 X X X6 X X7 X X12 
Complete blood count (CBC)  X    X9 X  
Serum creatinine (for estimated creatinine  clearance)  X  X6  X9 X  
Serum phosphate  X    X9 X  
AST/ALT  X  X6  X9 X  
Hepatitis B virus testing 13  X       
Sample storage: [ADDRESS_1024859] genetic testing    X6     
Lysed PBMCs for storage    X11 X X9 X  
DBS for storage for drug levels (Harlem only)    X11 X X9 X  
Hair for storage    X11 X X9 X  
Urine for storage    X11 X X9 X  
* All rapid testing (for HIV infection, pregnancy, and urine protein) and all sample collection for testing and for  storage should be completed 
prior to dosing study medication 
HPTN 067, Final Version 5.[ADDRESS_1024860] counseling will be performed at Weeks 10, 14, 18, 22 
and 26.   
8 Biologic females who were not found to be pregnant at a previous study visit.  Those with 
documented inability to become pregnant (tubal ligation, etc.) will not require testing.  
[ADDRESS_1024861] be performed at the indicated study visits acc ording to the 
algorithms provided in the SSP Manual.  The HPTN NL should be consulted in any case where 
HIV infection status is unclear, one or both HIV rapid tests is reactive, HIV seroconversion is 
documented, or acute HIV infection is suspected.  CD4 ce ll count testing, viral load monitoring, 
and HIV drug resistance testing will be performed for participants with confirmed HIV infection 
only (see Appendix 1B).  Participants that are confirmed to be HIV -infected according to the 
SSP Manual will have no fu rther HIV diagnostic testing performed at subsequent study visits.  
[ADDRESS_1024862] clinical signs/symptoms of hepatitis.  
14  Store samples on site until requested by [CONTACT_262312].  
HPTN 067, Final Version 5.0  Page 103 of 13 3 June 10 , 2013  
 Appendix IB.  Additional Procedures for Participants with Confirmed HIV Infection  
 
 Time of 
diagnosis  Weeks 10, 18, 
and 30  
(if after HIV 
diagnosis)  Weeks 14, 22 
and 26  
(if after HIV 
diagnosis)  Every 12 weeks 
after week 30  
 (until the last 
participant ends 
follow -up) 
CD4 cell count testing  X X  X 
HIV viral load testing  X X  X 
Shipment of samples to the HPTN 
NL1 X X   
HIV genotypi[INVESTIGATOR_007]2 X    
Other testing3 X X   
Additional plasma storage  X X X  
Lysed PBMCs for drug levels4 X    
 
1 Stored samples from HIV seroconverters  will be shipped to the HPTN NL; sites should store 
samples until they receive a request for shippi[INVESTIGATOR_749385].  At the discretion of the HPTN 
NL, samples may be transferred to a DAIDS -approved repository.  
2 The HPTN NL will coordinate HIV resistance testing using samples shipped to the HPTN NL.  
HIV genotypi[INVESTIGATOR_749386] (time of HIV diagnosis) will be provided to study 
sites at study closure.  Results from this testing may be provided to study sites prior to study 
closure with appr oval of the HPTN NL and the Protocol Chair.   
3 Additional testing may be performed at the HPTN NL for research purposes; at the discretion 
of the HPTN NL, additional testing for research purposes may also be performed at another 
laboratory ( e.g., at one o f the study sites, at the U.S. CDC, or at another laboratory with special 
expertise).  Those results will not be returned to study sites or study participants.  This testing 
may include additional HIV genotypi[INVESTIGATOR_007]/sequencing assays, HIV phenotypi[INVESTIGATOR_007], HIV subt ypi[INVESTIGATOR_007], 
minority variants assays, other assays to characterize HIV + viruses and/or the host response to 
HIV infection.  
4 Additional Lysed PBMCs do not need to be collected at the confirmatory blood draw 
(confirmatory diagnosis) if already drawn at a schedu led visit.  
Note: Participants  with confirmed HIV infection will continue in the study, off of study drug.  
Any enrolled participants who acquire HIV infection during the study will permanently 
discontinue study product and will be followed after Enrollmen t at regularly scheduled monthly 
visits and then every [ADDRESS_1024863] HIV uninfected participant reaches 
Week 34.  
HPTN 067, Final Version 5.0  Page 104 of 13 3 June 10 , 2013  
 Appendix II:  Additional power calculation with a range of average coverage rates 
for two primary hypothesis tests.  
 
Table 1  Non -inferiority region (δ) for hypothesis (1) assuming 60 participants per 
arm, 50 acts per participant, α =0.05 (one -tailed).  Power is computed against the 
alternative that coverage is exactly equal in the two arms ( i.e. δ = 0).  
CV Power  % ``uncovered’’ sex in 
daily arm (1 – pd) null δ  
 
.4 .9 .2 0.053  
.4 .95 .2 0.059  
.6 .9 .2 0.071  
.6 .95 .2 0.080  
.8 .9 .2 0.091  
.8 .95 .2 0.103  
.4 .9 .05 0.020  
.4 .95 .05 0.022  
.6 .9 .05 0.023  
.6 .95 .05 0.026  
.8 .9 .05 0.027  
.8 .95 .05 0.031  
 
  
HPTN 067, Final Version 5.0  Page 105 of 13 3 June 10 , 2013  
 Table 2  Minimum detectable difference between the rate of covered sex acts in 
one intermittent treatment arm as compared to the other intermittent arm, 
assuming 60 participants per arm , 50 acts per participant, α = 0.05 (two -tailed).  
CV Power  The rate of 
uncovered sex 
act in 
intermittent arm 
1 (1 – pi1) Minimum detectable rate of 
uncovered sex in intermittent arm 2  
(1 – pi2) 
 
.4 .8 .2 0.256  
.4 .9 .2 0.267  
.6 .8 .2 0.282  
.6 .9 .2 0.299  
.8 .8 .2 0.313  
.8 .9 .2 0.338  
.4 .8 .05 0.072  
.4 .9 .05 0.076  
.6 .8 .05 0.077  
.6 .9 .05 0.082  
.8 .8 .05 0.084  
.8 .9 .05 0.091  
 
  
HPTN 067, Final Version 5.0  Page 106 of 13 3 June 10 , 2013  
 Appendix III:  SAMPLE  INFORMED  CONSENT  FORMS  
 
SAMPLE SCREENING AND ENROLLMENT INFORMED CONSENT FORM  
 
 
The ADAPT study: A Phase II, Randomized, Open -Label, Pharmacokinetic and 
Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil 
Fumarate Pre -Exposure Prophylaxis (PrEP) (HPTN  067) 
 
Final Version 5.0  
June 10, 2013  
DAIDS Document  ID: [ZIP_CODE]  
 
Study Implementers:  Thailand Ministry of Public Health  - US Centers for Disease Control and 
Prevention Collaboration (TUC), Silom Community Clinic, Bangkok, Thailand; Emavundleni 
Desmond Tutu HIV Centre in Observatory, South Africa ; Division o f HIV/AIDS Prevention, US 
Centers for Disease Control and Prevention (CDC), Atlanta, GA, [LOCATION_003]; Harlem Prevention 
Center, Columbia University, [LOCATION_001],  NY, [LOCATION_003]; HIV Prevention Trials Network (HPTN), 
U.S. National Institutes of Health (NIH), Bethesda, MD, US A; US National Institutes of Mental 
Health (NIMH), Bethesda, MD, [LOCATION_003]; Gladstone Institute, University of [LOCATION_004] at San 
Francisco, San Francisco, CA, [LOCATION_003].   
 
Study Sponsors:  NIH, Division of AIDS (DAIDS), US National Institute of Allergy and 
Infectious Diseases (NIAID), and U.S. National Institute of Mental Health (NIMH).  Study drug 
is provided by [CONTACT_10869], Inc.  
 
PRINCIPAL INVESTIGATOR: [Insert Name]  
PHONE:  [Insert Number]  
 
INTRODUCTION  
You are being asked to take part in a research study .  The goal of this study is to find out more 
about whether people can take a drug that may prevent HIV infection and what that experience is 
like for them.  This drug is called Truvada ®.  Truvada ® is commonly used to treat HIV 
infection.  HIV is the virus that causes AIDS.  This study is being done among [men and 
transgender women who have sex with men/women who have sex with men] in your community.  
Whether you join the study or not is up to you.   If you choose to join the study, you may stop 
taking part at any time.   
 
There may be no direct benefits for you if you participate in this study.  There also may be some 
risks with taking part in the study.  Before you can make an informed decision abo ut whether to 
take part in this study, you should understand the possible risks and potential benefits of being in 
this study.  That process is called informed consent.  This informed consent document will give 
you an idea of what will take place during th e study and provides you with detailed information 
about this research study.  This consent form might contain some words that are not familiar to 
you.  Please ask us to explain anything that you do not understand before you sign this form.  If 
HPTN 067, Final Version 5.[ADDRESS_1024864] decided that you want to participate, you will be 
asked to read, sign, and date this form.  You will also be offered a copy of this form to keep.  
 
What happens if you do not want to take part?  
Before you learn more abo ut the study it is important that you know the following:  
 You do not have to be in this study if you do not want to and you can stop taking part in the 
study at any time without affecting the services you get at [insert clinic].  
 If you decide to stop takin g part in the study, you may still join another study if one is available 
and you qualify.  
 
Why is this study being done?  
Truvada® is a tablet that has two drugs in it.  These drugs are called “emtricitabine” and 
“tenofovir ”.  These drugs are commonly used to treat HIV infection.  Truvada® is generally safe 
when used as treatment for HIV.  Truvada® is not a cure for HIV or AIDS.  When given together 
with other drugs, Truvada® may help to prevent or delay AIDS in people with HIV.  The 
purpose of this study is to find out how different schedules of taking Truvada® affects how it 
works, whether these different schedules affects the safety of the drug and whether people like it.   
 
On July 16, 2012, the [LOCATION_002] Food and Dru g Administration’s (FDA) approved daily oral 
PrEP using Truvada® for prevention of HIV in adult men and women at high risk of getting HIV 
through sex. The daily dosing recommendation was based on published results from the iPrEx, 
TDF2, and Partner’s PrEP s tudies, which recommended daily use of the tablets.  Actual use 
varied among participants.  
 
Several studies have recently completed or are going on to find out whether an oral dose of 
Truvada® may help to prevent HIV infection.  They are listed as follows:   
 iPrEx : First study to demonstrate the effectiveness of a daily oral dose of  Truvada® in 
reducing the risk of HIV infections in HIV -uninfected men who have sex with men in 
Brazil, Ecuador, Peru, South Africa, Thailand and the [LOCATION_002] .  
 Partner’s Pr EP: This study of heterosexual couples in Kenya and Uganda found that a 
daily oral dose of either Tenofovir or Truvada® tablets by [CONTACT_749481].  
 TDF2 : In this study of sexuall y active HIV uninfected men and women (ages 18 -29) in 
Botswana, a daily oral dose of Truvada® was found to reduce the risk of HIV infection.   
 FEM -PrEP : This study tested the daily oral use of Truvada® for HIV prevention among 
women in Kenya, Tanzania and S outh Africa. The study was stopped after a review team 
found out  that it was unlikely that those who were assigned to take  Truvada® were going 
to have fewer HIV infections that those who were  not. The FEM -PrEP researchers looked 
more closely at their data and found that too few women had used the drug to be able to 
tell whether the drug would work to prevent HIV infection.   
HPTN 067, Final Version 5.0  Page 108 of 13 3 June 10 , 2013  
  VOICE : This study is testing different ways of preventing women in South Africa, 
Uganda and Zimbabwe from getting HIV infection. At first, the study was comparing 
people taking a daily dose of Truvada®, a daily dose of Tenofovir (another anti -AIDS 
medicine), or d aily use of a Tenofovir vaginal gel with people taking a tablet that did not 
contain  medication or using gel that did not have Tenofovir. Researchers found that too 
few women had used the gel or tablets to be able to tell whether they would work to 
prevent  HIV infection.  
 STRAND : This was a much smaller study that examined the levels of the drug tenofovir 
in hair and blood samples when this antiretroviral was taken at different time intervals.  
Tenofovir is one of the components of Truvada ®, the drug used i n our HPTN 
067/ADAPT study. As expected, the STRAND study found that the amount of drug in 
the body is higher when PrEP tablets are taken more frequently.  Using PrEP seven days 
per week resulted in the highest drug levels.  Using PrEP [ADDRESS_1024865] any protection.    
One clear finding from these studies is that Truvada ® can only prov ide protection if people take 
it consistently.  Participants are reminded that it is not certain how well non -daily use of PrEP 
will work to prevent HIV infection.  It is important that all study participants try to take the 
tablets, or tell us why the tab lets are not being taken. If you are having problems taking the 
tablets, or have concerns, or have decided not to take the tablets for personal reasons, please tell 
us. Telling us about your experience allows us to understand the most acceptable way to tak e 
PrEP regimens. The ADAPT trial aims to find ways to adapt PrEP regimens to make them easier 
to take.  All participants in this study will be updated with new information and findings that 
come out on this important issue. We encourage all participants to  discuss any concerns about 
these studies , or the safety of Truvada® , with the ADAPT study staff.   
 
[For the site s in Harlem and Bangkok only:  Participants who were born male but living as a 
female are eligible to enroll in this study if they are otherwis e eligible. However, it should be 
noted that t here have been too few transgendered women in PrEP studies to know whether PrEP 
is effective for them. ]  PrEP  does not prevent pregnancy or sexually transmitted infections like 
syphilis, gonorrhea, or herpes.  Using condoms for all intercourse is a good way to maintain your 
sexual health.  Thus, it is important to continue using condoms from start to finish every time you 
have sex.  
 
About [ADDRESS_1024866] sex with men.  People in the study will be asked to take part for a total of 34 
weeks (approximately 8 months and 2 weeks).  Everyone will take Truvada® for the first 30 of 
these 34 weeks ( approximatel y 7 months and 2 weeks)  based on their group.   
 
In this study there are three groups based on how often they will take Truvada®  
HPTN 067, Final Version 5.0  Page 109 of 13 3 June 10 , 2013  
  Group 1 will be asked to take a pi[INVESTIGATOR_592419] a day.   
 Group 2 will be asked to take a pi[INVESTIGATOR_749387] (every three or four day s) 
and another pi[INVESTIGATOR_749388].   
 Group 3 will be asked to take a pi[INVESTIGATOR_749389].   
 
 
What will happen during the study visits?  
 
Screening visit:  The first study visit is called the screening visit.  The screening visit will take 
about [ADDRESS_1024867] ices.  We will counsel you about HIV 
infection, risks you may be taking and how to avoid getting HIV.  We will draw ~XX mL of 
blood (about X tablespoons).  This blood will be tested for HIV, hepatitis B virus, and [insert 
other local testing as applicable] .  We will also ask you for a urine sample.  Your blood and urine 
will be tested to assess your overall health and whether your liver and kidneys are working 
normally.  [Insert for women - If you are pregnant or breastfeeding, you cannot join this study.  I f 
you are a woman that is able to become pregnant, we will test your urine for pregnancy.]  Study 
staff will inform you of the results of all tests which affect your health.  Some people may not be 
able to join the research study because of information the y provide during the screening process.   
If you are currently or have ever been part of another study to prevent HIV infection or HIV 
vaccine study, you may not be able to participate in this study.  Please also tell us if you join 
another study after agr eeing to take part in this one, as this may affect your health.   
 
What if your blood shows that you have HIV?  
We will give you the results of your HIV test during this visit.  If the test shows you have an HIV 
infection, you cannot be in the study.  If yo u have a test result at this or any study visit that 
indicates you may have been infected with HIV, we will arrange to confirm the test result.  If the 
confirmatory tests show that you do have HIV infection, we will perform tests to see how well 
your body can fight off infections and measure the amount of virus in your blood.  If we confirm 
that you are infected with HIV later in the study, you will have to stop taking Truvada ®, but we 
will ask you to continue to come to the study clinic as scheduled.  In t his case, we will also test 
your blood to see if Truvada ® can still be used to treat your HIV infection during these monthly 
visits.  [Insert any additional local testing that may be performed].  [Insert any local reporting 
requirements.]  We will also ref er you for HIV treatment and care.   
 
What if your blood shows that you have hepatitis?  
To protect your health, everyone who takes part in the study should be vaccinated for  hepatitis B 
virus infection ( unless  you have already had the disease or the vaccin e).  This is because the 
drugs used in Truvada ® can also be used to treat hepatitis B  virus  and taking Truvada ® now 
might result in less effective treatments for hepatitis B virus if you were ever infected.  You will 
need to come back to get the results of  the testing for hepatitis B virus.  If you are not immune, 
you will be offered a vaccine against the hepatitis B virus.  If you agree, we can give you the 
HPTN 067, Final Version 5.[ADDRESS_1024868] a hepatitis B virus infection you cannot be in the study.  If you later develop another 
form of hepatitis while in the study, you should stop taking the study drug.   
 
Enrollment visit: If you are eligible and agree to participate, you will be asked to come back to 
the clinic to start the study.  This will be your enrollment visit.  The enrollment visit will take 
about an hour.  During this visit, we w ill ask you questions about any changes in your health and 
medications and give you a full physical exam.  Study staff will confirm your name [CONTACT_749495] [CONTACT_3031].  We will ask you about anything that has happened as a result of your 
study p articipation.  We will again counsel you about HIV infection, risks you may be taking, 
and how to avoid getting HIV.  We will draw ~XX mL of blood (about X tablespoons) and your 
blood will be tested for HIV.  [Insert for women - If you are pregnant or breas tfeeding, you 
cannot join this study.  If you are a woman that is able to become pregnant, we will test your 
urine for pregnancy. We will ask you about what you use to prevent pregnancy and questions 
about use of lubricants (lubes) or things you might do t o clean your vagina.]  [Insert for men - We 
will ask you about hormones that you may use to make your body bigger or more feminine.] 
Study staff will inform you of the results of all tests which affect your health.  We will give you 
an electronic pi[INVESTIGATOR_173105] t hat sends an electronic message to our system when it is opened. We will 
explain to you how this pi[INVESTIGATOR_749390] a supply of vitamins so that you can get 
used to using it.  
 
Once we have completed all of these tests, we will give you your first  dose of Truvada®.  A 
nurse will observe you taking this dose and we will watch you to see how your body reacts to the 
study drug.   
 
Weeks 1 -5: For the first six weeks of the study after your enrollment visit, we will ask you to come 
to the clinic once a week and take Truvada®.  A staff member will observe you doing this.  You 
will not take a dose during week 5, but we will ask you to come to the clinic.  At weeks 4 and 5, w e 
will also take samples of your blood, urine and hair.  We will draw ~XX mL of blo od (about X 
tablespoons) and test it for HIV.  You will be counseled about HIV and how to avoid it. [Insert for 
women - We will ask you about what you use to prevent pregnancy  during the week 4 visit .]  [Insert 
for men - We will ask you about hormones that you may use to make your body bigger or more 
feminine  during the week 4 visit.] As noted above, there is no evidence that once weekly Truvada® 
is protective.  Throughout this study you should use condoms and take all available precautions to 
reduce your ri sk of HIV infection.  Remember that no PrEP regimen is a stand -alone solution.   
ADAPT study staff will provide further guidance.  These visits  will last about an hour.    
 
Weeks 6 -29, 30 and 34:  At the beginning of Week 6, we will use a lottery -like system  to determine 
which study group you will join.  You will be given a 4 -week supply of Truvada® and asked to take 
Truvada® according to the schedule in your group.  Your Truvada® will come in a pi[INVESTIGATOR_749391].  This way we can monitor when you take Truvada®.  A nurse will explain how this pi[INVESTIGATOR_749392] a pi[INVESTIGATOR_4382].  Study staff will also ask you 
to take  notes in a journal about your sex life and pi[INVESTIGATOR_4382] -taking.  This visit will last about two hours.   
 
[For women] If you are a woman who is able to become pregnant, we will perform a pregnancy test 
HPTN 067, Final Version 5.0  Page 111 of 13 3 June 10 , 2013  
 at every study visit.  If you become pregnant, you should sto p taking Truvada®.  At these visits, we 
will ask you about what you use to prevent pregnancy during every visit and questions about use of 
lubricants (lubes) or things you might do to clean your vagina at the week 30 visit.]  [Insert for men - 
We will ask y ou about hormones that you may use to make your body bigger or more feminine 
during the week 30 visit.]  
 
After six weeks, we will ask you to come to the clinic every four weeks for approximately seven 
visits.  This visit will last about an hour.  At every visit we will confirm your contact [CONTACT_749482].  We will ask you about any drug 
side effects you might be experiencing and discuss any health problems you might be having.  At 
these visits, w e will also take samples of your blood, urine and hair. We will draw ~XX mL of 
blood (about X tablespo ons) and test it for HIV.  You will be counseled about HIV and how to 
avoid it.  We will ask you to bring the pi[INVESTIGATOR_749393].  
A nurse will count your leftover pi[INVESTIGATOR_3353].  You will get a new supply of Truvada®.  For 24 weeks, 
(every week until about week 30) we will call you and ask you questions about the number of pi[INVESTIGATOR_749394].   
 
At some of these visits (weeks 6, 18, and 30) you will be asked to complete an interview (with a 
person o r by [CONTACT_749483]) which will take about [ADDRESS_1024869] side effects from taking 
Truvada®.  At weeks 10 and 18, your blood will be tested to assess your overall health, whether 
your liver and kidneys are working normally and the amount of Truvada® in your blood.  At week 
30 you will stop taking Truvada®, but we will ask you to come in for one more visit at week [ADDRESS_1024870] your blood tested for HIV.  I f you stop taking Truvada® before week 30, we will ask you to 
come for study visits at week 30 and 34 to complete the same procedures and we will also ask you 
why you chose to stop taking the study drug.  We will ask you to return any unused study drug as 
soon as possible after you stop taking the drug.   
 
Some people in the study may be asked to take part in a focus group ( a discussion among a small 
group of people  about a specific set of topi[INVESTIGATOR_1102]) or a one -on-one interview with site staff after they 
stop ta king Truvada® .  In these focus groups or interviews, people discuss their pi[INVESTIGATOR_4382] -taking and 
sexual behavior, HIV risk behavior, feelings about their group assignment, and whether they 
talked with anyone about pi[INVESTIGATOR_4382] -use or study participation.  If you are aske d to take part in a focus 
group we will explain more about this.  In that case, you will also be asked to sign another 
informed consent form.   
 
How Will Your Samples Be Used?  
As part of the study we will collect samples of your blood, urine and hair.  The se samples will be 
used for a number of laboratory tests  for your safety and measurements of study drug in your 
body. Samples of your blood, hair and urine will be sent to designated laboratories in the United 
States for further testing . No hair samples wi ll remain after testing has been completed.  There 
may be some leftover samples of blood and urine samples after all of the study -related testing 
has been completed.  We would like to use these samples for future research studies  to develop 
new HIV tests, H IV vaccines and treatments.  If you agree to this use of your samples, we will 
ask you to initial the end of this form.   
 
HPTN 067, Final Version 5.[ADDRESS_1024871] exactly the same genes .  That is 
what makes each of us different.  We will also be looking at your genes to study your body’s 
reaction to infections, including how genes turn on or off.  Understanding these  “genetic” 
differences may help us understand how the human body responds to HIV.  These tests are being 
performed for research only and may be performed in a research laboratory that does not do 
clinical (patient care) testing.  The type of DNA tests that  would be performed are unlikely to 
have any direct impact on your health or future treatments.  Some testing may be performed after 
the close of the study.  For these reasons, the results of the DNA testing will not be reported back 
to the study investiga tors or to you.  We will ask you at the end of this form if you agree to DNA 
testing.  You do not need to agree to DNA testing in order to be in this study.   
 
If you do not agree to have your left over samples stored you can still be in this study.  If yo u 
agree to store your samples but change your mind later, you can contact [CONTACT_464].  We will 
then destroy your samples.  If you agree, your left over samples will be stored indefinitely [insert 
local guidelines].  Any future use or the ability to store your samples longer needs to be reviewed 
and approved by [CONTACT_420042].  If these studies involve other laboratories, we 
will need approval from your local authorities to store or transfer them elsewhere.  Your left over 
samples will not be  sold or used for commercial reasons . 
 
 
What Are the Possible Risks or Discomforts?  
Study drug side effects  
 
About 5 to 10 out of 100 people with HIV taking Truvada® tablets have these occasional side 
effects which usually go away after stoppi[INVESTIGATOR_1478]   
 Upset stomach, vomiting, gas, loose or watery stools   
 Dizziness or headache  
 Abdominal pain  
 Lack of energy/general body weakness  
 Mild problems of kidney function that are only detected by [CONTACT_306900]   
 Shortness of breath or cough  
 Rash, including allergic reaction  
 Anxiety  
 Joint pain, muscle pain, or other pain syndrome  
 Fever  
 
Fewer than 5 out of 100 people with HIV taking Truvada® tablets have:  
 Skin discoloration/darkening of the palms and/or soles of the feet  
 
Rarely, people takin g Truvada® also have experienced:  
 Abnormal placement of body fat  
Some of these changes may include:  
HPTN 067, Final Version 5.0  Page 113 of 13 3 June 10 , 2013  
  Increase in fat around the waist and stomach area  
 Increase in fat on the back of the neck   
 Breast enlargement  
 Weight loss (wasting)  
Some of the se body ch anges include:  
 Thinning of the face, legs and arms  
 
Potentially serious side effects are rare, but include:  
 Liver function problems  
 Serious kidney damage or failure  
 Low phosphate levels (a chemical in the blood) or protein  or sugar in the urine  
 Inflammation or swelling and possible damage to the pancreas  
 Bone pain and bone changes such as thinning and softening which may 
increase the risk of  breakage  
 Allergic reaction  
 Lactic acidosis (too much acid in the body tissues and blood) and severe 
hepat omegaly (enlarged liver) with steatosis (fatty liver) that may result in 
liver failure, other complications and death have been reported with the use of 
antiretroviral nucleoside analogues alone or in combination.  The liver 
complications and death have be en seen more often in women on these drug 
regimens.  Some nonspecific symptoms that might indicate lactic acidosis 
include: unexplained weight loss, stomach discomfort, nausea, vomiting, 
fatigue, weakness, and shortness of breath.  
 If you are infected with both Hepatitis B and HIV, you should be aware that 
your liver function tests may increase, and symptoms associated with hepatitis 
(an acute inflammation of the liver) may worsen if emtricitabine or tenofovir 
is stopped.  
 
Some people taking emtricitabine, o ne of the ingredients in Truvada®, experienced the following 
side effects:  
 Inability to sleep, unusual dreams  
 Runny nose  
 Rash, itching, which sometimes can be a sign of an allergic reaction  
 Increases in pancreatic enzyme (substances in the blood), which co uld mean a 
problem with the pancreas  
 Increased triglycerides (fatty acid in the blood)  
 Increased creatine phosphokinase (CPK; an enzyme found in tissues and cells 
of the body), which could mean muscle damage  
 Skin darkening of the palms and/ or soles  
 
Some people taking tenofovir, one of the ingredients in Truvada®, experienced the following 
side effects:  
 Depression  
 Inflammation or swelling and possible damage to the pancreas and liver  
 Allergic reaction: symptoms may include fever, rash, upset stomach, 
vomiting, loose or watery stools, abdominal pain, achiness, shortness of 
HPTN 067, Final Version 5.0  Page 114 of 13 3 June 10 , 2013  
 breath, a general feeling of illness or a potentially serious swelling of the face, 
lips, and/or tongue  
 
The side effects listed above were reported in people with HIV infection.  They u sed Truvada ® 
for HIV treatment.  We do not know the side effects of Truvada ® when taken by [CONTACT_749484].  A small number of people in this study may have these side 
effects or other side effects that we do not know about.  H owever, we will screen your kidney 
function and overall health before you join the study.  This will reduce the chances of having any 
side-effects.   
 
HIV resistance  
If you become infected with HIV, there is a risk that the HIV you have become infected with 
could become "resistant" to Truvada ®.  This may then mean that you may not be  able to be 
treated with Truvada ® nor the drugs which are combined together to make Tru vada ® (Tenofovir 
and Emtricitabine ).  Viral drug resistance to these drugs can also cause cross resistance to more 
commonly used drugs such as Lamivudine (3TC). Your doctor would need to prescribe different 
drugs which are used to treat HIV infection .  These other drugs may have more side effects or 
may be less easy to take than a treatment that has Truvada ®.  Truvada ® alone is never enough 
for treatment of HIV infection, so additional drugs are always needed for treatment.  
 
Sensitive questions  
The question s we will ask you about your sexual behavior or drug use may make you feel 
uneasy.  However, you do not have to answer any question that you do not want to and you can 
stop answering the questions at any time.   
 
Blood and hair samples  
Taking blood samples  may cause some pain, bruise your arm, or make you feel lightheaded.  In 
rare cases,  you may faint.  There is also a slight chance of infection when blood is drawn.  You 
may be nervous while you are waiting for your HIV test result.  If the tests show that  you have 
HIV, you may worry about your health and future.  You will receive counseling before and after 
the test to help address your concerns.  We will make every effort to protect your confidentiality 
during the study.  However, it is possible that othe rs may learn that you are part of this study and 
they may think that you are infected with HIV or are at high risk for infection with HIV.  
Because of this you could have trouble finding or keepi[INVESTIGATOR_007] a job.  You could also have problems 
with your family, fri ends and community.   
 
Taking a sample of your hair may cause some discomfort.  You may worry that this is painful or 
affects how you look.  Approximately 100 strands of hair are needed for this procedure.  This is 
about the number of hairs that a person l oses from their body every day.   The collection 
procedure involves cutting the shaft of the hairs near the scalp ; the root of the hair will not be 
collected .  Each hair will be cut carefully and will be sampled around your scalp, this way people 
will not be able to tell that your hair has been removed.  We can also take a hair sample from 
another part of your body other than your scalp if you wish.   If you do not wish to provide a hair 
sample, you can still participate in the study and it will not affect the care you would normally 
receive.  
 
 
HPTN 067, Final Version 5.0  Page 115 of 13 3 June 10 , 2013  
 Other possible risks  
We do not know of other risks if you are using any other drugs than Truvada ®.  These drugs 
may include herbal or diet pi[INVESTIGATOR_749395].  Please tell study staff if you are using any of these.   
 
[For Women] How will the study drug affect pregnancy or breastfeeding?  
Women who join the study must agree to use effective contraception and must have pregnancy 
tests and answer questions about your current family planning method at the Enrollment Visit, 
and at other visits while in the study (about every 4 weeks).  Effective contraception includes 
barrier methods (including condoms), hormonal methods (such as the birth control pi[INVESTIGATOR_262270]), 
intrauterine contraceptive device (IUD), and sterilization.  Con doms are the only method which 
also protect you against HIV infection and should be used from start to finish every time you 
have sex even if you are using another contraceptive method.   
 
If you are pregnant or breastfeeding, you cannot join this study.  If you become pregnant during 
the study, or within [ADDRESS_1024872].  
The study staff will refer you to available sources of medical care and other services for you or 
your baby.  The study does not pay for this care.   
 
Please tell your doctor during your pr egnancy about your study participation.  Your study doctor 
will ask that you, or your doctor, provide updates on the progress of your pregnancy and its 
outcome.  The study doctor will make this information available to the study sponsor for safety 
monitori ng follow -up.   
 
We do not know if Truvada®  tablets have any effect on babies whose mothers take it during 
pregnancy or when breastfeeding.  Because of this, women who are pregnant or breastfeeding 
cannot participate in this study .   
 
What Are the Potential Benefits?  
At screening and other study visits we will check to see if you have HIV infection.  The 
counseling you get during this study may help you to avoid HIV and other sexually -transmitted 
infections.  If you have or become infected with HIV,  this counseling may help you to learn how 
to better care for yourself and avoid passing HIV to your sexual partners.  If you become HIV 
infected, we will refer you for care and/or treatment.  At the screening visit we will also check if 
you have hepatitis  B infection.  If needed, we will offer you a hepatitis B vaccination.  During 
the study you will have tests to check on the health of your blood, liver, and kidneys .  If any 
health problems are found, you will be referred for care.  At every visit you wil l receive condoms 
and lubricant free of charge.   
 
You may not receive any other direct benefit from being in this study however, you or others in 
your community may benefit from this study later.  The information gathered during this study 
may help to pre vent HIV and other infections.  This may be beneficial to you and your 
community.   
 
 
HPTN 067, Final Version 5.0  Page 116 of 13 3 June 10 , 2013  
 What are Some Reasons Why You May Be Withdrawn From the Study Without Your 
Consent?  
You may be withdrawn from the study without your consent for the following reasons:  
 The research study is stopped or canceled.  
 The study staff feels that staying in the study would be harmful to you.  
 The study investigators identify other reasons that they believe would prevent you 
from continuing in the study.  
 Finally, the study can be sto pped by [CONTACT_50844], such as the ethical review 
committee, or by [CONTACT_209298], such as the study sponsor or other oversight 
agencies.  
 During the study, you may be told of important new information about the study that 
may affect your safety.  For example, if the study shows that you taking part in it may be 
bad for your health, we will tell you.  It will be up to you to decide if you want to 
continue in the study.  If you decide to stay in the study, we may ask you to sign an 
updated informed conse nt form.  You will also be told when the results of the study may 
be available, and how to learn about them.   
 If you have any major health problems during the study, the doctor may require that you 
stop taking study drug for your own safety.   
 If you or y our doctor decides that you should withdraw from the study we may ask you 
to come in for a final visit.   
 
What are the alternatives to participating in this study?  
[Sites to amend as applicable]  If you choose not to take part in this study, it will have no effect 
on the regular medical care that is available to you at this clinic  or elsewhere .  There may be 
other studies going on at this study clinic or in the community for which you may be eligible.  If 
you wish, we will tell you about other studies that  we know about.  There may also be other 
places where you can go for HIV counseling and testing.  We will tell you about those places if 
you wish.  If you prefer to take daily Truvada® and not enroll in this study, we encourage you to 
discuss this with you r primary care provider.  
 
How will your privacy be protected?  
All the information you give us as part of this study will be kept secret.  All your laboratory test 
results will also be kept secret.  You will get a unique study identification number that will be 
used instead of your name [CONTACT_420055].  However, at every study visit we will ask you to 
identify yourself.  This is to make sure that it is you who provides samples and information to us.  
Also we want to make sure  that no other person than you can get your confidential laboratory 
test results.  Your personal information (name, address, phone number) will be protected by [CONTACT_749485].  Only the study staff will  be able to see records that identify you by [CONTACT_2300] .  This 
information will not be shared with others.  All records will be stored in locked files at the study 
clinic.  Results of your laboratory tests will be made available only to you when you visit the 
clinic.  Your name [CONTACT_749496].  
 
The [LOCATION_002] Food and Drug Administration (FDA) has been informed of this study and has 
allowed it to be done.  Your records may be reviewed by [CONTACT_115331] (US National Institutes 
of Health (NIH), US NIMH) and their representatives, [insert name [CONTACT_50854]]  IRB/EC, study staff, study 
monitors , the FDA, the [LOCATION_002] Office for Human Subjects Protections, [COMPANY_009] Sciences  and 
[insert applicable local regulatory authorities].  
HPTN 067, Final Version 5.0  Page 117 of 13 3 June 10 , 2013  
  
[For US  site only:  We cannot guarantee absolute confidentiality.  In addition to the efforts made 
by [CONTACT_749486], we have obtained a 
Certificate of Confidentiality from the U.S. Federal Government.  This cer tificate protects 
researchers from being forced to tell people who are not connected with this study, such as the 
court system, about your participation.  Any publication of this study will not use your name [CONTACT_107012].  
  
People who may re view your records include: the U.S. Food and Drug Administration (FDA), 
[insert name [CONTACT_50854]]  IRB, National Institutes of Health (NIH), study staff, study monitors, and 
drug companies supporting this study.  Also, the Certificate of Confidentiality does no t prevent 
you from releasing information about yourself and your participation in the study. The 
Certificate cannot be used to resist a demand for information from personnel of the [LOCATION_002] 
Government that is used for auditing or evaluation of Federal ly funded projects or for 
information that must be disclosed in order to meet the requirements of the federal Food and 
Drug Administration (FDA).  
  
Even with the Certificate of Confidentiality, if the study staff learns of possible child abuse 
and/or negle ct or a risk of harm to you or others, we wi ll tell the proper authorities.]  
 
What will be asked from you in this study?  
In this study you will be asked to come to the study clinic at least 13 times; every week during 
the first six weeks, and then once a month for seven months (total 34 weeks).  If you develop 
HIV during the course of the study, we will ask you to return to the clinic every 12 weeks after 
Week 30 until the study ends at this site.  If we need to do additional tests for your health, we 
may ask you to come for an additional visit.  We will ask you to take Truvada® according to the 
schedule in your group.  You w ill also be asked to remember every time you have sex and when 
you took Truvada®.  You will be asked to complete a phone interview every week (during 
approximately Weeks 7 -30) and a computer questionnaire at Screening, Weeks 6, [ADDRESS_1024873] with you  during the study?  
You will be asked to provide your address and phone number(s).  The staff will ask you for 
names of people who will always know how to find you and places where you can be found.  It 
is possible that the staff may visit you at your house  or contact [CONTACT_749487].  If 
we talk to people on this list, we will not tell them why we are trying to reach you.  If you are not 
willing to give us this information, you should not agree to be in this study.   
 
What happens if you are injured by [CONTACT_31295]?  
Taking part in this study may put you at risk for personal injury.  You may develop side effects from the 
study drug.  If such si de effects happen, study staff will assist you in getting medical care.  [Sites to 
specify institutional policy:]  It is unlikely that you will be injured as a result of taking part in this study.  
If you are injured, the [ institution ] will give you the tr eatment needed for your injuries.  You [ will/will 
not] have to pay for this treatment.  You will be told where you can get additional treatment for your 
HPTN 067, Final Version 5.[ADDRESS_1024874] any questions?  
We are happy to answer any questions that you may have.  It may be that you have questions 
about your rights as a study participant or that you t hink you have been injured because you were 
in this study.  In this case you can contact [insert name [CONTACT_50855]] at 
[[insert telephone number and physical address].   
 
If you have any questions or concerns about whether you s hould join this study, or your rights as 
a research participant, you should contact [insert name [CONTACT_749497]/EC or other 
organization appropriate for the site] at [insert physical address and telephone number].     
 
What is the cost of study participation?  
There is no cost to you for being in this study.  You will receive [insert local amount] for your 
time, effort, and travel to and from the clinic for each study visit.  In addition, you will receive 
[insert local amount] for each phone  call with study staff to discuss your pi[INVESTIGATOR_4382] -taking and sexual 
behavior.  If study staff has to call you to get this information, you will receive [insert local 
amount] for your time.  You will be given condoms and lubricants, free of charge at each visit.  
HPTN 067, Final Version 5.0  Page 119 of 13 3 June 10 , 2013  
 The ADAPT study:  A Phase II, Randomized, Open -Label, Pharmacokinetic and 
Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil 
Fumarate Pre -Exposure Prophylaxis (PrEP)  
 (HPTN  067) 
Final Version 5.0  
June 10, 2013  
DAIDS Document ID: [ZIP_CODE]  
 
US National Institute of Allergy and Infectious Diseases (NIAID)  
US National Institute of Mental Health (NIMH)  
 US National Institutes of Health (NIH)  
 
Sponsor: NIAID, NIMH, NIH  
 
SCREENING AND ENROLLMENT INFORMED CONSENT FORM  
 
INVESTIGA TOR OF RECORD:  [insert name ] 
PHONE:  [insert number ] 
 
SIGNATURE [CONTACT_749498]:  
_____  My initials indicate that any left over blood samples may be stored for future  
testing after study -related testing has been completed.  
_____   I do not agree to allow left over blood samples to be saved for long -term storage  
and future testing after study -related testing has been completed . 
____  I agree to allow genetic (DNA) testing of my blood for future testing . 
____  I do not agree t o allow genetic (DNA) testing of my blood.  
Urine  
____  My initials indicate that any left over urine samples may be stored for future testing after   
            study -related testing has been completed.  
____  I do not agree to allow left over urine sample s to be saved for long term storage and  
future testing after study -related testing has been completed . 
 
If you have read this consent form, or had it read and explained to you, and you understand the 
information, and you voluntarily agree to join the stud y, please sign your name [CONTACT_132827].  
 
____________________  ________________________  ______________  
Participant Name (print)  Participant Signature  [CONTACT_1782]  
 
____________________  ________________________  ______________  
Study Staff Conducting  Study Staff Signature  [CONTACT_420064] (print)  
HPTN 067, Final Version 5.0  Page 120 of 13 3 June 10 , 2013  
 SAMPLE FOCUS GROUP INFORMED CONSENT  
The ADAPT study:  A Phase II, Randomized, Open -Label, Pharmacokinetic and 
Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil 
Fumarate Pre -Exposure Prophylaxis (PrEP)  
 (HPTN  067) 
 
Final Version 5.0  
June 10, 2013  
DAIDS Document ID: [ZIP_CODE]  
 
Division of AIDS (DAIDS), US National Institute of Allergy and Infectious Diseases 
(NIAID)  
US National Institute of Mental Health (NIMH)  
 US National Institutes of Health (NIH)  
 
Sponsor: NIAID, NIMH, NIH  
 
FOCUS GROUP INFORMED CONSENT FORM – STUDY PARTICIPANTS  
 
INVESTIGATOR OF RECORD:  [insert name ] 
PHONE:  [insert number ] 
  
Introduction  
You have been invited to participate in a focus group wit h other participants  from the ADAPT 
study: A Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of the Use 
of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre -Exposure Prophylaxis 
(PrEP) (HPTN 067).  A focus group is a discussion among a small group of people about a 
specific set of topi[INVESTIGATOR_1102].  Focus groups are led by a focus group leader.  The comments made by 
[CONTACT_749488] t opi[INVESTIGATOR_749396].  The goal of this study is to find out more 
about whether people can take a drug that may prevent HIV infection and what that experience is 
like for them.  The purpose of this focus group is to help us learn more about :  
 How you feel about taking Truvada® according to the schedule in your pi[INVESTIGATOR_4382] -taking 
schedule group .   
 How taking part in this study made you feel about your risk for HIV.   
 Whether you told your partners, friends and families about taking part in this stud y.   
 How you feel about working with the staff at the study clinic.   
 
Approximately 36 to 48 participants at [insert site] will take part in these focus groups.  
Approximately 6 -8 participants at [insert site] in 6 focus groups (2 focus groups per pi[INVESTIGATOR_4382]-taking 
schedule group).  These focus groups will take place sometime after your Week 34 study visit.  
An equal number of people will take part in focus groups at [insert other site s] for a total of 
about [ADDRESS_1024875] of the study (HPTN 067).  Although we hope that you 
will be comfortable answering all of the questions openly and honestly, please keep in mind that 
you may refuse to answer any of the questions, or stop your participation completely, at any 
time.  If you choose not to parti cipate in a focus group discussion or refuse to answer any of the 
questions, you will not lose any of the benefits of your regular medical care at [study clinic].  
 
[To be modified to reflect site practices:  The focus group will take place in a location  t hat the 
study staff have determined will provide you with privacy and confidentiality such as a room at 
the clinic, or other appropriate places.  The study team will talk with you about this so you know 
where to go for the focus group.  ] 
 
Each focus group  should take about [ADDRESS_1024876] to you for participation.  You 
will receive [insert local amount] for your time and effort.  
 
To help assure that we get the best understanding possible from each focus group the participant 
answers will be  recorded .  After the focus group is finished, the recording will be typed (called 
a transcript) by [CONTACT_5944].  All identifying information will be removed from the 
transcript.  Your name [CONTACT_446933].  These recordings will be destroyed 
after all analysis is completed.   
 
What Are the Potential Benefits?  
You may not receive any other direct benefit from being in this study; however, you or others in 
your community may benefit from this study later.  The information gathe red during this study 
may help to prevent HIV and other infections.  This may be beneficial to you and your 
community.   
 
What Are the Possible Risks or Discomforts?  
The questions we will ask you may make you feel uneasy.  We hope that the focus group 
procedures described above will protect your confidentiality and minimize your discomfort when 
discussing sensitive topi[INVESTIGATOR_1102].  However, the greatest risk may involve your privacy and 
HPTN 067, Final Version 5.[ADDRESS_1024877] 
your privacy are described below.   
  
How Will Your Privacy Be Protected?  
Every effort will be made to keep your personal information confidential.  Your personal 
information (name, address, phone number) will be protected by [CONTACT_512350].  Your name, 
or anything else that might iden tify you personally, will not be used in any publication of 
information about this study.  We encourage you to make up a name [CONTACT_749499] a nickname [CONTACT_749500].   
 
The [LOCATION_002] Food and Drug Administration (FDA) has  been informed of this study and has 
allowed it to be done.  Your records may be reviewed by [CONTACT_115331] (US National Institutes 
of Health (NIH), US NIMH) and their representatives, [insert name [CONTACT_50854]]  IRB/EC, study staff, study 
monitors and  [insert applicable local regulatory authorities]. .   
 
[For US site only:  We cannot guarantee absolute confidentiality.   In addition to the efforts made 
by [CONTACT_749486], we have obtained a 
Certificate of Confidentiality from the U.S. Federal Government.  This certificate protects 
researchers from being forced to tell p eople who are not connected with this study, such as the 
court system, about your participation.  Any publication of this study will not use your name [CONTACT_107012].  
  
People who may review your records include: the U.S. Food and Drug Adminis tration (FDA), 
[insert name [CONTACT_50854]]  IRB, National Institutes of Health (NIH), study staff, study monitors, and 
drug companies supporting this study.  Also, the Certificate of Confidentiality does not prevent 
you from releasing information about yourself a nd your participation in the study. The 
Certificate cannot be used to resist a demand for information from personnel of the [LOCATION_002] 
Government that is used for auditing or evaluation of Federally funded projects or for 
information that must be disclo sed in order to meet the requirements of the federal Food and 
Drug Administration (FDA).  
  
Even with the Certificate of Confidentiality, if the study staff learns of possible child abuse 
and/or neglect or a risk of harm to you or others, we wi ll tell the p roper authorities.]  
 
 
HPTN 067, Final Version 5.[ADDRESS_1024878]:  
 
 [site insert name [CONTACT_50855]]  
 [site insert telephone number and physical address of abov e] 
 
For questions about your rights as a research participant, contact:  
 
 [site insert name [CONTACT_50856] (IRB)/Ethics 
Committee (EC) or other organization appropriate for the site]  
 [site insert telephone number and ph ysical address of above]  
  
HPTN 067, Final Version 5.0  Page 124 of 13 3 June 10 , 2013  
 The ADAPT study:  A Phase II, Randomized, Open -Label, Pharmacokinetic and 
Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil 
Fumarate Pre -Exposure Prophylaxis (PrEP)  
(HPTN  067) 
 
Final Version 5.0  
June 10, 2013  
DAIDS Document ID: [ZIP_CODE]  
 
US National Institute of Allergy and Infectious Diseases (NIAID)  
US National Institute of Mental Health (NIMH)  
 US National Institutes of Health (NIH)  
 
Sponsor: NIAID, NIMH, NIH  
 
FOCUS GROUP INFORMED CONSENT FORM – STUDY PARTICIPANTS  
 
INVESTIGATOR OF RECORD:  [insert name ] 
PHONE:  [insert number ] 
 
 
SIGNATURE [CONTACT_749501], if all of your questions 
have been answered and if you agree to take part in the f ocus group, please sign your name [CONTACT_749502].  
 
 
 
_______________________    ____________________________________  
Participant’s Name (print)    Participant’s Signature [CONTACT_50858]  
 
 
 
_______________________    ____________________________________  
Study Staff Conducting    Study Staff Signature [CONTACT_50861] (print)  
 
 
  
HPTN 067, Final Version 5.0  Page 125 of 13 3 June 10 , 2013  
 SAMPLE KEY INFORMANT INTERVIEW INFORMED CONSENT FOR SELECTED 
STUDY PARTICIPANTS  
The ADAPT study:  A Phase II, Randomized, Open -Label, Pharmacokinetic and 
Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil 
Fumarate Pre -Exposure Prophylaxis (PrEP)  
(HPTN  067) 
 
Final Version 5.0  
June 10, 2013  
DAIDS Document ID: [ZIP_CODE]  
 
Division of AIDS (DAIDS), US National Institute of Allergy and Infectious Disease s 
(NIAID)  
US National Institute of Mental Health (NIMH)  
 US National Institutes of Health (NIH)  
 
Sponsor: NIAID, NIMH, NIH  
 
KEY INFORMANT INTERVIEW INFORMED CONSENT FORM FOR SELECTED 
STUDY PARTICIPANTS  
 
 
INVESTIGATOR OF RECORD:  [insert name ] 
PHONE:  [insert number ] 
  
Introduction  
You have been invited to participate in an interview to discuss your study participation in the 
ADAPT study: A Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of 
the Use of Intermittent Oral Emtricitabin e/Tenofovir Disoproxil Fumarate Pre -Exposure 
Prophylaxis (PrEP) (HPTN 067).  .  A Key Informant Interview is an individual discussion about 
a specific set of topi[INVESTIGATOR_1102].  The purpose of this interview is to help us learn more about:  
 
 Perceived feasibility and  acceptability of each of the regimens (pi[INVESTIGATOR_4382] -taking schedule)  
 Facilitators and barriers to pi[INVESTIGATOR_4382] -taking overall and in relation to specific regimens  
 Preferred regimen  
 Best strategies to support pi[INVESTIGATOR_4382] -taking  
 Continued condom use in the context of PrEP trials  
 Best strategies to support staff and counselors working with PrEP users  
 
Two persons per study group at each of the three study centers will participate in key informant 
interviews after they have completed their Week 34 visit.  This means a total of six p articipants 
at [insert site] and an additional twelve participants at [site 2 , site 3 ].  The information from these 
interviews will help us better understand what we learn from the rest of the study.  We hope the 
HPTN 067, Final Version 5.[ADDRESS_1024879] of the 
information that is collected during this research study.   
 
Procedures  
The interview will be led by a memb er of the research team that you did not work with during 
the study .  You will be asked to share your views about the use of certain drugs to prevent HIV 
infection and about how [insert local population] make decisions about sex.  You will also be 
asked wh y you think people in the community would or would not want to take part in a study 
like this one in the future.  You will be asked to share your views about the use of the study 
regimen you were assigned and the regimen demands.   
 
If any of the questions  make you upset either you or the interviewer may stop the interview at any 
time.  You will also be provided with contact [CONTACT_749489] a later time.   
 
Your participation  in this interview is voluntary.  You are not required to participate in this 
interview in order to remain in the rest of the study (HPTN 067).  Although we hope that you 
will be comfortable answering all of the questions openly and honestly, please keep i n mind that 
you may refuse to answer any of the questions, or stop your participation completely, at any time 
and you will not lose any of the regular benefits of your regular medical care at [study clinic].   
 
[To be modified to reflect site practices: The interview will take place in a location that the 
study staff have determined will provide you with privacy and confidentiality such as the clinic, 
or other appropriate places.  The study team will talk with you about this so you know where to 
go for the interview.  
 
Each interview should take about [ADDRESS_1024880] to you for participation.  You 
will receive [insert local amount] for your time and effort.  
 
What Are the Potential Benefits?  
You may not receive any other direct benefit from being in this study; however, you or others in 
your community may benefit from this study later.  The information gathered during this study 
may help to prevent HIV and other infections.  This may be benefi cial to you and your 
community.   
 
What Are the Possible Risks or Discomforts?  
To minimize any discomfort and to protect your privacy the interview will be conducted in a 
private area that will allow you to speak comfortably without being overheard.  Altho ugh we 
hope that you will be comfortable answering all of the questions openly and honestly, please 
keep in mind that you may refuse to answer any of the questions, or stop the interview 
completely, at any time.  The greatest risk may involve your privacy and confidentiality.  The 
steps that the study team has taken to protect your privacy are described below.   
  
How Will Your Privacy Be Protected?  
HPTN 067, Final Version 5.0  Page 127 of 13 3 June 10 , 2013  
 Every effort will be made to keep your personal information confidential.  Your personal 
information (name, a ddress, phone number) will be protected by [CONTACT_512350].  Your name, 
or anything else that might identify you personally, will not be used in any publication of 
information about this study.   
 
To help assure that we get the best understanding possi ble from the interview your answers will 
be recorded .  After the interview is finished, the recording will be typed (called a transcript) by 
[CONTACT_5944].  All identifying information will be removed from the transcript.  Your name 
[CONTACT_749503].  These recordings will be destroyed after all analysis is 
completed.  
 
Your records may be reviewed by [CONTACT_115331] (US National Institutes of Health (NIH), US 
NIMH) and their representatives, [insert name [CONTACT_50854]]  IRB/EC, study staff, study monitors and [insert 
applicable local regulatory authorities]. .   
 
 [For US site only:  We cannot guarantee absolute confidentiality.  In addition to the efforts made 
by [CONTACT_749490], we have obtained a 
Certificate of Confidentiality from the U.S. Federal Government.  This certificate protects 
researchers from being forced to tell people who are not connected with this study, such as the 
court system, about your participation.  Any publication of this study will not use your name [CONTACT_107012].  
  
People who may review your records include: the U.S. Food and Drug Administration (FDA), 
[insert name [CONTACT_50854]]  IRB, National Institutes of Health (NIH), study staff, study  monitors, and 
drug companies supporting this study.  Also, the Certificate of Confidentiality does not prevent 
you from releasing information about yourself and your participation in the study. The 
Certificate cannot be used to resist a demand for informa tion from personnel of the [LOCATION_002] 
Government that is used for auditing or evaluation of Federally funded projects or for 
information that must be disclosed in order to meet the requirements of the federal Food and 
Drug Administration (FDA).  
  
Even w ith the Certificate of Confidentiality, if the study staff learns of possible child abuse 
and/or neglect or a risk of harm to you or others, we wi ll tell the proper authorities.]  
 
Persons to Contact [CONTACT_749491] a research -related injury, contact:  
 
 [site insert name [CONTACT_50855]]  
 [site insert telephone number and physical address of above]  
 
For questions about your rights as a research participant, contact:  
 
 [site insert name [CONTACT_50856] (IRB)/Ethics 
Committee (EC) or other organization appropriate for the site]  
 [site insert telephone number and physical address of above]  
  
HPTN 067, Final Version 5.0  Page 128 of 13 3 June 10 , 2013  
 The ADAPT study:  A Phase II, Randomized, Open -Label, Pharmacokineti c and 
Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil 
Fumarate Pre -Exposure Prophylaxis (PrEP)  
(HPTN  067) 
 
Final Version 5.0  
June 10, 2013  
DAIDS Document ID: [ZIP_CODE]  
 
US National Institute of Allergy and Infectious Disease s (NIAID)  
US National Institute of Mental Health (NIMH)  
 US National Institutes of Health (NIH)  
 
Sponsor: NIAID, NIMH, NIH  
 
KEY INFORMANT INTERVIEW INFORMED CONSENT FORM FOR SELECTED 
STUDY PARTICIPANTS  
 
INVESTIGATOR OF RECORD:  [insert name ] 
PHONE:  [insert number ] 
 
 
SIGNATURE [CONTACT_749501], if all of your questions 
have been answered and if you agree to take part in the Key Informant Interview, please sign 
your name [CONTACT_749504].  
 
 
 
____ ___________________    ____________________________________  
Participant’s Name (print)    Participant’s Signature [CONTACT_50858]  
 
 
 
_______________________    ____________________________________  
Study Staff Conducting    Study Staff Signature [CONTACT_749505] (print)  
 
 
 
HPTN 067, Final Version 5.0  Page 129 of 13 3 June 10 , 2013  
 SAMPLE KEY INFORMANT INTERVIEW INFORMED CONSENT FOR CLINIC 
STAFF  
The ADAPT study:  A Phase II, Randomized, Open -Label, Pharmacokinetic and 
Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil 
Fumarate Pre -Exposure Prophylaxis (PrEP)  
(HPTN  067) 
 
Final Version 5.0  
June 10, 2013  
DAIDS Document ID: [ZIP_CODE]  
 
Division of AIDS (DAIDS), US National Institute of Allergy and Infectious Diseases 
(NIAID)  
US National Institute of Mental Health (NIMH)  
 US National Institutes of Health (NIH)  
 
Sponsor: NIAID, NIMH, NIH  
 
KEY INFORMANT INTERVIEW INFORMED CONSENT FORM FOR SELECTED 
CLINIC STAFF  
 
 
INVESTIGATOR OF RECORD:  [insert name ] 
PHONE:  [insert number ] 
  
Introduction  
You have been invited to participate in a research study which includes an interview to discuss 
your role as a provider to participants in their counseling or pi[INVESTIGATOR_4382] -taking in the ADAPT study: A 
Phase II, Randomized, Open -Label, Pharmacokinetic and Behavioral Study of the Use of 
Intermittent Or al Emtricitabine/Tenofovir Disoproxil Fumarate Pre -Exposure Prophylaxis (PrEP) 
(HPTN 067) study.  A Key Informant Interview is an individual discussion about a specific set of 
topi[INVESTIGATOR_1102].  The purpose of this interview is to help us learn more about:  
 
 Whether  you think these regimens (pi[INVESTIGATOR_4382] -taking schedules) will work for and are accepted 
by [CONTACT_4317]  
 What helps or prevents how well participants follow their regimens overall and in 
relation to specific regimens  
 Preferred regimen  
 Best strategies to support pi [INVESTIGATOR_4382]-taking  
 Continued condom use in the context of PrEP trials  
 Best strategies to support staff and counselors working with PrEP users  
 
HPTN 067, Final Version 5.[ADDRESS_1024881] of the study.  We hope the information we learn will help us reduce 
the number of people who become infected with HIV in the future.  
 
Clinic Staff at [insert site] that provided care in the form of counseling or pi[INVESTIGATOR_4382] -taking in the 
Behavioral Aspects of PrEP Counseling for Intermittent Exposure (HPTN 067) will participate in 
these interviews after all participants have completed the Week [ADDRESS_1024882] of the information that is collected 
during this research study.   
 
Procedures  
[Sites to adjust as needed]  The interview will be led by [CONTACT_749492] a 
member of our research team here at [insert clinic], but is affiliated w ith our overall research 
organization.  The individual will not be someone who has a supervisory role for your position.  
You will be asked to share your views about the use of certain drugs to prevent HIV infection 
and about how [insert local population] make decisions about sex.  You will also be asked why 
you think people in the community would or would not want to take part in a study like this one 
in the future.  You will be asked to share your views about the use of each of the regimens and 
how partic ipants interacted with the study and the regimen demands.  
 
If any of the questions make you upset either you or the interviewer may stop the interview at any 
time.  You will also be provided with contact [CONTACT_749493] a later time.   
 
Your participation in this interview is voluntary.  You are not required to participate in this 
interview in order to remain employed at [insert site].  Although we hope that you will be 
comfo rtable answering all of the questions openly and honestly, please keep in mind that you 
may refuse to answer any of the questions, or stop your participation completely, at any time.  
 
[To be modified to reflect site practices]: The interview will take plac e in a location that the 
study team have determined will provide you with privacy and confidentiality.  The study team 
will talk with you about this so you know where to go for the interview.  
 
Each interview should take about 2 hours.  There will be no cos t to you for participation.  You 
will receive [insert local amount] for your time and effort.  
 
What Are the Potential Benefits?  
You may not receive any other direct benefit from being in this study; however, you or others in 
your community may benefit from  this study later.  The information gathered during this study 
may help to prevent HIV and other infections.  This may be beneficial to you and your 
community.   
 
HPTN 067, Final Version 5.0  Page 131 of 13 3 June 10 , 2013  
 What Are the Possible Risks or Discomforts?  
To minimize discomfort and to protect your privacy the interview will be conducted in a private 
area that will allow you to speak comfortably without being overheard.  Although we hope that 
you will be comfortable answering all of the questions openly and honestly, please keep in mind 
that you may refuse to answer any of the questions, or stop the interview completely, at any time.  
The greatest risk may involve your privacy and confidentiality.  The steps that the study team has 
taken to protect your priva cy are described below.   
 
What are the alternatives to participating in this study?  
[Sites to amend as applicable]  If you choose not to take part in this study, it will have no effect 
on your employment at this site.  We may have other studies now or in the future at this site, 
although there are none currently planned.    
 
How Will Your  Privacy Be Protected?  
Every effort will be made to keep your personal information confidential.  Your personal 
information (name, address, phone number) will be protected by [CONTACT_3476].  Your name, or 
anything else that might identify you personally, will not be used in any publication of 
information about this study.  You will be identified by a code number known only to you and 
the study staff.  This number – not your name – will mark all information about you.  However, 
because there are only a few staff at your site working on this study, it is likely that researchers 
will know your identity and the information you share.  
 
To help assure that we get the best understanding possible from the interview your answers will 
be recorded .  After the intervie w is finished, the recording will be typed (called a transcript) by 
[CONTACT_5944].  All identifying information will be removed from the transcript.  Your name 
[CONTACT_446933].  The recording will be destroyed after all analysi s is 
completed.   
 
Your records may be reviewed by [CONTACT_3133] (FDA), [COMPANY_009] Sciences, Inc, 
the OHRP and the US Centers for Disease Control and Prevention (CDC) as well as the sponsor of the 
study (US National Institutes of Health ( NIH), US NIMH) and their representatives, local regulatory 
authorities, [insert name [CONTACT_50854]]  IRB/EC, study staff and  study monitors .   
 
[For US site only:  We cannot guarantee absolute confidentiality.  In addition to the efforts made 
by [CONTACT_749494], we have obtained a 
Certificate of Confidentiality from the U.S. Federal Government.  This certificate protects 
researchers from being forced to tell people who are not connected with this study, such as th e 
court system, about your participation.  Any publication of this study will not use your name [CONTACT_107012].  
  
People who may review your records include: the U.S. Food and Drug Administration (FDA), 
[insert name [CONTACT_50854]]  IRB, National Inst itutes of Health (NIH), study staff, study monitors, and 
drug companies supporting this study.  Also, the Certificate of Confidentiality does not prevent 
you from releasing information about yourself and your participation in the study. The 
Certificate can not be used to resist a demand for information from personnel of the [LOCATION_002] 
Government that is used for auditing or evaluation of Federally funded projects or for 
HPTN 067, Final Version 5.[ADDRESS_1024883] be disclosed in order to meet the requirements of the federal Fo od and 
Drug Administration (FDA).  
  
Even with the Certificate of Confidentiality, if the study staff learns of possible child abuse 
and/or neglect or a risk of harm to you or others, we wi ll tell the proper authorities.]  
 
 
Persons to Contact [CONTACT_749491] a research -related injury, contact:  
 
 [site insert name [CONTACT_50855]]  
 [site insert telephone number and physical address of above]  
 
For questions about your rights as a research part icipant, contact:  
 
 [site insert name [CONTACT_50856] (IRB)/Ethics 
Committee (EC) or other organization appropriate for the site]  
 [site insert telephone number and physical address of above]  
  
HPTN 067, Final Version 5.0  Page 133 of 13 3 June 10 , 2013  
 The ADAPT study:  A Phase II, Randomized, Open -Label, Pharmacokinetic and 
Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil 
Fumarate Pre -Exposure Prophylaxis (PrEP)  
(HPTN  067) 
 
Final Version 5.0  
June 10, 2013  
DAIDS Document ID: [ZIP_CODE]  
 
US Na tional Institute of Allergy and Infectious Diseases (NIAID)  
US National Institute of Mental Health (NIMH)  
 US National Institutes of Health (NIH)  
 
Sponsor: NIAID, NIMH, NIH  
 
KEY INFORMANT INTERVIEW INFORMED CONSENT FORM FOR CLINIC STAFF 
WHO WERE DIRECTLY INVOLVED WITH PARTICIPANTS IN COUNSELING OR 
PI[INVESTIGATOR_93601] -TAKING  
 
INVESTIGATOR OF RECORD:  [insert name ] 
PHONE:  [insert number ] 
 
 
SIGNATURE [CONTACT_749501], if all of your questions 
have been answered and if you agree to take part in the Key Informant Interview, please sign 
your name [CONTACT_749504].  
 
 
 
_______________________    ____________________________________  
Participant’s Name (print)    Participant’s Signature [CONTACT_50858]  
 
 
 
______________________ _   ____________________________________  
Study Staff Conducting    Study Staff Signature [CONTACT_50861] (print)  
 
 
 